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ABSTRACT
Excessive deposition of ECM is the common characteristic of liver fibrosis. During
hepatic fibrosis, various inflammatory cytokines are released and trigger the activation of
quiescent HSCs. The activated HSCs play the major role in producing extra amount
collagen. It becomes very crucial to focus on HSCs to find out therapeutics, such as
inhibiting collagen synthesis, inhibiting activation to myofibroblasts, or controlling
inflammation.
To control excessive collagen synthesis, one triplex forming oligonucleotides (TFO),
was systemically administrated to prevent type I collagen mRNA transcription. To
enhance circulation time and targeted delivery efficiency, TFO was conjugated to
M6P-HPMA and showed efficient targeted delivery to HSCs. Two week short term in
vivo i.v. administration also showed the therapeutic effects on liver fibrosis by
M6P-HPMA-TFO.
Transforming growth factor β1 (TGF-β1) acts as the initial factor for liver fibrosis.
TGF-β1 gene was demonstrated to be interfered by siRNA in a sequence and dose
dependent mode in HSC-T6 cell line. Later, GFAP promoter driven HSC-specific
pri-miRNA mimic and pri-miRNA cluster mimic showed HSC-specific TGF-β1 gene
silencing to avoid nonspecific inhibition of TGF-β1 expression in other cells and organs.
The novel LPA antagonist, PTP, can interact with LPA receptor on the surface of
cells to inhibit the proliferation, which is also one consequence of HSCs activation.
However, the low aqueous solubility affects its in vivo application. Therefore,
poly(ethylene glycol)-b-poly(carbonate-co-lactide) copolymers were used to make
micellar formulation to enhance solubility. PEG-PCcL micelles were applied to increase
the aqueous solubility of PTP. In vivo administration of PTP loaded PEG-PCcL showed
therapeutic effects on fibrosis in common bile duct ligated mice.
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CHAPTER 1. INTRODUCTION
1.1.

Pathogenesis of Liver Fibrosis and Hepatic Stellate Cells (HSCs)

1.1.1.

Pathogenesis of Liver Fibrosis

Excessive deposition of extracellular matrix (ECM) is the common characteristic of
liver fibrosis. Liver fibrosis results from sophisticated interplaying among various liver
cell types.1 Chronic injuries, such as alcoholic abuse, hepatitis, cholestasis and
metabolism syndrome, damage the hepatocytes and then trigger infiltration of leukocytes.
At the same time, Kupffer cells (KC) are also activated. The filtrated leukocytes and
activated KCs continually release oxygen species (ROS) and inflammatory cytokines,
which lead to the activation of quiescent HSCs. Part of the activated HSCs go to
apoptosis, while part of them survive. The remaining activated HSCs themselves release
growth factors, such as transforming growth factor (TGF) and platelet-derived growth
factor (PDGF), and further activate quiescent HSCs.
The damage to hepatocytes may be necrosis or apoptosis,2 which depends on the type
of injury.3,4 There are two mechanisms for hepatocytes apoptosis, the extrinsic pathway
and the intrinsic pathway. The hepatic diseases involved in the extrinsic pathway of
apoptosis include autoimmune or viral hepatitis, alcohol abuse and ischemia/reperfusion
associated liver injury.4 In contrast, the intrinsic pathway of apoptosis may come from
hepatotoxin induced liver injury.5 Death of hepatocytes amplifies the inflammation of the
liver by recruiting inflammatory cells or directly activating excessive ECM production6
by the over made apoptotic bodies.7 Meanwhile, the apoptotic bodies by KCs can
accelerate hepatocytes apoptosis by inducing expression of death ligands, especially Fas.8
In some liver diseases, HSCs can be activated directly without induction of inflammatory
by some reagents, such as alcohol metabolites and bile acids.9-11 One crucial protein
factors triggered by apoptotic bodies is TFG-β1,12,13 which is considered as the initial
factor in liver fibrosis.
Special soluble growth factors and cytokines, such as IGF-1,14,15 PDGF16 and
TNF-α,17 and fibrotic ECM components18 maintain the survival of the activated HSCs.
The cytokines like TNF-α may act via the Fas/Fas-ligand (Fas-L) system17 to worsen
hepatic fibrosis. Compared to the apoptosis inducing ability from other reagents, PDGF
has relatively little anti-apoptotic but more proliferating activity. The separation of
proliferation and apoptosis in HSCs make the control on HSCs survival regulation easier
and safer. Except for the factors directly relating apoptosis and fibrosis, TIMP-1, even not
a survival factor, inhibits Matrix metalloproteinases (MMPs) activity19 and consequently
leads to less HSC apoptosis in an autocrine manner. Part of the increased production of
ECM also results from down-regulation of TIMP-1. Besides over-production of ECM,
progression of liver fibrosis is caused by remodeling process of ECM, degradation of
normal ECM and substitution with scar matrix.20,21 The whole process is a kind of
complicated network. Activated HSCs, as the principle fibrogenic cells, played the
1

critical role in producing major components of ECM, collagen type I and III, in fibrotic
livers.22-25 This combination of overproduction and remodeling provides a mechanism for
the progression of liver fibrosis.
1.1.2.

HSCs

HSCs, firstly described by Kupper as a vitamin A storing cells, locate in the
sub-endothelial space, between the basolateral surface of hepatocytes and the
anti-luminal side of sinusoidal endothelial cells.
During liver injury, many properties of HSCs changed eventually. The most
significant difference is the lost of lipid droplets. Under microscope, it can be observed
that rER enlarges and Golgi apparatus develops more. This phenomenon suggests the
up-regulated protein synthesis and indicates activation of quiescent HSCs.26 The
activated HSCs then play the major role in producing extra amount collagen. It becomes
very crucial to focus on HSCs to find out therapeutics. Actually, to treat the hepatic
fibrosis, many strategies have been developed based on the understanding of
mechanisms, including inhibiting collagen synthesis, inhibiting activation to
myofibroblasts, or controlling inflammation.26
To control excessive collagen synthesis, we use is one triplex forming
oligonucleotides (TFO), which can incorporate with C1 sequence in the collagen α (I)
promoter by hydrogen bonds, leading to transcriptional inhibition on type I collagen. This
triplex may prevent both the binding of transcription factors to the gene promoter and
duplex unwinding during transcription. TFO was conjugated to M6P-HPMA and showed
efficient targeted delivery to HSCs.27 Two week short term in vivo i.v. administration
suggested M6P-HPMA-TFO might be a potent pro-drug for liver fibrosis.
Transforming Growth factor (TGF-β1) is believed to be the earliest and most potent
stimulus to quiescent HSCs in hepatic fibrosis.28 Even though there is no definitive
therapeutics basing on anti-TGF-β1 found to treat liver fibrosis, many scientific
approaches have been achieved to inhibit TGF-β action. These approaches include
administration of synthetic small molecular compounds, antisense oligonucleotides, small
interference RNAs, antioxidants, neutralizing antibodies and etc. In our group, we
introduced GFAP promoter driven HSC specific anti-TGF-β1 shRNA plasmid to achieve
pro-inflammatory control to treat liver fibrosis.29,30
The small molecule we applied is one LPA antagonist, PTP, which can interact with
LPA receptor on the surface of cells to inhibit the proliferation, which is also one
consequence of HSCs activation.
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1.2.

TFO for Liver Fibrosis Treatment

Triplex forming oligonucleotides (TFOs) perform in a different strategy on gene
interference compared with antisense oligonucleotides and siRNAs. Not like antisense,
TFO can form triplex with the specific genomic DNA and interfere with transcription,
replication, repair and recombination.31 TFOs, usually 13-20 nt long, are composed of
either polypurine or polypyrimidine, but bind only to the purine-rich strand of their target
DNA duplex in the major groove.32 According to their base composition, TFOs
containing C and T nucleotides bind in a parallel and TFOs containing G and A or T
nucleotides binds in an anti-parallel orientation to the target strand, respectively.33,34
Type I collagen, as the major structural protein in ECM, is an ideal target to treat liver
fibrosis. Type I collagen consists of two α1 (I) and one α2 (I) polypeptide chains encoded
by the α1(I) and α2(I) genes. It was demonstrated that the up-regulated expression of type
I collagen by activated HSCs can be at both the transcriptional and post-transcriptional
levels.28 It was shown that the synthesis and stability of α1 (I) collagen mRNA were
highly increased in the process of hepatic fibrosis. Therefore, there are possibility to
prevent fibrosis by inhibiting the transcription of type α1 (I) collagen gene.Mammalian
α1 (I) collagen gene promoter contains two contiguous 30-bp polypurine tracts C1 and
C2, located at -141 to -170 and -171 to -200 upstream from the transcription initial site.35
It was demonstrated that 18-, 25-, and 30-mer antiparallel phosphorothioate (APS) TFOs
specific for C1 tract inhibit transcription in cultured fibroblasts by forming triplex with
the genomic DNA.35,36
Actually, systemic delivery of TFOs is been applied a lot for the treatment of both
genetic and acquired diseases. In 1998, Fomivirsen (brand name Vitravene), as the first
TFO drug, was approved by FDA to treat cytomegalovirus retinitis (CMV) in
immunocompromised patients, including those with acquired immune deficiency
syndrome (AIDS). The major advantage of TFOs over antisense ODNs and siRNAs is
that it interacts with the only gene copy in genomic DNA rather than mRNA, usually
existing as hundreds or thousands of copies per cell. Furthermore, specific mRNAs are
continuously transcribed from genomic DNA in the nucleus, even though those in the
cytoplasm have been silenced. Therefore, inhibition of gene transcription might decrease
the mRNA level in a more efficient way at least in some cases.
The TFO investigated in our group have two advantages compared to other TFO.
Firstly, this TFO is polypurine TFO without any CpG motifs. Since CpG motifs are
considered as immunostimulants in 1997 by Wooldridge et al.,37 DNA with CpG motifs
were utilized to trigger innate immune defense mechanisms. However, stimulation of
immune system may worsen liver fibrosis and not good in our case. Secondly, the TFO
we are using can forms triplex under physiological conditions, which facilitate triplex
formation at target sites. The triplex is more stable to make the silence more efficient.
Therefore, the TFO against α1 (I) collagen can be used as a potent anti-fibrotic drug.
We determined the biodistribution of free TFO at whole body, organ, cellular, and
subcellular levels after systemic administration in both normal and liver fibrotic rats.38
3

The pharmacokinetic profile showed rapid distribution for our TFO to tissues, which was
also reported by other groups for PS and G-rich ODNs.39,40 PS modification is by far the
most extensively studied chemical modification for ODNs to enhance stability and
therapeutic time. TFO uptake by tissues was observed as dose dependent but saturated
kinetic mode at high dose. The hepatic uptake of the TFO was shown linear at low doses,
where nonlinear at higher doses. The hepatic uptake curve of free TFO fit the saturation
kinetic equation very well. Liver has the highest affinity to our TFO. The saturation of
uptake in liver may suggest a receptor-mediated mechanism for TFOs and lead to
redistribution of TFOs to other organs.
However, it was also shown that TFOs are cleared rapidly from the circulation and
the accumulation in HSCs is not that promising. To enhance a receptor-mediated TFO
delivery to HSCs, BSA was considered as a delivery carrier and M6P as target ligand.41
BSA has been utilized for many years as a carrier because it is neither phagocytosed by
macrophages in the liver nor excreted by the kidney so as to increase the circulation time
of conjugated drugs. The mannose 6-phosphate/insulin like growth factor II (M6P/IGF II)
receptor is expressed on the surfaces of HSCs and up-regulated by the stimulation from
chronic liver injury. TFO was synthesized to M6P-BSA via a disulfide bond. The
percentage of the injected dose accumulated in the liver significantly increased with
increase in M6P density. This confirmed the uptake of M6P-BSA-33P-TFO is mediated
by M6P/IGF II receptor-mediated endocytosis in the liver.
However, because of repeated injections of TFO at high dose to treat liver fibrosis,
high molecular weight globular BSA (66430 Da) may not be a suitable carrier for TFO
delivery to the HSCs due to possible immune reaction. Furthermore, the high molecular
weight of BSA also decreased the total liver up-take, which may results from the
narrowed sinusoidal gap in liver after fibrosis. N-(2-Hydroxypropyl) methacrylamide
(HPMA) copolymer has shown great potential for delivery of small molecular drugs
because of its non-immunogenecity. HPMA has also been used for oligonucleotide
delivery by other group, however, no targeting ligands were used achieve site-specific
delivery. Therefore, we conjugated M6P to HPMA and then to TFO via GFLG linker,
which is known to lysosomal degradable link.27 An enzymatic dissociation experiment
was applied to M6P-GFLG-HPMA-GFLG-TFO to determine whether TFO could be
released from the conjugate. Papain was used as model enzyme because it is a cysteine
protease hydrolase enzyme and belongs to the same family as cathepsin B, which is the
most important enzyme in the lysosomes to cleave GFLG spacer. It was shown that free
TFO release concentration increased with incubation time with papain.
To make sure the TFO released from the conjugate can form a triplex to the target
duplex DNA, M6P-GFLG-HPMA-GFLG-TFO was incubated with papain for 24 h to
mimic in vitro release. It was also observed that the TFO released from the conjugate
formed a triplex with duplex DNA. After that, in vivo effects of
M6P-GFLG-HPMA-GFLG-TFO were determined in common bile duct ligated (CBDL)
rats. Following the systemic administration of M6P-HPMA-TFO to CBDL rats three
times a week for two weeks, liver samples were analyzed by real time RT-PCR, Western
blot, histochemistry and immunofluorescence staining to determine the extent of liver
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fibrosis. M6P-GFLG-HPMA-GFLG-TFO showed the more inhibition ability on collagen
synthesis in hepatic fibrotic rats compared to free TFO.
HPMA co-polymers were also proved non-immunogenic. The serum TNF-α, an
indicator to inflammation, level is slightly different between TFO group and
M6P-GFLG-HPMA-GFLG-TFO group after two weeks short term therapeutics.
However, neutrophil infiltration was much less in M6P-GFLG-HPMA-GFLG-TFO group
compared to TFO injected group. This result implies that reduced neutrophil
accumulation might not only come from exposure to pro-inflammatory factors, which
were thought as one reason for neutrophil infiltration. The extra relief of neutrophil
infiltration may come from HPMA to protect TFO from the attack by immune system to
the intruder.
Another fact unveiled by our data is the continual function of TFO to help the
damaged hepatocytes to recover. CK-7 can be expressed in the bile duct epitheliums, no
matter in healthy or hepatic fibrotic rats. However, CK-7 can only be expressed in injured
hepatocytes before their apoptosis. The staining of CK-7 in liver parenchyma were
reduced a lot especially in M6P-GFLG-HPMA-GFLG-TFO group. This result indicates
damaged hepatocytes recovered because of the inhibition on synthesizing excessive
collagen. M6P-GFLG-HPMA-GFLG-TFO group showed higher effects resulting from
target delivery of TFO.
1.3.

RNA Interference on TGF-β1 to Treat Hepatic Fibrosis

After activated by liver injury, HSCs exerts TGF-β1 in both autocrine and paracrine
ways.42,43 For potent fibrogenic effects, autocrine is the most important pattern.
Therefore, down-regulation of the TGF-β1 produced by HSCs becomes very crucial in
treating liver fibrosis.
RNA interference strategies have been frequently applied to TGF-β1 silencing
recently, since the discovery in 1998. Park and his colleagues constructed a
complementary 21-nucleotide sequence, 5′-AACCAAGGAGACGGAATACAG-3’, into
the plasmid vector pU6-shX, containing promoter regions of the mouse small nuclear
RNA U6.44 The constructed TGF-β1 shRNA expression plasmids were IV injected to
fibrotic mice induced by CCl4. After 3 weeks administration of shRNA plasmids after
first CCl4 injection, the level of TGF-β1, type I collagen, and α-SMA in mice were
significantly down-regulated, demonstrating that not only the reduced production but also
less remodeling of ECM happened. Furthermore, serum ALT/AST level was decreased in
the treatment group compared with group without treatment, indicating that TGF-β1
siRNA might effectively attenuate liver damage and improve physiological status. It was
also reported by our group that several siRNA sequences could silence TGF-β1
expression in rat cell line.29 Moreover, two selected siRNAs, 769 and 1033, showed pool
inhibition of TGF-β1 mRNA. The same results were proved in U6 promoter driven
shRNA plasmids. Furthermore, consequent data also demonstrated both TNF-α and IL-1β
levels after TGF-β1 gene silencing, indicating pro-inflammatory factor relief.
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However, neither U6 nor H1 promoter can provide spacial or temporal control on
silencing TGF- β1. The whole body non-specific inhibition of TGF-β1 will create
disaster. The promoter which can only drive TGF-β1 shRNA expression by specific cell
types in the body should be utilized for target gene silencing. We utilize glial fibrillary
acidic protein (GFAP) promoter to construct an HSC-specific expression plasmid to
avoid the side effect of nonspecific TGF-β1 gene shut-down.30 GFAP promoter driven
shRNAs efficiently and specifically inhibit TGF-β1 silencing in HSCs.
1.4.

LPA Antagonist for Liver Fibrosis Therapeutic

LPA is a growth factor-like mediator acting on G-protein-coupled receptors (GPCR)
presenting in various physiological fluids. LPA has been reported to involve in many
diseases, such as cardiac ischemia, atheriosclerosis, obesity and hepatic fibrosis. It is
shown that LPA can activate hepatic myofibroblasts45 and increase the proliferation and
survival of stellate cells.46,47 The correlations between plasma LPA concentration and the
histological stages of liver fibrosis markers have been established in patients with chronic
hepatitis C.48,49 Despite a growing number of LPA antagonists have shown
pharmacological ability, few of them have been validated for treatments in animals. It
becomes very urgent that to develop more efficient anti-fibrotic drugs that may have
important preclinical effects to imply the potent clinical applications in the management
of liver fibrosis.
PTP, a novel synthesized LPA antagonist, showed significant inhibition effect on the
proliferation of HSC-T6 cell line, which suggests the potent application on liver fibrosis
therapeutics. However, the most difficult issue for PTP in vivo administration is the low
water solubility. To solve this problem, novel polymers synthesized by our group,50
poly(ethylene glycol)-b-poly(carbonate-co-lactide) copolymers, were used to make
micellar formulation to enhance solubility. PEG-PCcL micelles were applied to increase
the aqueous solubility of PTP. In vivo administration of PTP loaded PEG-PCcL showed
therapeutic effects on fibrosis in common bile duct ligated mice.
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CHAPTER 2. DELIVERY AND TARGETING OF OLIGONUCLEOTIDES AND
SIRNA
Oligonucleotides (ODNs) are increasingly being recognized as potential therapeutic
agents to modulate aberrant gene expression for treating various diseases, including
cancers51-53 and viral infections.54,55 Concerted efforts have made significant progress in
turning these nucleic acids into therapeutics. Apart from immune-stimulation and
enzymatic cleavage, the most important feature of ODNs is their ability to block mRNA
function by sequence-specific hydridization with target mRNA.56 Theoretically, the
antisense strategy can be used to target any gene in the body, which makes these nucleic
acids achieve broader therapeutic potential than small molecules.
Antisense therapeutic strategies for inhibiting aberrant protein expression have been
developed a lot and some of them have already been in clinical trials.57 In 2005, the first
antisense ODN drug, Vitravene (Fomivirsen), was approved by the United States Food
and Drug Administration (FDA).58 After this approval, more and more clinical trials are
being conducted, not only for ODNs, but also for other nucleic acids drugs, which are
discussed in details in this chapter.
Because of their large molecular weight and negative charge, the delivery of gene
drugs is still a big challenge to scientists. For the most popularly used two therapeutic
nucleotides, single stranded antisense oligodeoxyribonucleotides (AS-ODNs) and double
stranded small interfering RNAs (siRNAs), the molecular weight is at least 6 kDa and
13kDa, respectively. The size of other ODNs is also very big. The large molecular weight
prevents them from passing the endothelium smoothly, which is the most important
physiological barrier for systemic administration. For many organs and tissues, systemic
administration is the only way to be reached by the therapeutic agents in bloodstream.
Phosphodiester ODNs are degraded by endo- and exo- nucleases after systemic and local
administration. Besides big size and poor biostability, the toxicity induced by these
nucleic acids is another big barrier to their therapeutic application. How to achieve
efficient gene silencing at non-toxic dose is the most important issue for the success of
ODN and siRNA delivery. Various polymer and lipid carriers have been synthesized for
their delivery and targeting. In addition, chemical and backbone modifications are used to
increase the stability of ODNs.
This chapter discusses about the mode of action, stability and delivery considerations
of ODNs and siRNAs as well as ways to overcome their biological barriers.
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2.1.

Single Stranded Oligonucleotides

2.1.1.

Antisense Oligodeoxyribonucleotides

An AS-ODN is a short single stranded nucleic acid which binds to specific mRNA
and forms a short double stranded hybrid. The length of AS-ODNs is about 13 to 25 base
pairs. AS-ODNs can inhibit the translation of mRNA by binding to the mRNA
molecules.59 The term as "antisense" ODNs is commonly used because their sequences
are complementary to target mRNA, which is called the "sense" sequence. The binding
affinity and sequence specificity determine the ability of an AS-ODN to form a hybrid
with a target mRNA. Binding affinity depends on the number of hydrogen bonds formed
between the AS-ODN and the target mRNA sequence. The affinity can be determined by
measuring the melting temperature (Tm), at which half of the double-stranded hybrid is
dissociated into single strands. Binding affinity is also determined by the concentration of
AS-ODNs and the ionic strength of the solvent in which hybridization occurs.60
Most antisense ODNs follow the two major mechanisms of action (Figure 2-1). One
is RNase-H dependent degradation of mRNA61,62 and steric-hindrance of the translational
machinery.63 RNase-H dependent cleavage of mRNA is the most effective and frequently
used mechanism for antisense knockdown. RNase-H is a ribonuclease that can recognize
RNA-DNA hybrid duplex and cleave 3'-O-P-bond of the mRNA strand in the
mRNA-ODN complex. This endonuclease catalyzes the cleavage of RNA via a
hydrolytic mechanism with the assistance from an enzyme-bound divalent metal ion.
Once the mRNA is cleaved, the AS-ODN dissociates from the duplex and induces
another round of RNase-H dependent degradation. Thus, it can be looked as a catalytic
process because this prodedure decreases the required concentration of AS-ODNs.
Nevertheless, RNase-H recognition is limited to only a few compounds. Some chemically
modified AS-ODNs, which have higher stability than unmodified ODNs, cannot be
recognized by RNase-H. The steric hindrance mechanism is also termed as ‘translational
arrest’, in which an AS-ODN binds to the single stranded mRNA by Watson-Crick base
pairing. This hybrid formation can stop sterically the translation of target mRNA. During
the process, the binding of the translational related factors to mRNA may be blocked
sterically.
2.1.2.

Triplex Forming Oligonucleotides

Triplex forming oligonucleotides (TFOs) show different strategy of gene silencing
compared with AS-ODNs. TFOs, around 10-30 nt in length, can form triplex with the
specific genomic DNA sequences to interfer with transcription, replication, repair and
recombination.64 TFOs bind to the major groove of duplex DNA, which have runs of
purines on one strand and pyrimidines on the other. TFOs are composed of either
polypurine or polypyrimidine, but bind only to the purine-rich strand of their target DNA
duplex.65 According to their base composition, TFOs containing C and T nucleotides bind
in a parallel and TFOs containing G and A or T nucleotides binds in an anti-parallel
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Figure 2-1 Mechanisms of action of antisense-oligodeoxynucleotides (AS-ODNs). A)
RNase-H dependent degradation of mRNA. In this strategy, RNase-H recognizes
RNA-DNA hybrid duplex and cleaves 3'-O-P-bond of the mRNA strand in the
mRNA-ODN complex. B) Steric-hindrance of the translational machinery. In this
strategy, an AS-ODN binds to the single stranded mRNA by Watson-Crick base pairing
strength and forbids the translational machine to move forward.
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orientation to the target strand, respectively.66,67 After binding, the transcription of the
target gene is blocked.
Transcriptional inhibition gives TFOs several advantages over other gene silencing
technologies.68,69 Since there are only two copies (two alleles) of a target gene in the
genomic DNA, blockage of them means there will be no transcription of DNA into RNA.
Since there may be thousands of copies of an mRNA for a specific gene, antisense may
not block all these mRNAs. Furthermore, specific mRNAs are continuously transcribed
from genomic DNA in the nucleus, even though those in the cytoplasm have been
silenced. Therefore, inhibition of gene transcription might decrease the mRNA level in a
more efficient way at least in some cases.
2.1.3.

Immunomodulatory Oligonucleotides

Bacterial DNA can stimulate the proliferation of B cells and the production of
inflammatory cytokines by monocytes and other cells, while vertebrate DNA cannot.70
Several studies have found that the unmethylated CpG dinucleotide sequence in DNA is
required for this immune-stimulatory activity.71,72 Furthermore, single-stranded ODNs
containing unmethylated CpG motifs, which derives from bacterial DNA, are also
immunostimulatory, especially with a nuclease-resistant phosphorothioate backbone.
CpG ODN, 18-24 bp in length, binds endosomal Toll-like receptor 9 (TLR9) and is taken
up by the cells via endocytosis. Once TLR9 is triggered, it may activate numerous
signaling transduction pathways and lead to the release of many cytokines, such as IFN-γ,
IL-12, and IL-18. The released cytokines directly stimulate B-lymphocytes, dendritic and
natural killer (NK) cells, resulting in innate immunity and antibody-dependent cell
cytotoxicity. The signaling pathways activated by CpG DNA in B cells drive them to
secrete IL-6, IL-10, and immunoglobulin73,74 and to proliferate in a polyclonal T-cell
independent manner.75 A CpG ODN can also indirectly modulate T-cell responses by
increased levels of costimulatory molecules from dendritic cells after application of
CpG-ODN.76
The activation of Th1-dominant immune responses by CpG ODN result in the
production of several cytokines and CpG ODNs are promising candicates for treating
cancer and allergic diseases as vaccine adjuvants and as immune-therapeutics. A
therapeutic application for CpG ODN is an adjuvant for cancer treatment. Current
oncogoing clinical trials combine CpG ODN with chemotherapy or vaccines to treat
tumor because CpG ODN can induce protective immune responses against a lethal tumor
challenge.77,78 Another important utility of CpG ODN is for treating allergic diseases
such as asthma. Due to the favorable Th1-based response induced by CpG ODN, it will
redirect the undesirable Th2 responses of allergic disease.72,79 Ongoing clinical trials will
give us a complete evaluation of this immunomodulatory ODN.
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2.1.4.

Ribozyme and DNAzymes

A ribozyme, also called RNA enzyme or catalytic RNA, is an RNA molecule that
specifically cleaves RNA sequences of choice. Natural ribozymes can form and dissolve
covalent bonds by transexterfication, hydrolysis, and peptidyl transfer.80 They catalyze
not only either the hydrolysis of one of their own phosphodiester bonds or that of bonds
in other RNAs, but also the aminotransferase activity of the ribosome. Natural ribozymes
can be put into three distinct catogeries: the self-splicing introns (group I and II),
ribonuclease P (RNase P), and the small catalytic ribozymes.80-82 Groups I and II introns
and RNase P belong to the larger, more complicated ribozymes with hundreds of
nucleotides in length. The small ribozymes include hammerhead and hairpin ribozymes,
which contain 50-70 nucleotides and are commonly used in molecular biology research.83
For each category, the specificity of ribozymes for a particular cleavage site is
determined by different mechanisms. For the hammerheads, hairpins or group I introns, it
is determined by base-pairing between the ribozyme and its RNA target. For the RNase P
category, it is determined by the pairing of a guide RNA with the RNA target. For group
II introns, it is determined by the pairing of the ribozyme to its DNA target. For all
categories, the target length is another important key.
The ability to engineer small ribozymes that can cleave heterologous RNAs in a
sequence-specific manner has enabled the extensive application of hammerhead and
hairpin ribozymes as gene knockdown tools and potential therapeutic agents to treat
AIDS and cancer patients.84 Actually, ribozymes have been investigated to inactivate
specific genes for the last two decades and have been used as functional genomic study
tools, especially in pre-RNAi era.83 Phase I clinical trials using ribozyme to treat AIDS
patients have been conducted and got initial success. However, some aspects require
further investigation, such as ribozyme stability, ribozyme-substrate colocalization and
tissue-specific delivery.85
DNAzymes (or deoxyribozymes) are RNA-cleaving analogues of ribozymes.
DNAzymes are composed of a catalytic domain flanked by a target-recognition
complementary domain. DNAzymes are more stable than ribozymes due to their DNA
backbones.
2.1.5.

Nucleic Acid Aptamer

Aptamers are ODNs or peptides that can bind to their specific targets, ranging from
small molecules,86 peptides,87 amino acids,88 to proteins.89 A nucleic acid aptamer is a
linear sequence of nucleotides, typically 15-40 nucleotides long. Mostly, when we talk
about aptamers, we refer to nucleic acid aptamers. The intramolecular interaction folds
the chain of nucleotides to a complex three-dimensional shape. The shape of the aptamer
allows it to bind tightly against the surface of its target. Since some aptamers have tight
interaction with their targets, they are also chosen as target ligands for site-specific drug
delivery. These aptamers are selected according to pre-defined equilibrium (Kd), rate
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constants (koff, kon) and thermodynamic parameters (ΔH, ΔS) of aptamer-target
interaction. Kinetic capillary electrophoresis technology is used for the selection of these
smart aptamers. Nucleic acid aptamers are usually created by isolating from synthetic
combinatorial nucleic acid libraries by in vitro selection, Systematic Evolution of Ligands
by EXponential enrichment (SELEX). The first aptamer-based drug, called Macugen and
discovered by OSI Pharmaceuticals, has been approved by the FDA for treating
age-related macular degeneration (AMD).
The discovery of the RNA switches made the nucleic acid aptamers be investigated
more and more.90-92 RNA switches (commonly known as riboswitches) are also capable
of binding to small molecule ligands and can control gene expression. Riboswitches are
found in the untranslated regions (5’-UTR) of mRNA and therefore belong to the
noncoding part of the mRNA. Many riboswitches consist of an aptamer domain or a
sensor region, which is responsible for ligand binding. Riboswitches modulate gene
expression at the level of transcription or translation. Since the similar properties of
riboswitches to aptamers, many natural aptamers were found to exist in riboswitches.
2.2.

Double Stranded Therapeutic Oligonucleotides

2.2.1.

Decoy Oligodeoxynucleotides

Decoy ODNs are double-stranded DNA sequences which interact with proteins based
on Watson-Crick base paring and prevent the targeting transcription factors from their
natural interaction partners. Therefore, transcription factors will be removed from their
endogenous cis-elements. Decoy ODNs against positive transcription factors can inhibit
expression of activated genes and those against negative transcription factors can enhance
expression of suppressed genes.93 After the first artificial 14 mer E2F decoy ODN,
targeted to E2F transcription factor (E2F TF), was synthesized by Morishita et al in
1995,94 other decoy ODNs to target different proteins such as creb, NF-κB, STAT-1,
AP-1, have also been found.95-97 Decoy ODNs have been applied to treat cancer, renal
diseases, viral diseases or cardiovascular diseases because many of these diseases are due
to deregulation of different transcription factors. The decoy ODN strategy may not only
offer a powerful target-based gene therapy method but also provide a genetic tool to
study cellular regulatory processes including upstream transcription regulation and
downstream production.93,98 In 1996, the FDA approved the clinical application of decoy
ODN against E2F to treat neointimal hyperplasia in vein bypass grafts.76
2.2.2.

Small Interfering RNA (siRNA)

siRNAs are a class of double stranded RNA sequences, which are 21 nucleotides
long. Since the discovery of siRNAs in 1998, more and more investigations have been
focused on this RNA interference (RNAi) technology.99 RNAi can be initiated not only
by siRNA, but also by long double-stranded RNA (dsRNA), plasmid or virus-based short
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hairpin RNA (shRNA), and microRNA (miRNA). Long dsRNA, shRNA, and
pre-miRNA are processed by Dicer into 21-23 nt siRNA duplexes with symmetric 2 or 3
nt 3’-overhangs and 5’-phosphate groups. The processed siRNA is incorporated into a
protein complex called the RNA induced silencing complex (RISC). Dicer also plays an
important role in the early steps of RISC formation.100 Argonaute 2, the catalytic
component contained within RISC, unwinds siRNA and cleaves the sense strand, which
is also called passenger strand.101 The activated RISC selectively degrades sequence
specific mRNA with the assistance from the antisense strand of siRNA still remaining.102
After RISC cleaves the target mRNA, the antisense strand siRNA is not affected. Thus,
the RISC can undergo numerous cycles of mRNA cleavage, which further propagates
gene silencing.103
2.3.

Barriers to Oligonucleotide Based Therapeutics

2.3.1.

Instability of ODNs and siRNAs

Native ODNs and siRNAs are rapidly degraded by serum and cellular proteins, and
their stability is greatly affected by physiological pH environments. Clinical applications
of these nucleic acids require increasing their stability while retaining their capacity to
inhibit aberrant protein expression. One approach is the chemical modifications of ODNs
and siRNAs. Figure 2-2 illustrates different structural modifications. These include at
backbones, phosphorothioates and boranophosphates, or riboses, 2’position of ribose
modification, to enhance their stability without losing their bioactivity.
Since native phosphodiester ODNs are quite unstable, oligonucleotide backbone is
often modified not only to improve the stability of ODNs and siRNAs, but also to help
them cross the highly impermeable lipid bilayer of the cell membrane.104
Phosphorothioate (PS) or boranophosphate modifications of inter-nucleoside linkage are
the two types that improve the stability of ODNs and siRNAs.
Phosphorothioates are a variant of natural oligonucleotides in which one of the
non-bridging oxygens is replaced by a sulfur atom. This modification lowers the melting
temperature (Tm) of the mRNA and hybridization efficiency with target mRNA compared
to their phosphodiester counterparts. Fortunately, the modified AS-ODN can still be a
substrate for RNase-H to trigger an RNase-H dependent mRNA degradation process.
Nevertheless, the main drawback of the phosphorothioate modification is that modified
nucleotides may induce undesirable effects by binding to plasma proteins.105,106
Thioate linkages do not always enhance siRNA stability, because phosphorothioate
may reduce the affinity between the two strands of the siRNA duplexes as compared with
unmodified RNA.107 One interesting study showed that only phosphorothioate modified
siRNAs reduced inhibition ability to enhanced green fluorescent protein (EGFP)
mRNA.108 In this study, the PS linkages were incorporated into the sense strand of siRNA
and led to 62% unmodified siRNA induced inhibition, whereas PS linkages in either the
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Figure 2-2 Backbone and ribose modifications of ODNs and siRNAs. Backbone and
ribose modifications of ODNs and siRNAs. X means backbone modification. X=-S is
phosphorothioate, X=-BH3 is boranophosphate. Y means 2’-position of ribose
modification. Including 2’-O-methyl (Y=-CH3), 2’-O-methoxy-ethyl
(Y=-O-CH2-CH2-OCH3), 2’-fluoro (Y=-F). In case of Locked nucleic acid (LNA), ribose
ring is “locked” by a methylene bridge connecting the 2’-O atom (Y=-O) and the 4’-C
atom.
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antisense or both strands of the siRNAs led to just less than 50% inhibition of that
observed using unmodified siRNA. However, modification involving both 2’-position
and phosphorothiate in the antisense strand showed lower levels of EGFP gene silencing.
Phosphorothioate modification can be easily placed in the nucleic acid sequences at
any desired position by two major routes. The first one is the sulfurization in a solution of
elemental sulfur in carbon disulfide on a hydrogen phosphonate.109 However, the toxicity
of carbon disulfide is a barrier for clinical application. The second synthetic method
avoids the problem of elemental sulfur's insolubility in most organic solvents and the
toxicity of carbon disulfide. This method sulfurize phosphite triesters with either
tetraethylthiuram disulfide (TETD) or 3H-1, 2-bensodithiol-3-one 1, 1-dioxide (BDTD)
and can yield higher purity phosphorothioates than before.110
An alternate backbone modification to increase biological stability of ODNs and
siRNAs is the boranophosphate linkage. In boranophosphate ODNs and siRNAs, the
non-bridging phosphodiester oxygen is replaced with an isoelectronic borane (-BH3)
moiety. Boranophosphates have many of the same advantages as phosporothioates.
Boranophosphates maintain the ability to make base pair with high specificity and
affinity to targets as the unmodified gene drugs. They can also be readily incorporated
into DNA and RNA molecules by DNA and RNA polymerases to synthesize
stereoregular boranophosphate DNA and RNA.111-113 Other additional properties of
boranophosphates make them more suitable for clinical use than phosphorothioates.114
Since each boranophosphate linkage has a negative charge, the charge distribution of
boranophosphates differs from that of normal phosphates and phosphorothioates, and
thus increases their hydrophobicity, which facilitates their efficient internalization into
the cells. Furthermore, boranophosphate ODNs are minimally toxic to rodents and
humans.115
Unfortunately, boranophosphate-modified RNAs cannot easily be manufactured using
standard chemical synthesis methods. Since boranophosphate bases are incorporated into
RNA by in vitro transcription,116 which makes specific site selective incorporation of this
modification very difficult.
The sugar moiety of oligonucleotides and siRNA can be modified at the 2’ position of
the ribose, replacing the non-bridging oxygen by 2’-O-methyl (2’-OMe),
2’-O-methoxy-ethyl (2’-MOE) or 2’-fluoro (2’-F).
2’-O-methyl and 2’-O-methoxy-ethyl modifications are the most important members
of this class. The DNA/RNA hybrid by AS-ODNs made of these building blocks is very
stable. Furthermore, these AS-ODNs are less toxic than phosphorothioates ODNs and
even have a slightly enhanced affinity towards their complementary RNAs.117 The
2’-O-methyl and 2’-O-methoxy-ethyl modified ODNs are also called the second
generation ODNs, while phosphorothioate is called the first generation ODNs. For
siRNA, 2’-OMe and 2’-F modified siRNAs have enhanced not only their plasma stability
but also their in vivo potency.118
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2’-O-alkyl AS-ODNs cannot trigger RNase H dependent cleavage of the target
mRNA, because the correct width of minor groove of the DNA/RNA hybrid is necessary
for the substrate recognition by RNase H. The absence or change of 2'-OH function in
DNA/RNA hybrid duplex in the minor groove might alter the interactions between the
duplex and the outer sphere Mg2+-water complex in RNase H.119 Thus, 2’-O-alkyl
AS-ODNs can only take their antisense effect due to a steric block of translation.117,120
In contrast to the typical role of AS-ODNs in inhibiting protein expression, blocking
of a splice site in an mRNA by an ODN can increase the expression of a specific protein.
For example, in one form of β-thalassemia, a genetic blood disorder, a mutation in intron
2 of the β-globin gene causes aberrant splicing of β-globin pre-mRNA and leads to
β-globin deficiency. When 2’-O-methyl ODNs with or without phosphorothioate were
targeted to the aberrant splice site, correct splicing was restored generating correct
β-globin mRNA and protein in different mammalian cell lines.121
Another interesting study related to 2’-position modified siRNAs has shown that 2'-F
modified siRNA may not be more potent than unmodified siRNAs in animals. Even
though the modified siRNAs have greatly increased resistance to nuclease degradation in
plasma, this increase in stability did not translate into enhanced or prolonged silencing of
a target gene in mice after tail vein injection.122 In this study, siRNAs modified with 2’-F
pyrimidines were functional in cell culture and had greatly increased the stability and
prolonged half-life in human plasma, compared to unmodified siRNAs. Although the
2’-F modified siRNAs inhibited the expression of the target gene in mice, the inhibitory
ability of modified siRNAs was not better than that of unmodified ones. The reason may
be that 2’-F modified siRNAs and unmodified siRNAs have different non-specific
binding tendency in vivo.
Locked nucleic acid (LNA), also referred to as inaccessible RNA, is a family of
conformationally locked nucleotide analogs in which the ribose ring is “locked” by a
methylene bridge connecting the 2’-O of the ribose with the 4’-C atom. LNA nucleotides
can be mixed with DNA or RNA bases in the ODNs and siRNAs whenever desired. LNA
ODNs showed an enhanced stability against nucleolytic degradation123 and high target
affinity. However, LNA appears to show hepato-toxicity as indicated by serum
transaminases concentration, organ and body weights.124 LNA were also compatible with
siRNA intracellular machinery, increased nuclease resistance, and furthermore, reduced
sequence-related off-target effects.107,125
2.3.2.

Non-specific Binding and Toxicity

Non-specific binding (commonly known as off-target effect) of ODNs has troubled
the scientists since the beginning of this area, even though one off-target effect initiated
by CpG-ODNs is now being investigated for therapeutic purposes. Off-target reaction
with un-intended sequences is also adversely affecting the progress of RNAi technology.
These off-target effects come from the binding not only to non-target sequences, but also
to the plasma proteins.
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High concentration of ODNs and siRNAs increases their interaction with non-target
sequences, leading to toxic side effects. Off-target effects of AS-ODN usually occurres if
the concentration is higher than 200 nM.126 Semizarov et al. also found similar results for
siRNA that the specificity of siRNA is concentration dependent.127 When the
concentrations of siRNA reached 100 nM, siRNA nonspecifically stimulated a significant
number of apoptosis related non-target genes. These evidences suggest that gene
silencing experiments should be designed under the concentration threshold. Since a
siRNA recognizes its targets by sequence complementarity, potential off-target effects of
siRNAs could also be decreased by the proper selection of siRNA sequences within 100
nt from the 5' termini of the target mRNA.128 Off-target effects of siRNA can also be
minimized by using smart pools of siRNAs, which means the mixture of siRNAs
targeting different regions of mRNA of the same gene and reduces the off-target effect
induced by only one siRNA in the same total concentration, but that is higher than single
one in the pool. Moreover, 2’-MOE modification was also reported to reduce the
‘off-target’ effect,129 suggesting that proper chemical modifications can reduce the
off-target effects.
The binding to plasma protein also affects the target specificity and gene silencing
efficiencies of ODNs and siRNAs. Even though PS modification increases the stability of
ODNs and siRNAs, it promotes their binding to plasma proteins. To minimize binding to
plasma proteins, while still maintaining high stability, ODNs are often partially
phosphorothioated. Since the main reason for the degradation of ODNs and siRNAs is
exonuclease attack, the entire sequence can be protected by a few phosphorothioate
linkages at the terminals. The incorpration of several central phosphorothioate residues in
a potent AS-ODN, that is termed as ‘gapmers’, can still activate RNase H dependent
cleavage but retaining many of the valuable properties of the unmodified nuclei acid
sequence.130
Besides off-target effects, systemic administration of siRNA duplexes may lead to
innate immuo-response, inducing high level of inflammatory cytokines, such as tumor
necrosis factor alpha (TNF-α), interleukin-6 (IL-6) and interferons (IFNs), and innate
immunity, which can be mediated by Toll like receptors (TLRs).131 Innate immunity of
siRNAs can also be triggered by non-TLR-mediated pathways, such as siRNA binding to
retinoic acid inducible gene 1 (RIG1) in the cytoplasm. 2′-OMe modified siRNAs have
shown to prevent recognition by the innate immune system.132 Combined with the ability
of reducing off-target effects of siRNA, 2′-OMe modification of ribose does reduce the
toxicity of synthetic siRNAs.
2.3.3.

Physiological Barriers

Different physiological structures prevent the nucleotides from being delivered to the
target successfully. The most important three physiological barriers are capillary
endothelia, endosome/lysosome membranes and nuclear membranes (Figure 2-3).
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Figure 2-3 Physiological barriers of oligonucleotides and siRNA. A) Capillary
endothelium. B) Endosomal and lysosomal membranes. C) Nuclear membranes.
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The most important physiological barrier to ODN and siRNA delivery is the capillary
endothelium, which is a thin monolayer of cells that line the interior surface of blood
vessels with or without special basement membranes. Although the endothelial cells are
also the therapeutic targets in some diseases, for example, high blood pressure, in most
situations ODNs and siRNAs have to extravastate the endothelium to reach tissue
parenchymal cells.
The capillary endothelia in various organs and tissues have different extravastation
properties according to the morphology and continuity of the endothelial layer and the
basement membrane.133 The capillary endothelia, found in cardiac, smooth muscles, lung,
skin, subcutaneous and mucous membranes, have little fenestrations because these
endothelial cells are joined by tight junctions and continuous subendothelial basement
membranes.134 Therefore, the particles larger than 2.0 nm are very hard to be
extravasated. In some organs, the endothelial cells with tight junctions make unique
structure for self-protection and filter function, such as the blood-brain barrier (BBB).
The capillary endothelia, found in kidney, small intestine and salivary glands, are
composed of fenestrated endothelial cells and a continuous basement membrane.135
Except the glomerular capillaries in kidney, these type capillaries allow the extravasation
of particles less than 11 nm in diameter. For the glomerular capillaries, the effective
permeation is allowed for the particles smaller than 30 nm. Moreover, due to the negative
charges on the glomerular capillary walls, the extravasation is also affected by the
molecular charge of ODNs and siRNAs or their formulated complexes. The capillary
endothelia, found in the liver, spleen and bone marrow, have fenestrations up to 150
nm.134 In addition, the basement membrane is absent in the liver and discontinuous in the
spleen and bone marrow. All of these properties allow the ODNs and siRNAs to pass
through the sinusoidal gaps of the liver to reach the hepatocytes.
Inflammation, tumor formation and fibrosis lead to changes in endothelial barriers.
Inflammation facilitates the distribution of ODNs and siRNAs to the interstitial spaces,
not only due to the increased fenestration between endothelial cells,136 but also due to the
increased permeability of the endothelial cells themselves.137 In case of solid tumors,
many newly formed tumor vessel endothelial cells are poorly-aligned with wide
fenestrations, lacking a smooth muscle layer. Combined with other factors, such as
non-effective lymphatic drainage, solid tumor tissues have enhanced permeability and
retention (EPR) effect, which will allow efficient distribution of ODNs and siRNAs to the
tumor cells. In these tissues, low molecular weight drugs are cleared with short plasma
half-lives, with little distribution to the tumor, whereas high molecular weight drugs or
nanoparticles accumulate in inflammatory and tumor tissues eventually.138 However, for
liver fibrosis it is a different case. After fibrosis, sinusoidal gaps, which are up to 150nm
in width under non-pathological conditions, are almost closed, leading to decreased free
exchange flow between hepatocytes and sinusoidal blood. This change makes the
delivery of ODNs and siRNAs formulated in large size nanoparticles much more
difficult. Cheng et al. showed that the accumulation of TFO in fibrotic rat livers
decreased from 44% to 34% of total IV injection compared to normal liver.139
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Another barrier is endosomal and lysosomal membranes. Endocytosis appears to be
the major pathway for the cellular uptake of ODNs and siRNAs.140 After endocytosis,
ODNs and siRNAs have to escape from the endosome and lysosome before being
degraded. There are several strategies for ODNs and siRNAs to escape into the
cytoplasm, including destabilization of endosomal compartment,141 an exchange of
cationic lipids with anionic phospholipids in cytoplasm-facing membrane monolayer,142
and endosomolysis by osmotic swelling.143 For cationic liposome formulated ODNs and
siRNAs, the choice of proper co-lipids, which can disrupt the endosomal or lysosomal
membrane, help them to escape more efficiently.
Unlike AS-ODNs and siRNAs, TFOs must enter the nucleus to form triple helix with
genomic DNA to inhibit transcription. Although particles smaller than 30 kD can pass
through the nuclear pore complex by passive diffusion, intra-nuclear concentration of
TFOs must be high enough to compete with transcriptional factors at the same genome
gene site. Fortunately, many sorting signals, such as nuclear localization signal (NLS)
peptides, have been discovered,144 which can facilitate the nuclear translocation of
proteins and RNAs.
2.4.

Synthetic Carriers for Nucleic Acid Delivery

2.4.1.

Complex Formation

Cationic lipids are by far the most commonly used transfection agents for ODNs and
siRNAs. Cationic liposomes can be used to either encapsulate these nucleic acids or form
lipid/nucleic acid lipoplexes. Cationic liposomes have been used for nucleic acid delivery
for more than 20 years. In 1987, the efficiency of the cationic lipid
N-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethlyl ammonium chloride (DOTMA) to deliver
both DNA and RNA into mouse, rat and human cell lines was firstly investigated.145
However, many of the cationic lipids used in early clinical trials, such as
3-[N-(N,N -dimethylaminoethane)-carbamoyl] cholesterol (DC-Chol),
1,2-dimyristyloxypropyl-3-dimethyl-hydroxy ethyl ammonium bromide (DMRIE), and
GL-67, did not show high efficiency in vivo. Therefore, more and more cationic lipids
were synthesized and tested for nucleic acid delivery.
Recently, for in vivo siRNAs studies, Morrissey and colleagues reported the
inhibition of hepatitis B virus (HBV) replication in mice after systemic administration of
stable nucleic acid/lipid particles (SNALPs) that targeted HBV mRNA (HBV263M).
Dose-dependent reduction in serum HBV DNA levels was observed seven days after
three daily intravenous injections of anti-HBV siRNA SNALP at the dose of 3
mg/kg/day. Furthermore, the similar reduction in HBV replication had been maintained
for more than six weeks. Zimmerman and colleagues also encapsulated ApoB-specific
siRNAs in SNALP and injected intravenously to cynomolgus monkeys at doses of 1 or
2.5 mg/kg.146 A single siRNA injection resulted in dose-dependent silencing of ApoB
mRNA expression in the liver 48 h after administration, with gene silencing of more than
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90%. The silencing effect persisted for 11 days at the highest administered dose of 2.5
mg/kg.
In our laboratory, Zhu et al. synthesized a series of pyridinium lipids with a
heterocyclic positively charged ring linked to different types of fatty acids via ester or
amide spacers.147 These lipids showed enhanced in vitro transfection efficiency both for
plasmid and siRNAs. Transfection efficiency of these pyridionium lipids was dependent
on their hydrophobic chain lengths used. Length beyond 16 C decreased the transfection
efficiency. Increase in the aliphatic chain length of amphipathic compounds is known to
increase both the phase transition temperature and bilayer stiffness of the resulting
vesicles, and having a stiff bi-layer is unsuitable for membrane fusion.148
Transfection efficiency of cationic liposomes can also been improved by conjugation
to targeting ligands. When vitamin-A-coupled liposomes were used for delivery of
anti-gp46 siRNA dimethylnitrosamine (DMN) induced liver fibrotic rats,149 there was
prolonged survival of liver fibrotic rats in a dose dependent manner. Rats were almost
cured of liver fibrosis after administrations.
Lipidoids is another class of lipid-like material to deliver siRNAs to the liver after
systemic administration.150 The basic synthesis idea is to conjugate alkyl-acrylates or
alkyl-acrylamides to primary or secondary amines. Among the huge library of lipidoids,
98N12-5 (5-tail) was found to be optimal for in vivo delivery of siRNA compared to other
similar compound (Figure 2-4). Almost 80% of the injected dose distributed to the liver
and could induce persistent gene silencing without loss of activity following repeated
administration. The lipidoids showed high safety and efficiency in all the three animal
models, mice, rats and nonhuman primates.
Various cationic polymers including polyethyleneimine (PEI),151 poly(L-lysine)
(PLL),152 poly(amidoamine) (PAMAM) dendrimer,153 polyallylamine104 and
methacrylate/methacrylamide polymers154 have been synthesized for nucleic acid
delivery and targeting. Polymeric carriers hold promise due to their versatile chemistries,
targetability and low toxicity, but they usually have poor transfection efficiency.
Among various cationic polymers, PEI remains very popular, which has either
branched or linear form. PEI is available in a broad molecular weight ranging from less
than 1 kDa to 1.6×103 kDa, but PEI of 5 to 25 kDa are widely used for gene transfer since
high molecular weight PEI is cytotoxic to the cells.155,156 Low molecular weight PEI, by
contrast, has shown low toxicity in cell culture studies.157,158 Forrest et al. has combined
the low toxicity properties of low molecular weight PEI with the high transfection
efficiency of high molecular weight PEI by coupling low molecular weight PEIs (800
Da) together to form conjugates of 14-30 kDa using short diacrylate cross-linkers.159
These degradable polymers have similar DNA-binding properties to commercially
available 25 kDa PEI, but exhibit two- to sixteen-fold higher transfection efficiency and
are essentially nontoxic. Other strategies to reduce the toxicity and improve the stability
are synthesizing PEI with graft copolymers such as linear poly(ethylene glycol)
(PEG)160,161 or glycosylated.162 Petersen et al. have synthesized two series of
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Figure 2-4 In vivo efficacy of siRNA formulated with lipidoid 98N12 with different tail
numbers. A) Structure of N12 and 98 lipidoids; B) Transfection efficiency of different
98N12 compounds. From left to right are blank control, the 6-tail compound (98N12-6),
one isomer of the 5-tail compound, mixture of the two 5-tail isomers, another isomer of
the 5-tail compound and the 4-tail compound. Factor VII-targeting siRNA was
formulated using these compounds and administered to C57BL6 mice at 2.5 mg/kg via
single i.v. bolus injection. Twenty-four hours after administration, serum factor VII
protein levels were quantified.
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polyethylenimine-graft-poly(ethylene glycol) (PEI-g-PEG) block copolymers112 by
grafting PEI (25 kDa) to PEG (5 kDa) or a series of PEG of 550 Da to 20 kDa. The size
and morphology of resulting polyplexes were drastically changed. PEG (5 kDa)
significantly reduced the diameter of complexes from 142±59 to 61±28 nm. Copolymers
with PEG (20 kDa) yielded small, compact complexes with DNA while copolymers with
PEG (550 Da) resulted in large and diffuse structures. The zeta-potential of complexes
was reduced with increasing degree of PEG grafting if molecular weight was more than 5
kDa. Cytotoxicity was independent of PEG molecular weight but was affected by the
degree of PEG substitution. The copolymers with more than six PEG blocks formed
DNA complexes of low toxicity.
Dendrimers consist of a central core molecule as roots, from which some tree-like
branches originate in an ordered way. This unique architecture gives dendrimers various
distinctive properties. The intrinsic viscosity of dendrimer solution does not increase
linearly with mass,163 which make the application of the formulation by polymer
dendrimers much easier. Furthermore, the tree-like structure can maximize the exposed
surface area, which facilitates the interaction between dendrimers and nucleic acids. The
multiple surface groups of dendrimer allow conjugation of various targeting ligands and
other moieties to confer site-specificity and reduced toxicity.
Among various dendritic polymers, polyamidoamine (PAMAM) dendrimers have
recently attracted interest for nucleic acid delivery because of their well-defined surface
functionality, low polydispersity, good water solubility, and non-toxicity. Bielinska et al.
transfected ODN/PAMAM complexes into D5 mouse melanoma and Rat2 embryonal
fibroblast cell lines in vitro.164 The ODN/dendrimer complexes showed good silencing
effect with very little cytotoxicity compared to Lipofectamine and DEAE dextran
complexes. PAMAM dendrimers also showed strong binding affinity for siRNA
molecules.165 These nondegraded dendrimers condensed siRNAs into nanoscale particles
and protect them from enzymatic degradation, leading to gene silencing.
2.4.2.

Bioconjugation

Most cationic lipids and polymers used as transfection agents are toxic, which limits
their clinical applications. To avoid the use of polycations, Rajur et al. conjugated ODNs
to asialoglycoprotein (ASGP) using sulfosuccinimidyl 6-[3’-(pyridyldithio)
propionamido] hexanoate (sulfo-LC-SPDP).166 Direct conjugation of molecules to the
ODNs often tends to disturb the bio-ability of the ODNs, which is essential for errant
protein knocking down. Therefore, ODNs were covalently conjugated to carbohydrate
cluster for specific delivery to the hepatocytes167 and other cells.
Various carriers are also utilized for conjugation of siRNAs, including cholesterol and
VE, and PEG. The site for conjugation is crucial for siRNAs. The integrity of the
5’-terminus of the antisense strand of siRNA which is complementary to the target
mRNA and incorporated into RISC to initiate the mRNA cleavage, is crucial for initiation
of RNAi.168 Therefore, the 5’-terminus cannot be used for conjugation. Either the 3′- or
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5′-terminus of the sense strand is generally used for conjugation. Moreover, the linkages
between carriers and siRNAs should be acid or enzyme sensitive to allow complex
formation between RISC and siRNA in the cytoplasm. Since matrix metalloproteinase 1
(MMP1) is upregulated in liver fibrosis, a special six amino acid peptide, substrate for
MMP1, is used as an enzyme-sensitive linker.
Then, how to decrease the toxicity and increase the target efficiency of therapeutic
oligonucleotides? The most important strategy is the addition of targeting ligands. Many
diseases change the physiology of cells, such as special-receptor upregulation. For
example, liver fibrosis leads to the activation of hepatic stellate cells (HSCs) which
affects the liver architecture and eventually liver function. Since Mannose-6-phosphate
(M6P) receptors of HSCs get upregulated upon HSC activation, Mahato’s lab synthesized
M6P-bovine serum albumin (M6P-BSA) and conjugated the TFOs via a disulfide bond
for enhanced TFO delivery to the HSCs.169 They also checked the influence of the M6P
number per conjugate molecule on the biodistribution and hepatic uptake of
M6P-BSA-TFO.170 The molar ratio of M6P: BSA to 21 and 27 resulted in an increased
liver accumulation to 52.6% and 67.4%, respectively, whereas free TFO showed liver
accumulation about 45%.
Since the treatment of liver fibrosis may require repeated injections of TFO at high
doses, high molecular weight globular BSA (MW=67000) may not be a suitable carrier
for TFO delivery to the HSCs due to possible immune reaction. N-(2-Hydroxypropyl)
methacrylamide (HPMA) copolymer has shown great potential for delivery of small
molecular drugs.171 Therefore, Yang et al. synthesized M6P-GFLG-HPMA-GFLG-ONP
and conjugated it to TFO via GFLG linker, which is a lysosomally degradable
tetrapeptide linker and known to be cleaved by lysosomal enzymes, allowing TFO release
the cytoplasm after cellular uptake. The HPMA copolymer (MW=40000Da) conjugate of
TFOs increased the liver accumulation of the TFO to 80% of the total injected dose,
which is quite high compared to free TFO (45%) (Figure 2-5).172
PEGylation is known to significantly enhance the ODN stability against exonuclease
and reduces renal clearance compared to unmodified ODNs.173 Conjugation of PEG to
ODNs can decrease the RES clearance of administered nucleotides and prolong the
circulating time of them in blood.174,175 Zhu et al. conjugated Gal-PEG to ODNs via an
acid-labile linker. The conjugation of PEG prolonged the circulation time, but also
decreased the binding of ODNs, which were G-rich PS ODNs, to the serum protein. With
the assistance of galactose as the ligands, Gal-PEG-ODNs were delivered to the
hepatocytes (Figure 2-6). After endocytosis, the low pH in the endosome made the
β-thiopropionate linkage cleaved and ODN were released from conjugate gradually. After
conjugation with PEG, the elimination half life of ODNs increased from 34 min to 118
min.139,175
In 2004, cholesterol was covalently linked to the 3’-terminus of the sense strand of
siRNAs which contain selective stabilizing modification and were designed to target the
apolipoprotein B mRNA.176 In this case, Soutschek and his colleagues used a pyrrolidone
linkage that is not bio-cleavable. Cholesterol-siRNA conjugate (Chol-siRNA) showed not
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Figure 2-5 Delivery efficiency of M6P-GFLG-HPMA-GFLG-32P-TFO. A) Structure of
M6P-GFLG-HPMA-GFLG-32P-TFO. B) Enzymatic dissociation of 32P-TFO from
M6P-GFLG-HPMA-GFLG-32P-TFO by papain. C) Intrahepatic distribution of
M6P-GFLG-HPMA-GFLG-32P-TFO in fibrotic rats. Cells were isolated at 30 min
post-injection of M6P-GFLG-HPMA-GFLG-32P-TFO, HPMA-GFLG-32P-TFO or
32
P-TFO at dose of 0.2 mg TFO/kg of body weight. The associated radioactivity was
measured. The contribution of each liver cell type was exposed as percentage of total
liver uptake. Results are expressed as the mean±SD (n=3).
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Figure 2-6 Delivery efficiency of Gal-PEG-33P-ODN. A) Structure of
Gal-PEG-33P-ODN. B) Intrahepatic distribution of 33P-ODN and Gal-PEG-33P-ODNs
after systemic administration in rats. Liver cells were isolated at 30 min post-injection of
33
P-ODN or Gal-PEG-33P-ODN by liver perfusion. The associated radioactivity was
measured. Results are expressed as the mean±SD (n=4).
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only significantly higher cellular uptake but also enhanced gene silencing compared to
the un-conjugated siRNA. Following intravenous injection into mice Chol-siRNAs are
taken up by several tissues, including the liver, jejunum, heart, kidneys, lungs and fat
tissue. Significant silencing of apoliporotein B (apoB) gene was observed at mRNA and
protein levels in the liver and the jejunum. Furthermore, this reduction resulted in a
decreased plasma apoB protein level and consequent decreased level of blood cholesterol.
However, the siRNA dose (50 mg/kg) in animal experiments is too high for clinical
applications. Cholesterol conjugate was also applied to deliver ODNs.177 Cheng et al.
conjugated cholesterol to ODNs by a disulfide bond and showed high cellular uptake,
because the cholesterol conjugation increases hydrophobicity and cellular association.
In addition to Chol-siRNA conjugate, a series of siRNAs have been conjugated with
lipid like carriers, including α-tocopherol (vitamin E), steroid and lipids.146,178,179
Lipoproteins may facilitate the cellular uptake of these conjugates. A critical factor
determining the affinity of fatty acid–conjugated siRNAs to lipoprotein particles is the
length of the alkyl chain, a major determinant of lipophilicity.146 So far, only lipophilic
siRNAs showed lipid-metabolism-related-gene silencing, Apo B. Therefore, here rises a
question. Does the lipid-like-molecule-siRNA conjugate only silence lipid metabolism
related genes? More research is needed to clarify this question.
2.5.

Pharmacokinetics and Biodistribution

ODNs are accumulated in most peripheral tissues after systemic administration,
particularly kidney and liver, but little distribution to the central nervous system. The
biphasic plasma half-lives of ODNs are several minutes, while phosphorothioate ODNs
showed distribution half-lives ranging from many minutes to hours.180-183 The major route
of ODN elimination is the kidneys, even though phosphorothioate ODNs efficiently bind
to plasma proteins. This highly protein bound ODNs usually have a longer circulation
time than would be expected of a simple phosphodiester ODNs.
Pharmacokinetics profiles of various chemically modified ODNs, especially for the
2’-MEO AS-ODNs, has been determined and found to be similar to those of
phosphorothioate ODNs.182,184 The in vivo fate of 2’-MEO modified ODNs were also
studied and compared in rodents, monkeys and humans.185 In this study, plasma
pharmacokinetics of 2'-MOE partially modified AS-ODNs was similar in mice, rats,
dogs, monkeys, and humans. After intravenous administration, plasma concentration-time
profiles are polyphasic as characterized by a rapid distribution phase (half-lives in hours),
and followed by slower elimination phase with half-lives, but longer in the study of
humans, from 5 to 31 days. The plasma clearance of monkeys and humans was similar,
about one tenth of the mice. Allometric comparison of clearance estimated at similar
doses across all species was done. From mouse to man, there showed a linear relationship
based on body weight alone.
The pharmacokinetic profile of LNA ODNs in rodents is similar to that of PS ODNs,
except that there was high urinary excretion of intact LNA ODNs compared to PS
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ODNs.186 This is possibly due to extensive binding of PS ODNs to serum proteins
leading to poor renal clearance, while LNA ODNs do not bind to serum proteins and thus
are easily filtered out of the kidney.187 Even though this property of LNA ODNs reduces
non-specific interaction, it also makes the clearance of LNA ODNs faster. Furthermore,
chimeric DNA/LNA ODNs are more stable than isosequential PS ODNs, which have
half-lives of more than 10 hours. Peptide nucleic acids (PNAs) did not show any increase
in the distribution half-life.188
Native siRNAs had an elimination half-life of 6 min only,176 shorter than that of
ODNs. The shorter half-life may be partly due to the higher instability of siRNAs
compared to ODNs. The biodistribution of radiolabeled siRNAs in mice showed an
accumulation primarily in the liver and kidneys, which is similar to that of ODNs.189
They were also detected in the heart, spleen and lung. Actually, the high renal uptake
facilitates the target delivery of siRNA to this tissue.190
Conjugation of cholesterol,176 tocopherol,179 or other lipid moieties,191 enhances the
binding of ODNs to serum lipoproteins and/or albumin. This results in enhanced
circulation time and, more importantly, hepatic uptake via the low-density lipoprotein
receptor. Other conjugation with macro molecular materials also changed the
pharmacokinetic profiles of ODNs and siRNAs.
Bioimaging allows real time analysis of ODN and siRNA.192 Micro SPECT or other
radioimaging techniques can provide detailed information on the distribution of ODNs
and siRNAs. However, there are several underlying issues. One is how to separate the
label from the molecule being studied, which is a common problem for almost all
radiolabeling methods. More importantly, there may be a discrepancy between physical
biodistribution and functional biodistribution of ODNs and siRNAs. For example, in a
study, LNA ODNs were designed to cause an alteration in mRNA splicing. The major
effects were observed in liver, colon, and small intestine; however the major site of
accumulation of the LNA was the kidney.193 Therefore, one should be carefully in
predicting pharmacological effects when using radiolabeling data although it represents
the pharmacokinetics and biodistribution of gene drugs.
2.6.

Clinical Trials

Several companies initiated clinical trials of ODNs in the early 1990s. The most
intensively studied ODNs are phosphorothioate ODNs, which are well absorbed and
distributed widely to most peripheral tissues, but poorly distributed to the brain.194 Other
modified ODNs also proceeded to clinical trials. Table 2-1 shows a universal
applicability of antisense strategies to treat a broad range of diseases including viral
infections, cancer and inflammatory diseases. In 1998, the first antisense drug Vitravene
(Fomivirsen) was approved by the FDA for treating cytomegalovirus (CMV) induced
retinitis in patients with AIDS.58 However, it is the only ODN drug approved by the FDA
so far, even though several PS ODNs have been in Phase III trials, such as Affinitac (ISIS
3521) and Alicaforsen (ISIS 2302). However, Alicaforsen failed to show significant
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Table 2-1 Current clinical trials for oligonucleotides and siRNA.
Products

Nucleic acids

Disease

Status

Genasense

AS-ODN

Cancer

Phase II/III

AP 12009

AS-ODN

Astrocytoma, glioblastoma

Phase IIb/III

AEG35156

AS-ODN

Cancer

Phase I/II

OGX-427

AS-ODN

Bladder neoplasm

Phase I

SPC2996

AS-ODN

Chronic lymphocytic leukaemia

Phase I/II

G4460

AS-ODN

Chronic myelogenous leukemia

Phase II

Alicaforsen (ISIS)

AS-ODN

Crohn's disease

Phase III

Angiozyme

Ribozyme

Matastatic colorectal cancer

Phase II

Herzyme

Ribozyme

Cancer

Phase I

Angiozyme

Aptamer

Cancer

Phase II

Herzyme

Aptamer

Cancer

Phase I

AGN211745

siRNA

AMD

Phase II

DOTAP:Chol-fus1

siRNA

Non-small-cell lung cancer

Phase I

I5NP

siRNA

AKI

Phase I

Cand5

siRNA

Diabetic macular edema

Phase II

AVI-4658 (PMO)

Other

Becker's muscular dystrophy

Phase I/II
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efficacy in a Phase III study for treating Crohn’s disease195 and is now being investigated
in a restructured Phase III trial. Many other ODNs have reached the stage of clinical
trials. ISIS 104838 against tumor necrosis factor-α (TNF-α) is being tested for treating
inflammatory diseases such as rheumatoid arthritis and psoriasis.184
A retrovirally expressed ribozyme that targets the HIV tat and rev exons, entered
clinical testing in late 1996 and is currently in phase II testing for patients with
AIDS-related lymphoma. Ribozyme Pharmaceuticals (Boulder, CO, USA) performs
clinical trials on ANGIOZYME (Table 2-1). ANGIOZYME is a stabilized hammerhead
ribozyme that is targeted against the vascular endothelial growth factor (VEGF) receptor.
It is designed to reduce tumor growth by inhibiting angiogenesis. The third,
HEPTAZYME, a ribozyme targeting the 5′-untranslated region (5′-UTR) of the hepatitis
C virus (HCV) RNA genome, has recently completed a phase I/II clinical trial in patients
with chronic hepatitis C.
Acuity Pharmaceuticals performed the first clinical trial for siRNA therapy to
Age-related Macular Degeneration (AMD) in 2004. After the successful Phase II trials
reported that all doses were well tolerated without adverse systemic effects, testing has
now moved into Phase III trials. The siRNA treatment for AMD was also performed by
Allergan to Phase II trial. The trials related to various diseases, such as solid tumor cancer
and acute kidney injury (AKI), are in good progress. The active trials so far are listed in
the Table 2-1. However, another interesting report about a Phase II clinical trial by
OPKO Health on the treatment of diabetic macular edema, which is swelling of the retina
in diabetes mellitus due to leakage of fluid from blood vessels within the macula. It was
shown that anti-VEGF siRNA efficacy in the eye is not due to specific gene silencing but
because of nonspecific stimulation of the TLR3 pathway,196 which can reduce
angiogenesis, but the therapeutic effects observed in other applications of siRNA are still
encouraging.
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CHAPTER 3. HPMA POLYMER-BASED SITE-SPECIFIC DELIVERY OF
OLIGONUCLEOTIDES TO HEPATIC STELLATE CELLS
3.1.

Introduction

Chronic liver injury and inflammation of hepatocytes may lead to overproduction of
type I collagen and other extracellular matrix (ECM) by hepatic stellate cells (HSCs),
which are distributed throughout the hepatic lobule and serve as the principle fibrogenic
cells.197 Activation of HSCs affects liver architecture and eventually liver function.198
Until now, no pharmaceutical intervention is available to treat this fibrotic disease.199 The
application of most antifibrotic drugs has not been successful, partly because these drugs
do not accumulate in the target liver cells or cause serious side effects elsewhere in the
body. Alteration of the pharmacokinetic profiles of antifibrotic drugs by means of drug
targeting represents a promising approach in the development of an effective antifibrotic
drug.200
Direct inhibition of type I collagen synthesis by HSCs is a potential target to prevent
liver fibrosis. Earlier, we developed a triplex-forming oligonucleotide (TFO), which can
form a triplex with the target sequence (C1) located in the rat α1(I) collagen gene
promoter and inhibit the transcription of this gene.34 Mannose-6-phosphate/insulin like
growth factor II (M6P/IGFII) receptor is expressed on HSCs, and its expression is
up-regulated upon activation of these cells due to acute or chronic liver injury.201
Therefore, this TFO molecule is a potential candidate for treating liver fibrosis.
Following systemic administration, oligonucleotides (ODNs) widely distribute
throughout the body with higher accumulation in the liver and kidney.202-204 We
determined the in vivo distribution of the TFO molecules in normal and fibrotic rats.38
Almost 45% of the injected dose was accumulated in the liver at 30 min post tail vein
injection in normal rats, but only 35% of injected dose in fibrotic rats. Since the
intrahepatic distribution of the TFO was non-specific, we synthesized
mannose-6-phosphate-bovine serum albumin (M6P-BSA) and conjugated to TFO via a
disulfide bond for its enhanced delivery to HSCs.41 Since the treatment of liver fibrosis
may require repeated injections of TFO at high dose, high molecular weight globular
BSA (66430 Da) may not be a suitable carrier for TFO delivery to the HSCs due to
possible immune reaction. N-(2-hydroxypropyl) methacrylamide (HPMA) copolymer has
shown great potential for delivery of small molecular drugs.205-207 Although HPMA has
also been used for oligonucleotide delivery, no targeting ligands were used for its sitespecific delivery to target cells and its biodistribution and uptake by different liver cell
types was not determined after systemic administration. Even though biodistribution of
oligonucleotides to the liver has been reported before,208-210 the authors did not determine
oligonucleotides delivery to HSCs, which are the principal liver fibrotic cells.
In this chapter, we conjugated M6P to HPMA and then to TFO via GFLG linker,
which is known to be cleaved by lysosomal enzymes.208 Following bioconjugation and
purification, we determined i) whether TFO can be released from the conjugate after
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cellular uptake, ii) biodistribution of M6P-GFLG-HPMA-GFLG-32P-TFO at the whole
body, organ (liver) and cellular (liver cells) levels after tail vein injection into rats.
3.2.

Experimental Procedures

3.2.1.

Materials

Poly (HPMA-co-GFLG-ONP) was purchased from Varian Inc (Amherst, MA).
p-Nitrophenyl-α-D-mannopyranoside (pnpM), phosphorous oxide chloride, palladium (10
wt % on activated carbon), papain, methylene blue, N,N'-diisopropylethylamine,
Histodenz (nycodenz) and pronase were purchased from Sigma-Aldrich (St. Louis, MO).
Sephadex G75 (superfine) was procured from Pharmacia Fine Chemicals AB (Uppsala,
Sweden). Dialysis tubing (molecular weight cutoff of 1000 Da) was purchased from
Spectrum Laboratories, Inc. (Houston, TX). BioGel P-6 DG Gel was from Bio-Rad
Laboratories (Hercules, CA). [γ-32P]-dATP was purchased from MP Biomedicals (Irvine,
CA), and T4 polynucleotide kinase was from New England Biolabs (Beverly, MA).
Soluene-350 (tissue solubilizer) and HionicFluor (scintillation fluid) were purchased from
Perkin-Elmer (Boston, MA). Hydrogen peroxide (H2O2) was purchased from Fisher
Chemical (Fair Lawn, NJ). Heparin was purchased from American Pharmaceutical
Partners, Inc. (Los Angeles, CA). Ca2+/Mg2+-free Hank’s balanced salt solution (Cellgro)
was purchased from MediaTech (Washington, DC), and type IV collagenase was from
Worthington Biochemical Corporation (Lakewood, NJ). Isoflurane was purchased from
Baxter Pharmaceutical Products, Inc. (Deerfield, IL). TFO, which was a 25 mer
antiparallel fully phosphorothioate ODN
(3’-GAGGGGGGAGGAGGGAAAGGAAGGG-5’) targeting rat α1 (I) collagen gene
promoter, and TFO-3’-NH2 were synthesized by Invitrogen (Carlsbad, CA). All solvents
and chemicals used in this study were used as available without further purification.
3.2.2.

Animals

Male Sprague-Dawley rats weighing 130-150 g were purchased from Harlan Co. (San
Diego, CA) and were housed individually under the controlled light (12/12 h) and
temperature conditions and had free access to food and water.
3.2.3.

Synthesis of p-Isothiocyanatophenyl-6-phospho-α-D-mannopyranoside

p-nitrophenyl-α-D-mannopyranoside (pnpM) (3 g, 10 mmol) was dissolved in
pyridine (4 mL, 50 mmol), acetonitrile (10 mL, 190 mmol), and water (0.4 mL, 22
mmol). To this solution, phosphorus oxide chloride (4 mL, 44 mmol) was added, and the
mixture was stirred for 1 h at 0°C. The reaction mixture was poured onto 120 g of ice. pH
was adjusted to 7.0 by slowly adding 2.5 M NaOH on ice and the neutralized solution
was evaporated to dryness. The solid material was dissolved in 150 mL water. The
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solution was concentrated under reduced pressure at 35°C in a rotary evaporator to a final
volume of 3-4 mL. The concentrated solution was kept at 4°C overnight for
crystallization and crystals was filtered and washed with 10 mL absolute ethanol. The
compound was recrystallized from a 10 mL water/100 mL ethanol mixture, redissolved in
water, and lyophilized to give p-nitrophenyl-6-phospho-α-D-mannopyranoside
(pnpM6P). pnpM6P (1 mmol) was dissolved in 20 mL of a 4:1 (v/v) methanol-water
mixture. To this solution, 30 mg of 10% palladium on activated carbon was added. The
suspension was stirred under hydrogen (1 atm) at room temperature for two hours. After
filtration, the methanolic solution was evaporated under reduced pressure at 40°C and
lyophilized to give p-aminophenyl-6-phospho-α-D-mannopyranoside (papM6P).
3.2.4.

Synthesis of M6P-GFLG-HPMA-GFLG-TFO Conjugate

The synthesis scheme of M6P-GFLG-HPMA-GFLG-TFO is shown in Figure 3-1.
Poly(HPMA-co-MA-GFLG-ONP) (5 mg, 2.25 μmol of ONP) and TFO-NH2 (0.8 mg, 0.1
μmol) were dissolved in anhydrous dimethyl sulfoxide (DMSO, 100 μL). Then,
N,N'-diisopropylethylamine (DIPEA, 3 μL) was added and reacted overnight at room
temperature. papM6P (3 mg, 10 µmol) was dissolved in H2O (100 µL) and dimethyl
sulfoxide (DMSO) (200 µL) mixture, and DIPEA (3 μL) was added. Reaction was
allowed to proceed for 24 h at room temperature. The reaction mixture was dialyzed
against H2O for a day, purified on a Sephadex G75 Gel column with pure water,
freeze-dried, kept in -80°C and resuspended in 0.9% saline before use.
3.2.5.

In Vitro Characterization

The purity of intermediate and final products were monitored by reverse phase-high
performance liquid chromatography (RP-HPLC), which was carried on Altech Prosphere
C18 column (250 mm×4.6 mm×5 µm) by Waters Breeze HPLC/GPC system (Waters,
Milford, MA) with detection at 260 nm using a gradient of 40% to 100% acetonitrile in
0.1 M triethylammonium acetate (TEAA) at a flow rate of 1 mL/min at room
temperature. M6P-GFLG-HPMA-GFLG-32P-TFO was analyzed by 20% polyacrylamide
gel electrophoresis (PAGE) at 80 V for 2 h. The gels were stained with methylene blue or
autoradiographed.
The molecular weight of M6P-GFLG-HPMA-GFLG-TFO was also measured by gel
permeation chromatography (GPC), which was carried on Waters Ultrahydrogel 250
column (7.8×300 mm) by Waters Breeze HPLC/GPC system (Waters, Milford, MA) with
Waters 2414 Refractive Index detector and mobile phase containing 0.02% sodium azide
(NaN3) in HPLC water, at a flow rate of 0.5 mL/min. Polyethylene oxide (PEO) of
different molecular weights (MW=20000, 31380, 50450 and 71700 Da) was used as
standards for calibration. HPMA-co-MA-ONP was used as a positive control and the
molecular weight of M6P-GFLG-HPMA-GFLG-TFO was determined.
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Figure 3-1 Synthesis scheme of M6P-GFLG-HPMA-GFLG-TFO.
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3.2.6.

Determination of Sugar Content

Sugar content was determined by the resorcinol-sulfuric acid method.211 Two
hundred microliters of 6 mg/mL resorcinol and 1 mL of 75% sulfuric acid were added to
M6P-GFLG-HPMA-GFLG-TFO solution containing 5-100 nmol of sugar in 200 μL. The
mixtures were vortexed and heated at 90°C for 30 min and subsequently placed in a cold
water bath for 30 min in the dark. The optical density of the solution was measured at 430
nm. PnpM was used to generate the standard curve to calculate the number of M6P per
conjugate.
3.2.7. In Vitro Enzymatic Dissociation and Triplex Formation of
M6P-GFLG-HPMA-GFLG-32P-TFO
To determine whether TFO will be dissociated from M6P-GFLG-HPMA-GFLG-TFO
conjugate after cellular uptake, papain (10 μM), glutathione (GSH, 250 mM) and
M6P-GFLG-HPMA-GFLG-32P-TFO (TFO concentration 100 μM) were incubated
together at 37°C in 0.1 M phosphate buffer containing 1 mM EDTA (PE buffer, total
volume of 300 μL). At 1, 2, 8 and 24 h, 100 μL of the sample was collected and analyzed
by 20% PAGE at 80 V for 2 h, followed by autoradiography.
To determine whether the TFO released from M6P-GFLG-HPMA-GFLG-TFO can
still form triplex, the target duplex DNA was prepared by equal amounts of ODNs, T1:
5’-GAGGGGGGAGGAGGGAAAGGAAGGGAAAGG-3’ and T2:
5’-CCTTTCCCTTCCTTTCCCTCCTCCCCCCTC-3’, being heated at 80°C for 5 min in
0.25 M NaCl, followed by slow cooling to room temperature. Triplex formation was
initiated by the mixing of 3 µL of 3×buffer (135 mM Tris-acetate, pH 7.0, 30 mM
MgCl2), 3.5µL of duplex DNA (~3 µg), and 2.5 µL of the released 32P-TFO (~1×105
cpm). The reaction mixture was incubated at 37°C for another 24 h. Two microliters of a
50% glycerol solution containing bromophenol blue was added, and samples were
directly loaded onto 15% native polyacrylamide gel, prepared in a buffer containing 50
mM Tris-acetate, pH 7.0, and 10 mM MgCl2. Electrophoresis was performed at 8 V/cm at
4°C in the buffer containing 89 mM Tris-Borate and 20 mM MgCl2. The gel was
autoradiographed at 4°C overnight.
3.2.8.

Transfection of TFO and M6P-GFLG-HPMA-GFLG-TFO

Immortalized rat hepatic stellate cells (HSC-T6) kindly provided by Dr Scott
Friedman of Mount Sinai School of Medicine, New York were seeded in 6-well plates at
a density of 11×105 cells 12 h until 50% confluence in DMEM containing 10% of FBS.
The growth medium was replaced with a pre-warmed serum-free DMEM medium. TFO
was mixed with pyridinium cationic liposome at 3/1 (+/-) charge ratio and then used for
transfection at the dose of 5 µg TFO/well. For the conjugate,
M6P-GFLG-HPMA-GFLG-TFO was dissolved in saline and applied to the cells at the
dose of 5 µg TFO. Negative control wells were added the same amount
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M6P-GFLG-HPMA. Six hours later 10% FBS was added to each well, and then the cells
were cultured for additional 72 h. Following transfection, the cell culture medium was
concentrated using Microcon YM-30 columns (Millipore) to retain proteins of >30 kDa.
The concentrated medium was lysed using 2×Laemmli sodium dodecyl sulfate (SDS)
sample buffer containing 100 mM Tris, pH 6.8, 200 mM dithiothreitol (DTT), 4% SDS,
20% glycerol and 0.2% bromophenol blue. To detect β-actin which was used as an
intrinsic reference of sample loading, the cells were lysed directly with 1×Laemmli SDS
sample buffer. The lysate samples were boiled at 100°C for 5 min and subjected to 4% to
15% SDS-polyacrylamide (SDS-PAGE) gel electrophoresis and subsequently transferred
to Immobilon polyvinylidene fluoride (PVDF) membrane (Millipore). After blocking
with 5% non fat dried milk in 1×PBST containing 0.05% Tween-20 in PBS for 1h at
room temperature, the membrane was incubated with goat anti-rat type I collagen and
anti-actin primary antibodies (Santa Cruz) for 16 h at 4°C. The membranes were then
incubated with horseradish peroxidase (HRP)-conjugated donkey anti-goat secondary
antibody (Santa Cruz) for 1 h at room temperature. Target proteins were detected by
enhanced chemiluminescence (ECL, GE Healthcare).
3.2.9.

Biodistribution of M6P-GFLG-HPMA-GFLG-32P-TFO

The animal protocol was approved by the Animal Care and Use Committee (ACUC),
Department of Comparative Medicine, University of Tennessee Health Science Center,
Memphis, TN 38163. Male Sprague-Dawley rats weighing 130-150 g were used in this
study and three rats were used for each time point. Unlabeled and
M6P-GFLG-HPMA-GFLG-32P-TFO were mixed in saline to give a final concentration of
1 mg/mL and specific activity of 1×106 cpm/mL. Rats were anesthetized by inhalation of
isoflurane, and M6P-GFLG-HPMA-GFLG-32P-TFO was injected via tail vein at a dose
of 0.2 mg/kg body weight. At 2.5, 5, 15, 30, 60 and 90 min postinjection, 0.5 mL blood
was collected by cardiac puncture in heparinized tubes, and urine was collected directly
from the bladder using a 0.26 gauge needle syringe. The animals were then sacrificed and
major tissues (liver, kidney, spleen, heart, and lung) were collected, washed, blotted dry,
weighed, and stored at -80°C. The radioactivity of the urine sample was counted directly
after adding 10 mL of scintillation fluid. One hundred and fifty microliters of plasma and
150 mg of each tissue were incubated with 2 mL tissue solubilizer for 3 h at 55°C and
overnight at 37°C in a shaker. Four hundred microliters of H2O2 was added and incubated
at 55°C for another 30 min. Ten milliliters of scintillation fluid was added to each sample
and the radioactivity was counted using a liquid scintillation counter.
3.2.10. Determination of Pharmacokinetic Profiles
Plasma data were analyzed using WinNonlin Professional (version 5.2, Pharsight
Corporation, Mountain View, CA). M6P-GFLG-HPMA-GFLG-32P-TFO plasma
concentration data versus time were fitted into a two-compartment model. The tissue
uptake clearance and index were calculated using the values up to 90 min after injection,
assuming that TFOs were fairly stable within this period.
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3.2.11. Induction of Liver Fibrosis
Dimethylnitrosamine (DMN) induced liver fibrosis in rats has been shown to have a
pathology closely resembling that of human cirrhosis. Male Sprague-Dawley rats
weighing 130-150 g (Harlan Co., San Diego, CA) were housed individually under
controlled light (12/12 h) and temperature conditions and had free access to food and
water. To induce liver fibrosis, dimethyl nitrosamine (DMN) was injected
intraperitoneally into rats at a dose of 10 mg/kg of body weight in saline. Injections were
given in the afternoons of the first three consecutive days of each week for 4 weeks.
3.2.12. Competition in Hepatic Uptake of M6P-BSA-33P-TFO
Two minutes before the injection of M6P-GFLG-HPMA-GFLG-32P-TFO at a TFO
dose of 0.2 mg/kg (specific activity: 1×106 cpm/mL), liver fibrotic rats received 10 mg/kg
of (M6P)16-GFLG-HPMA. At 30 min postinjection, blood and other major organs were
harvested as described above for radioactivity measurement.
3.2.13. Isolated Rat Liver Perfusion
To determine the effect of M6P on the hepatic uptake of TFOs by hepatocytes, HSCs,
Kupffer and endothelial cells, the livers of normal and fibrotic rats were perfused in situ
after intravenous administration of M6P-GFLG-HPMA-GFLG-32P-TFO,
HPMA-GFLG-32P-TFO or 32P-TFO at the dose of 0.2 mg of TFO/kg body weight. At 30
min post-administration, rats (200-250 g) were anesthetized by inhalation of isoflurane,
100 U heparin was injected via the tail vein, the abdomen was opened, and the portal vein
was cannulated with PE-60 polyethylene tube. The liver was first perfused with 2 mL of
diluted heparin solution at 20 units/mL to avoid blood clogs in the liver. The liver was
pre-perfused in situ with 200 mL of Ca2+/Mg2+-free Hank’s balanced salt solution at a
flow rate of 15 mL/min and was then perfused with Hank’s balanced salt solution
containing 0.05% type IV collagenase and 0.1% pronase for additional 250 mL at a flow
rate of 10 mL/min. All the perfusion solutions were incubated at 37°C. After perfusion,
different liver cell types were separated and radioactivity was measured as described by
Cheng et al.38 The contributions of various cell types to the total liver accumulation were
calculated as the percentage of total hepatic uptake.
3.2.14. Statistical Analysis
Data were expressed as the mean ± standard deviation (SD). The difference between
any two groups was determined by ANOVA. p<0.05 was considered statistically
significant.
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3.3.

RESULTS

3.3.1.

Synthesis and In Vitro Characterization of M6P-GFLG-HPMA-GFLG-32P-TFO

The synthesis scheme of M6P-GFLG-HPMA-GFLG-TFO is shown in Figure 3-1.
p-nitrophenyl-α-D-mannopyranoside (pnpM) was phosphorylated to give p-nitrophenyl
6-phospho-α-D-mannopyranoside (pnpM6P). This intermediate product was
characterized by electron spray ionization-mass spectrum (ES-MS) as described before
(data not shown).41 RP-HPLC was used to monitor the purity of the intermediate and final
products. From the RP-HPLC chromatograms of M6P, TFO, HPMA and
M6P-GFLG-HPMA-GFLG-TFO (Figure 3-2), almost all free M6P and TFOs were
removed from the conjugate after purification. M6P-GFLG-HPMA-GFLG- TFO was
separated from free TFO using G75 column. As shown in Figure 3-2,
M6P-GFLG-HPMA-GFLG-32P-TFO conjugate was eluted earlier than 32P-TFO. PAGE
analysis of M6P-GFLG-HPMA-GFLG-32P-TFO was also confirmed successful
conjugation and purity of the conjugate. As shown in Figure 3-3, unlike free TFO, there
was no band shift for the conjugate. We also measured the molecular weight of
M6P-GFLG-HPMA-GFLG-TFO by gel permeation chromatography (GPC) and
determined molecular weight was 51418 Da, which matched well with the calculated
molecular weight by calculation of 51362 Da. Although poly(HPMA-co-GFLG-ONP)
contains 8.33 mole % of ONP, the average number of M6P per conjugate was determined
to be 14.67.
3.3.2. In Vitro Enzymatic Dissociation and Triplex Formation of
M6P-GFLG-HPMA-GFLG-32P-TFO
To determine whether TFO can be dissociated from
M6P-GFLG-HPMA-GFLG-32P-TFO endocytosis in the lysosome, the radioactivity was
measured after polyacrylamide gel electrophoresis and autoradiography at 1, 2, 8 and 24
h post-incubation of the conjugate with papain at 37°C.212 The band of the conjugate
gradually disappeared along the incubation time (Figure 3-4). In contrast, this conjugate
resulted in no band shift in the absence of papain.
GFLG linker is expected to be stable in the bloodstream but cleaved inside the cells
by enzymatic dissociation by lysosomal enzymes.213 The release from the
M6P-GFLG-HPMA-GFLG-TFO conjugate will enable TFO to traffic to the nucleus for
triplex formation with genomic DNA. There should be no adverse effect on triplex
formation due to this conjugation and cleavage. The M6P-GFLG-HPMA-GFLG-TFO
conjugate was treated with papain and incubated with the target duplex DNA for another
24 h, and the sample was then applied on a 15% native polyacrylamide gel at 4°C.
Following electrophoresis, the gel was autoradiographed at 4°C overnight. As shown in
Figure 3-5, there was triplex formation observed with target duplex DNA not only for
free TFO (lane 2) but also for released TFO (lane 6), which was at a molar ratio of 200
between duplex DNA and TFO.
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Figure 3-2 HPLC chromatography of M6P-GFLG-HPMA-GFLG-TFO conjugate. There
is a new peak for conjugate different from the reactants, such as M6P,
poly(HPMA-co-GFLG-ONP), and TFO.
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Figure 3-3 Polyacrylamide gel electrophoresis (PAGE) of
M6P-GFLG-HPMA-GFLG-TFO. Methylene blue staining was on the left and
autoradiography was on the right. There was no band shift for the conjugate.
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Figure 3-4 TFO dissociation from M6P-GFLG-HPMA-GFLG-TFO by papain. The
conjugate was treated with papain for 1, 2, 8, and 24 h, followed by polyacrylamide gel
electrophoresis (PAGE) and autoradiography. The conjugate not treated with papain was
used as a control.
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Figure 3-5 Triplex formation with target duplex DNA after release from
M6P-GFLG-HPMA-GFLG-32P-TFO conjugate. Samples were applied on 15% native
PAGE at 4°C in 89 mM Tris-borate buffer, containing MgCl2 (20 mM) for 4 h. Lane 1:
32
P-TFO. Lane 2: duplex DNA/32PTFO (200:1) incubated for 24 h. Lane 3: Duplex
DNA/32P-TFO (200: 1) and papain incubated for 24 h. Lane 4:
M6P-GFLG-HPMA-GFLG-32P-TFO. Lane 5: M6P-GFLG-HPMA-GFLG-32P-TFO
incubated with papain for 24 h at 37°C. Lane 6: duplex
DNA/M6P-GFLG-HPMA-GFLG-32P-TFO (200:1) incubated for 24 h at 37°C with
papain.
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3.3.3. Inhibition of Collagen Type I Gene Expression by
M6P-GFLG-HPMA-GFLG-TFO
To confirm that TFO conjugation to M6P-HPMA does not adversely affect its ability
to inhibit the transcription of type I collagen, we transfected HSC-T6 cells with TFO and
M6P-GFLG-HPMA-GFLG-TFO. Compared to the control cells treated with M6P-HPMA
(lane 1), type I collagen gene expression by the cells treated with
M6P-GFLG-HPMA-GFLG-TFO (lane 2) decreased as efficiently as that by the cells
treated with the TFO (lane 3) (Figure 3-6). Since the molecular weight of collagen type 1
precursor is 130-140 kDa and that of mature collage type I is 70-90 Da, there were 2
bands for collagen.
3.3.4.

Biodistribution of M6P-GFLG-HPMA-GFLG-TFO

Following synthesis and purification of M6P-GFLG-HPMA-GFLG-32P-TFO, we
determined the biodistribution of this conjugate at 2.5, 5, 15, 30, 60 and 90 min post
injection into the rat tail vein. Figure 3-7 shows the time course of radioactivity in the
plasma, urine, liver, kidney, lung, and heart. Conjugation with
M6P-GFLG-HPMA-GFLG -ONP significantly increased the accumulation of 32P-TFO in
the liver, as compared to our previously reported biodistribution data of free 32P-TFO.38
Almost 70% of the conjugate accumulated in the liver at 30 min postinjection and 60% at
60 min postinjection (Figure 3-7), however, only 40% of free 32P-TFO was in the liver at
30 min.38 Figure 3-8 shows the tissue concentration of
M6P-GFLG-HPMA-GFLG-32P-TFO in the plasma (µg/mL) and tissues (µg/g) after tail
vein injection into rats. The conjugation with M6P-GFLG-HPMA-GFLG-ONP
significantly increased the accumulation of radioactivity in the liver and was the highest
at 30 min post-injection. The conjugate concentration was high not only in the liver, but
also in the spleen and kidney. However, radioactivity in the kidney rapidly decreased
with time. We also included the tissue accumulation data of 32P-TFO at 30 min
post-injection for comparison.
We also calculated the pharmacokinetic profiles using two-compartment model by
plotting plasma concentration versus time, analyzing data using WinNonlin professional
software. As shown in Figure 3-9, there was good fit between observed and predicted
results. Plasma elimination of M6P-GFLG-HPMA-GFLG-32P-TFO was biphasic with a
distribution half-life (T1/2α) of 12.37 min and elimination half-life (T1/2β) of 2886.48
min. Figure 3-9 also summarizes the pharmacokinetic parameters such as AUC, Vd and
CL. Consistent with the rapid clearance (0.059 mL/min),
M6P-GFLG-HPMA-GFLG-32P-TFO had a large Vd of 231.33 mL, Table 3-1
summarizes the AUC, tissue uptake rate index, and organ clearance for representative
organs at 90 min after systemic administration of 32P-TFO and
M6P-GFLG-HPMA-GFLG-32P-TFO in rats. The liver uptake rate indices and clearance
of the conjugate were significantly higher than those of 32P-TFO: 2176±58 versus 376±38
μL/h/g and 11531±308 versus 2218±206 µL/h, respectively. The tissue uptake rate
indices and organ clearances of heart, kidney, and lung were significantly higher than
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Figure 3-6 Inhibition of collagen gene expression. Transfection of HSC-T6 cells with
TFO (lane 3) and M6P-GFLG-HPMA-GFLG-TFO (lane 2) inhibited collagen gene
expression compared to the control group (lane 1).
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Figure 3-7 Biodistribution of M6P-GFLG-HPMA-GFLG-32P-TFO and free 32P-TFO after
tail vein injection into rats at a dose of 0.2 mg TFO/kg of body weight.
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Figure 3-8 Concentration time profiles of radioactivity in different organs and the plasma
after tail vein injection of M6P-GFLG-HPMA-GFLG-32P-TFO and free 32P-TFO into rats
at a dose of 0.2 mg TFO/kg of body weight.
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Figure 3-9 Pharmacokinetic profiles of M6P-GFLG-HPMA-GFLG-32P-TFO at 30 min
after post vein injection. Plasma data was analyzed using a two-compartment model with
WinNonlin Enterprise (v 5.2) software. AUC: area under the curve; CL: clearance; Vd:
volume of distribution.
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Table 3-1 Tissue uptake rate index and clearance of 32P-TFO and M6P-GFLG-HPMA-GFLG-32P-TFO after systemic administration
into rats.

Sample

AUC90
(μg/min
/mL)

Tissue uptake rate index (μL/h/g)
Liver

Kidney

Conjugate

67.11

2176±58 1033±391

TFO

95.15

376±38

235±29

Heart
578±31
49±3

Organ clearance (μL/h)

Spleen

Lung

1146±68 450±112
205±10

55±9
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Liver

Kidney

Heart

Spleen

Lung

11531±308 1137±430 318±17 436±26 383±26
2218±206

241±41

23±2

83±7

42±8

those of 32P-TFO, possibly due to increase in vivo stability of TFO upon conjugation with
M6P-GFLG-HPMA-GFLG-ONP.
3.3.5.

Effect of Fibrosis on Biodistribution

We recently reported significant decrease in the hepatic uptake of 33P-TFO when
injected into fibrotic rats.38 To make sure that there is no decrease in the hepatic uptake of
M6P-GFLG-HPMA-GFLG-32P-TFO, we determined the bio-distribution of this
conjugate at 30 min post injection in fibrotic rats. To exclude the possibility that HPMA,
the backbone, is not involved in the specific uptake of the TFO, we also determined the
biodistribution of HPMA-GFLG-32P-TFO at 30 min post-injection. There was no
decrease in the hepatic uptake of M6P-GFLG-HPMA-GFLG-32P-TFO in fibrotic rats
(Figure 3-10). As expected, HPMA-GFLG-32P-TFO accumulation in the liver was much
less than that of M6P-GFLG-HPMA-GFLG-32P-TFO and decreased when fibrotic rats
were used (Figure 3-10). This may be due to the fact that M6P/IGFII receptors are
up-regulated during fibrosis,214 which should increase the uptake by HSCs via receptor
mediated endocytosis and cancel out any adverse effect created by decrease in sinusoidal
gap.
3.3.6.

Competition in Hepatic Uptake

To determine whether the hepatic uptake of M6P-GFLG-HPMA-GFLG-32P-TFO is
mediated by M6P/IGFII receptor mediated endocytosis, we preinjected excess amount of
(M6P)16-GFLG-HPMA followed by injection of the conjugate in fibrotic rats. This
resulted in a significant decrease in the hepatic uptake of the conjugate in fibrotic rats
(Figure 3-11), possibly due to M6P/IGFII receptor mediated endocytosis of the
conjugates.
3.3.7.

Hepatic Cellular Localization

To determine the uptake of M6P-GFLG-HPMA-GFLG-32P-TFO by different liver
cell types, the livers of normal and fibrotic rats were perfused at 30 min post tail vein
injection, and hepatocytes, HSCs, Kupffers and endothelial cells were isolated for
determining the amount of radioactivity in these cells. As shown in Figure 3-12, HSCs
were the major site for the uptake of this conjugate. Furthermore, the uptake of
M6P-GFLG-HPMA-GFLG-32P-TFO by HSCs was significantly higher compared to free
32
P-TFO. Although there was no significant decrease in the overall hepatic recovery of
M6P-GFLG-HPMA-GFLG-32P-TFO, uptake by the HSCs of DMN-induced liver fibrotic
rats was much higher than that of normal rats (79.63 ±2.56% versus 51.55±2.02%)
(Figure 3-12). We also perfused the livers of both normal and fibrotic rats at 30 min
post-injection of HPMA-GFLG-32P-TFO and determined the intrahepatic distribution of
the TFO by different liver cells. As can be seen in Figure 3-12, the conjugation of
32
P-TFO with GFLG-HPMA did not significantly increase the TFO uptake by HSCs of
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Figure 3-10 Effect of fibrosis on hepatic uptake of M6P-GFLG-HPMA-GFLG-32P-TFO
and HPMA-32P-TFO after systemic administration into DMN-induced fibrotic rats. At 30
min post-injection of this conjugate (1×106 cpm) at a dose of 0.2 mg/kg, blood was
collected by cardiac puncture. Rats were sacrificed; major organs were isolated, washed
with saline, and subjected into scintillation counting. Values are the mean±SD of 3 rats.
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Figure 3-11 Effect of excess M6P-GFLG-HPMA on the biodistribution of
M6P-GFLG-HPMA-GFLG-32P-TFO in fibrotic rats.
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Figure 3-12 Intrahepatic distribution of M6P-GFLG-HPMA-GFLG-32P-TFO in normal
and fibrotic rats. The liver was perfused in situ by collagenase/pronase digestion at 30
min post-injection of M6P-GFLG-HPMA-GFLG-32P-TFO, HPMA-GFLG-32P-TFO, or
32
P-TFO at dose of 0.2 mg TFO/kg of body weight. Hepatocytes, Kupffer and endothelial
cells, and hepatic stellate cells (HSC) were separated, and the associated radioactivity
was measured. The contribution of each liver cell type was exposed as percentage of total
liver uptake. Results are expressed as the mean±SD (n=3).
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both normal and fibrotic rats, suggesting the HPMA backbone is not involved in the
specific uptake of the TFO.
3.4.

Discussion

Excessive production of extracellular matrix (ECM), primarily type I collagen, by
activated HSCs is known to be one of the major causes of liver fibrosis.197 The entire
region spanning from -140 to -200 of α1(I) collagen gene promoter exist as a symmetric
polypurine-polypyrimidine tract in which the polypyrimidine sequence at -141 to -170 is
called C1 region present on the non-coding strand, whereas the adjacent polypurine
sequence from -171 to -200 is called C2 region located on the coding strand. The
cis-acting element is the C1 and C2 regions, playing an important role in collagen
transcription.35 We have previously demonstrated that TFOs could form triplex in this
region and inhibit the activity of α1(I) collagen promoter in vitro.34,36 In addition, TFOs
have been shown to partly reverse fibrosis in a dimethylnitrosamine (DMN) induced liver
fibrosis rats, indicating the therapeutic potential of these TFOs.38
M6P is a ligand for M6P/IGF II receptor, which is up-regulated in activated HSCs
during liver fibrosis, enabling selective accumulation of M6P-conjugated carrier or drug
molecules.215 M6P conjugation to albumin increased the uptake of M6P-BSA by HSCs in
liver fibrotic rats.216 Conjugation of M6P to virus recombinant interleukein-10 (νIL-10)
significantly increased the hepatic uptake of νIL-10 by the liver.
To avoid the use of polycations, Rajur et al. conjugated ODNs to asialoorosomucoid
via disulfide bond.217 However, this strategy is not suitable for the TFO, since direct
conjugation of molecules to the TFOs often disrupts the triplex-forming ability of the
TFOs, which is essential for transcription inhibition. Furthermore, liver fibrosis results in
the loss of sinusoidal fenestrae, suggesting that particulate delivery systems may not be
good for TFO delivery to the HSCs.
To avoid any non-specific ionic interaction and the large particle size, we recently
conjugated TFO to M6P-BSA via a disulfide bond and demonstrated enhanced uptake by
the HSCs after systemic administration of M6P-BSA-TFO into normal and fibrotic
rats.218 However, repeated administration of this conjugate is likely to cause immune
reaction due to BSA and thus we synthesized M6P-GFLG-HPMA-GFLG-ONP and
conjugated to TFO, where GFLG is a lysosomally degradable tetrapeptide, and thus will
facilitate lysosomal release of TFO and its escape to the cytoplasm after cellular uptake.
Following synthesis and characterization using RP-HPLC and GPC, we determined
whether TFO could be dissociated from the conjugate by incubating
M6P-GFLG-HPMA-GFLG-TFO with papain and TFO release was monitored. As shown
in Figure 3-4, free TFO release concentration increased with incubation time with papain,
which is consistent with the literature.213 Papain is a cysteine protease hydrolase enzyme
and belongs to the same family as cathepsin B, which is the most important enzyme in the
lysosomes to cleave GFLG spacer.210,212,213
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To make sure the TFO released from the conjugate can form a triplex to the target
duplex DNA, we incubated M6P-GFLG-HPMA-GFLG-TFO with papain for 24 h and
then used the released TFO to form triplex with the target duplex DNA. As can be seen in
Figure 3-5, the TFO released from the conjugate formed triplex with duplex DNA.
To confirm that TFO conjugation to M6P-GFLG-HPMA does not adversely affect its
ability to inhibit the transcription of type I collagen, we transfected HSC-T6 cells with
M6P-GFLG-HPMA-GFLG-TFO. Compared to the control cells treated with
M6P-HPMA, type I collagen gene expression by the cells treated with
M6P-GFLG-HPMA-GFLG-TFO decreased as efficiently as that by the cells treated with
the TFO (Figure 3-6).
Conjugation of TFO to M6P-GFLG-HPMA-GFLG-ONP significantly increased TFO
delivery to the liver from 47% for 32P-TFO to 70% for
M6P-GFLG-HPMA-GFLG-32P-TFO at 30 min post injection. To determine whether the
hepatic uptake of M6P-GFLG-HPMA-GFLG-32P-TFO is mediated by M6P/IGF II
receptor mediated endocytosis, we preinjected rats with excess amount of
M6P-GFLG-HPMA-GFLG-ONP. This resulted in a significantly decrease in the hepatic
accumulation of this conjugate in fibrotic rats (Figure 3-11). This confirmed the
receptor-mediated uptake of this conjugate, since M6P/TGF II receptor is up-regulated in
liver fibrotic rats, the hepatic accumulation was almost completely inhibiting by
saturating this receptor. Rachmawati et al also demonstrated almost 50% inhibition in the
hepatic uptake of M6P-IL-10 conjugates in fibrotic rats.219
To determine the hepatic cellular localization, the liver was perfused at 30 min
post-injection of M6P-GFLG-HPMA-GFLG-32P-TFO, HPMA-GFLG-32P-TFO or
32
P-TFO and different liver cells were separated by fractionation on the Histodenz
gradient. As shown in Figure 3-12, almost 80% of the total liver uptake was contributed
by HSCs cells of fibrotic rats, but only 55% by HSCs of normal rats. The percentage of
uptake by hepatocytes was relatively low in both normal and fibrotic rats. However, the
conjugation of TFO with GFLG-HPMA did not significantly increase the TFO uptake by
HSCs of both normal and fibrotic rats (Figure 3-12); suggesting the HPMA backbone is
not involved in the specific uptake of the TFO.
In conclusion, conjugate with M6P-GFLG-HPMA-GFLG-ONP significantly enhance
the uptake of the TFO by HSCs and thus this conjugate may be suitable for inhibiting α1
(I) collagen gene expression by HSCs and potentially treat liver fibrosis.
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CHAPTER 4. TREATMENT OF LIVER FIBROSIS AFTER SYSTEMIC
ADMINISTRATION OF M6P-HPMA-TFO
4.1.

Introduction

Liver fibrosis is the excessive accumulation of extracellular matrix (ECM) proteins
including type I collagen in the liver due to chronic hepatitis C (HCV), alcohol abuse and
cholestasis.220 There is no drug available to really treat liver fibrosis until now. The
commonly used method to treat liver fibrosis is to control the liver inflammation,221 as the
inflammatory cytokines released due to liver injury activate hepatic stellate cells (HSCs),
which are known to be vitamin A and fat storing cells. Following activation, HSCs
transdifferentiate into myofibroblast-like cells and acquire contractile and profibrogenic
properties, resulting in increased synthesis of type I collagen and other ECM proteins.201
Therefore, the reduction of excessive production of ECM, especially type I collagen is
crucial to reverse hepatic fibrosis.
Type I collagen is the major component of ECM in the fibrotic liver. It is a
heterotrimer composd of two α1 chains and one α2 chain. These chains are encoded by
two distinct genes, COL1A1 and COL1A2, respectively.35 Recently, we used an
antiparallel polypurine phosphorothioate TFO, which can form a triplex with the C1
sequence located in the rat α1 (I) collagen promoter,34 resulting in the transcription
inhibition of type α1(I) collagen. Systemic administration of TFO could decrease liver
injury, inflammation and fibrosis. Common bile duct ligation (CBDL) leads to the
formation of α-smooth muscle action (SMA) positive myofibroblasts, which produce
excessive type I collagen and fibrogenic cytokines and resulted in excessive accumulation
of ECM.
TFOs distribute throughout the body after systemic administration, with higher
accumulation in the liver and kidney.38 However, the cellular population which plays a
major role in producing collagen in livers is HSCs. Therefore, it is critical to target TFOs
to HSCs for efficient anti-fibrotic therapy. M6P/IGF II receptors on the surface of HSCs
are up-regulated in fibrotic livers. We have demonstrated that TFO conjugated to
mannose-6-phosphate bovine serum albumin (M6P-BSA) enhances TFO accumulation to
HSCs.41 Since the repeated injection of M6P-BSA-TFO may not be good due to the
potential immune reaction of high molecular weight globular BSA (66430 Da) and the
closure of sinusoid gap in fibrotic livers, an alternative carrier with less immune reaction,
lower molecular weight and size becomes necessary. Therefore, we conjugated M6P via
GFLG linker to N-(2-hydroxypropyl) methacrylamide (HPMA) copolymer and then to
TFO for target delivery to activated HSCs in the fibrotic liver.27 This conjugate enhanced
both the elimination half life and target delivery of TFO.
In this chapter, we determined the effect of M6P-HPMA-TFO on treating liver
fibrosis in rats undergoing CBDL. Following the systemic administration of
M6P-HPMA-TFO three times a week for two weeks, liver samples were analyzed by real
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time RT-PCR, Western blot, histochemistry and immunofluorescence staining to
determine the extent of liver fibrosis.
4.2.

Methods and Materials

4.2.1.

Materials

Poly (HPMA-co-GFLG-ONP) was purchased from Varian Inc. (Amherst, MA).
p-Nitrophenyl-α-D-mannopyranoside (pnpM), phosphorus oxide chloride, palladium (10
wt % on activated carbon), N,N′-diisopropylethylamine, hydroxyproline, Chloramine-T,
3,3 -diaminobenzidine (DAB) and goat serum were purchased from Sigma-Aldrich (St.
Louis, MO). Dialysis tubing (molecular weight cutoff 1000 Da) was purchased from
Spectrum Laboratories, Inc. (Houston, TX). Sephadex G75 (superfine) was procured
from Pharmacia Fine Chemicals (Uppsala, Sweden). Rabbit anti-rat and goat anti-rat
transforming growth factor (TGF)-β1 and β-actin primary antibodies, bovine anti-mouse,
donkey anti-goat and donkey anti-rabbit secondary antibodies were purchased from Santa
Cruz Biotech, Inc. (Santa Cruz, CA). Other primary and secondary antibodies are all from
Abcam Inc. (Cambridge, MA). Tumor necrosis factor (TNF)-α enzyme-linked
immunosorbent assay (ELISA) kit was purchased from eBioscience, Inc. (San Diego,
CA). Serum alanine transaminase (ALT) and aspartate transaminase (AST) kits were
purchased from ID Labs, Inc (London, Canada). Citric acid and sodium citrate were
procured from Curtin Matheson Scientific, Inc (Houston, TX). Sodium hydroxide was
purchased from Fisher Scientific (Fair Lawn, NJ). TFO, which was a 25 mer anti-parallel
fully phosphorothioate ODN (3′-GAGGGGGGAGGAGGGAAAGGAAGGG-5′)
targeting rat α1 (I) collagen gene promoter, and TFO-3′-NH2 were synthesized by
Invitrogen (Carlsbad, CA). Isoflurane was purchased from Baxter Pharmaceutical
Products, Inc. (Deerfield, IL). All solvents and chemicals used in this study were used as
available without further purification.
4.2.2.

Synthesis and In Vitro Characterization of M6P-HPMA-TFO Conjugate

For targeted delivery, TFO was conjugated to M6P-GFLG-HPMA as described
previously.27 The conjugate was dialyzed against H2O for 24 h, purified on a Sephadex
G75 Gel column with pure water, freeze-dried, kept at -80°C, and resuspended in steriled
saline before use.27 The conjugation was confirmed by polyacrylamide gel
electrophoresis as described before. We also confirmed this by 1H nuclear magnetic
resonance (NMR) (JOEL, 270 MHz, T=25 ̊C) using deuterated water (D2O) as solvent.
The chemical shifts were calibrated using D2O as an internal reference and given in parts
per million.
TFO and M6P-HPMA-TFO solution dissolved in saline were injected to rats every
two days by tail veins at the same dose of 8 mg/kg.
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4.2.3.

Animals

Male Sprague Dawley rats weighing 200-250 g were purchased from Harlan Co. (San
Diego, CA) and were housed individually under the conditions as per the NIH
(http://grants1.nih.gov/grants/olaw/references/phspol.html) and Institutional Animal Care
and Use committee (IACUC) using the approved protocols. All animals were housed in
microisolator cages in virus-free facilities and fed laboratory chow and water ad labium.
4.2.4.

Bile Duct Ligation and Treatment

Common bile duct ligation (CBDL) or sham operation was performed. In the first day
of CBDL, animals were divided into 4 groups: sham (midline abdominal incision and
closure), CBDL, CBDL+TFO; and CBDL+M6P-HPMA-TFO. TFO and its conjugate
were given via the tail vein injection from the first day of CBDL three times a week for
two consecutive weeks. At the end of experiment, blood was collected when animals
were sacritificed under isoflurane anesthesia by puncture of the right heart vehicle and
exsanguinations. Liver tissues were collected, washed, blotted dry and frozen.
4.2.5.

Standard Serum Parameters

Serum levels of aspartate aminotransferase (AST) and alanine aminotransferase
(ALT) were used as markers of liver injury. Serum ALT and AST concentrations were
measured using IDToxTM Alanine Transaminase color endpoint assay kit and IDToxTM
Aspartate Transaminase Enzyme Assay Kit (ID LabsTM Inc, London, ON, Canada)
according to the manufacturer’s instructions and absorbance was measured using a
spectrophotometer. Total bilirubin levels were measured using a MaxDiscovery™ Total
bilirubin assay kit from Bioo scientific (Austin, TX) and absorbance at 560 nm was
measured using a UV spectrophotometer.
4.2.6.

Hydroxyproline Assay

Hepatic hydroxyproline content was quantified colorimetrically from 30 mg of fresh
liver tissue as previously described after hydrolyzing with 6N HCl and heating in an oven
at 110 ̊C for 18 h. Citrate buffer and Chloramine-T reagent were added to the samples and
allowed to react for 20 min at room temperature. Fresh prepared Ehrlich’s reagent was
then added to each sample and allowed to react for 15 min at a warm water bath (60.8 ̊C).
Following cooling to room temperature, absorbance was read at 550 nm and the results
were expressed as micrograms of hydroxyproline per grams of liver.
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4.2.7.

ELISA for Tumor Necrosis Factor-α

TNF-α concentration in serum of different groups were measured using
enzyme-linked immunosorbent assay (ELISA), according to the manufacturer's protocol
(eBioscience, San Diego, CA).
4.2.8.

Real Time RT-PCR

Total liver RNA was isolated from 20 mg of liver tissue by RNAeasy Mini Kit
(Qiagen, Valencia, CA) and the RNA concentration was measured using a Nanodrop UV
spectrophotometer (Thermo Scientific, Pittsburgh, PA). Then, 385 ng of the total RNA
per sample was reverse transcribed into cDNA and amplified by real time PCR using
SYBR Green-1 dye universal master mix on ABI Prism 7700 Sequence Detection System
(Applied Biosystems, Inc., Foster City, CA). The sequences of primers for detecting
TGF-β1, α-SMA, TIMP-1 and 18S as an internal control are the same as our previous
report.222
4.2.9.

Histological Staining

Formalin-fixed liver specimens from M6P-HPMA-TFO treated, TFO treated, BDL
and non-fibrotic rats were dehydrated in 70% alcohol, incubated in xylene, and embedded
in paraffin. Five-micron-thick tissue sections were cut and stained with Masson’s
Trichrome staining for collagen.
4.2.10. Immunofluorescent Staining
Immunofluorescent staining was performed on snap frozen liver tissue as described
before. Briefly, 14 μm cryosections were cut on lysine coated slides and fixed in 95%
cold ethanol. Slides were air dried and stored at -80 ̊C till further use. The sections were
blocked with 10% goat serum with 1% BSA in PBS for 1 h at room temperature and then
incubated with the following primary antibodies, rabbit anti-rat α-SMA, mouse anti-rat
cytoketain-7 and mouse anti-rat CD11 for 1h at room temperature. Then anti-rabbit Alexa
Fluor 488 and anti-mouse Alexa Fluor 594 were applied to the cytosections. Nuclear
staining was performed using 4’,6-diamidino-2-phenylindole (DAPI) and was visualized
on a Zeiss Apoplan Microscope.
4.2.11. Western Blot
Effect of M6P-HPMA-TFO conjugates on TGF-β1, α-SMA and CK-7 was
determined by Western blot analysis as described.222 Briefly, the liver tissues were
homogenized and then lysed using Laemmli sodium dodecyl sulfate (SDS) buffer. The
lysate was then boiled for 10 min and subjected to 4-15% precast SDS-polyacrylamide
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gel electrophoresis (SDS-PAGE) and subsequent transfer to Immobilon polyvinylidene
fluoride membrane by iBLOT (Invitrogen, Carlsbad, CA). After blocking with 3% nonfat
dry milk in TBST containing 0.05% Tween-20 for 1 h at room temperature, the
membranes were incubated with various primary antibodies for 16 h at 4 ̊C. β-Actin
polyclonal antibody was used as an internal control. After additional washing in blocking
medium, horseradish peroxidase (HRP)-conjugated secondary antibody was added,
followed by washing in TBST buffer before visualization using enhanced
chemiluminescence (ECL) reaction and X-ray film exposure.
4.2.12. Statistics Analysis
Data are expressed as the mean ± standard deviation (S.D.). Comparison was
performed by the one-way ANOVA. p<0.05 was considered statistically significant.
4.3.

Results

4.3.1.

In Vitro Characterization of M6P-HPMA-TFO

Following synthesis and purification, M6P-HPMA-TFO was characterized by 1H
NMR. As depicted in Figure 4-1, the chemical shifts at δ=7.8 is characteristics of the NH2
groupsin TFO. δ=8.1 and δ=7.6 are characteristics of ONP groups in HPMA. The
chemical shift of protons in TFO base pairs (δ=1.2) and protons in phenol groups in M6P
(δ=6.8) were found in M6P-HPMA-TFO (arrow heads, Figure 4-1), confirming TFO
conjugation to M6P-HPMA-ONP.
4.3.2.

M6P-HPMA-TFO Inhibits Collagen and Attenuates Liver Fibrosis

To confirm TFO conjugation to M6P-HPMA does not adversely affect the
transcription inhibiting ability of TFO, the level of type I collagen gene expression was
determined by Western blot analysis. Both TFO and M6P-HPMA-TFO treated groups
significantly down-regulated type I collagen expression (Figure 4-2A), with relatively
higher level of collagen gene silencing in M6P-HPMA-TFO treated group (Figure 4-2A).
To examine the effect of this conjugate on liver fibrosis, CBDL rat livers were
isolated to confirm liver fibrosis by hydroxyproline assay and Masson’s trichrome
staining for total collagen. There was significant increase in hydroxyproline content in the
liver after CBDL, suggesting the liver fibrosis model was successfully established.
Hydroxyproline content of the livers of normal, fibrotic, TFO treated and
M6P-HPMA-TFO treated rats were 4.64±1.55, 12.56±1.66, 8.51±1.58 and 7.04±1.95 µg
per mg liver tissues, respectively (Figure 4-2B). Both TFO and M6P-HPMA-TFO
injected groups showed significant reduction in total collagen. Compared to TFO treated
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Figure 4-1 NMR characterization of M6P-HPMA-TFO.
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Figure 4-2 Measurement of type I collagen and total collagen. A) Western blot for type I
collagen. B) Hydroxyproline level of total collagen. C) Histochemistry staining of total
collagen, a) non-fibrotic rat, b) CBDL rat, c) free TFO group, d)
M6P-GFLG-HPMA-GFLG-TFO group.
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rats, M6P- HPMA-TFO injected group showed relatively more inhibition of
hydroxyproline (Figure 4-2B).
Figure 4-2C shows micrographs of Masson’s trichrome staining of rat liver tissues at
2 weeks after CBDL. In sham operated rats, collagen expression was very low (Figure
4-2C.a). In rats administrated with M6P-HPMA-TFO (Fig 4-2C.d) and free TFO (Figure
4-2C.c), there was a significant decrease in collagen deposition compared to CBDL rats
(Figure 4-2C.b).
4.3.3.

M6P-HPMA-TFO Inhibits Profibrogens

TGF-β1 is a potent fibrogenic cytokine believed to regulate fibrosis. Therefore, we
next determined the effect of M6P-HPMA-TFO on hepatic TGF-β1 expression by
RT-PCR. Hepatic TGF-β1 expression after CBDL was dramatically up-regulated.
However, TFO and M6P-HPMA-TFO significantly decreased hepatic TGF-β1 gene
expression (Figure 4-3A). M6P-HPMA-TFO injected group showed even less TGF-β1
gene expression. TGF-β1 protein expression in the liver was also examined by Western
blot. As shown in Figure 4-3D, TGF-β1 protein expression reduced markedly in
M6P-HPMA-TFO treated group than TFO group.
4.3.4.

Inhibition of Collagen Intrinsic Degradation

TIMP-1 is the tissue inhibitor of metalloproteinases which can inhibit most interstitial
collagenases and matrix metalloproteinases (MMPs), which have the ability to degrade
the normal liver matrix. After CBDL, there was a significant increase in TIMP-1
expression in the liver, but its expression significantly decreased by TFO and
M6P-HPMA-TFO treatment (Figure 4-3B). M6P-HPMA-TFO treatment showed better
reduction in TIMP-1 level compared to TFO treatment (Figure 4-3B).
4.3.5.

Inhibition on Myofibroblast Activation

The presence of α-smooth muscle actin (α-SMA) positive cells has been reported to
increase in the fibrotic liver.222 Therefore, we determined α-SMA concentration in
mRNA level before and after treatment. There was significant increase in α-SMA mRNA
level at two weeks after CBDL only (Figure 4-3C). Both TFO and M6P-HPMA-TFO
treatment significantly decreased α-SMA mRNA synthesis in CBDL rats.
M6P-HPMA-TFO injection in alternative day for two weeks decreased α-SMA
expression even less (Figure 4-3C). α-SMA gene expression was also determined at
protein levels by Western blot in whole liver lysis showed the same trend as RT-PCR
(Figure 4-3D).
There was significant increase in α-SMA immunostaining in CBDL liver forming
whorls of layers (onion skinning) around the proliferated bile ducts (Figure 4-4).
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Figure 4-3 mRNA and protein expression level screening of fibrotic related factors. A)
mRNA level of TGF-β1, B) mRNA level of TIMP1, C) mRNA level of α-SMA, D)
protein expression of TGF-β1, α-SMA and CK-7.

63

Figure 4-4 Co-localization of α-SMA and CK-7. M6P-GFLG-HPMA-GFLG-TFO group
showed higher expression of CK-7 and α-SMA.
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Furthermore, two weeks after CBDL, CK-7 expression in hepatocytes was up-regulated
but decreased with TFO and M6P-HPMA-TFO treatment (arrows). CK-7 is up-regulated
in injured hepatocytes before they go to apoptosis even though it is always expressed in
the epithelia around the bile ducts.223 M6P-HPMA-TFO treatment attenuated CK-7
expression in hepatocytes more than TFO treatment, which may imply the function of
damaged hepatocytes was at least partially restored (Figure 4-4). Western blot showed the
same trend (Figure 4-3D). Besides hepatocytes, clear co-localization of CK-7 and
myofibroblast marker α-SMA was observed in biliary epitheliums. M6P-HPMA-TFO
injection decreased this co-localization, suggesting higher inhibition ability on
myofibroblastic phenotypic transition compared to only TFO treatment (Figure 4-4).
4.3.6.

Effects on Serum Fibrotic and Pro-inflammatory Markers

CBDL caused jaundice in rats, leading to the urine color change to dark yellow
several days after CBDL. The level of traditional liver disease markers such as ALT and
AST were determined. ALT and AST levels were higher in CBDL group. However,
administration of TFO and M6P-HPMA-TFO resulted in decreased levels of ALT and
AST. M6P-HPMA-TFO group showed even less ALT and AST levels compared to TFO
group (Figure 4-5A & B).
Jaundice comes from the decreased processing of total bilirubin. The amount of
bilirubin was reduced in therapeutic groups, especially in M6P-HPMA-TFO group
(Figure 4-5C), which may indicate the treatment makes the liver more robust and
prevents it from being continually damaged by the retro-flowing bile.
There was a significant decrease in TNF-α, one pro-inflammatory factor, level in
treatment group. When CBDL rats were treated with TFO and M6P-HPMA-TFO,
M6P-HPMA-TFO treatment control the inflammation better than free TFO (Figure
4-5D).
4.3.7.

Inhibition on Neutrophil Infiltration

Bile duct obstruction causes neutrophilic inflammation of the liver and leads to liver
fibrosis.224 Activated neutrophils up-regulate adhesion molecules receptor (CD11/CD18)
on its membrane surface, then adheres to endothelial cells of hepatic sinusoids.225 In this
study, CD 11 was used as a bio-marker to measure the neutrophil infiltration in fibrotic
livers. The accumulated CD 11 staining indicated enhanced activated neutrophil
accumulation in CBDL rats (Figure 4-6B). M6P-HPMA-TFO injection group (Figure
4-6D) decreased this accumulation more than free TFO group (Figure 4-6C). This
phenomenon is partially due to the reduction of pro-inflammation, which was shown in
the data of TNF-α level (Figure 4-5D). Increase in neutrophil infiltration is due to
systemic or local exposure to pro-inflammatory mediators, such as TNF-α, IL-1 and CXC
chemokines. Another reason of the reduction of neutrophil infiltration may come from the
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Figure 4-5 Blood chemistry assay. A) ALT, B) AST, C) Bilirubin, D) TNF-α.
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Figure 4-6 CD-11 staining to indicate neutrilphil infiltration. A) non-fibrotic rat, B)
CBDL rat, C) free TFO group, D) M6P-GFLG-HPMA-GFLG-TFO group.
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protection of HPMA to TFO to prevent or relieve extra immune response compared to
free TFO after systemic administration.
4.4.

Discussion

Liver fibrosis is characterized by excessive production of collagen, primarily by
activated HSCs. Therefore, we recently conjugated TFO targeting type I collagen
transcription to M6P-HPMA for targeted delivery to HSCs after systemic administration.
Triplex formation happens at sequences containing a stretch of pyrimidines on one
DNA strand and complementary purines on the other DNA strand. TFOs containing C
and T nucleotides bind in a parallel direction to the purine-containing strand of double
stranded DNA, whereas TFOs containing G and A nucleotides bind in an anti-parallel
orientation. This combination is involved in gene regulation in many areas, including
transcription, replication, repair and recombination.41,226,227 We demonstrated that TFO
can form triplex with type I collagen promoter in genomic DNA to inhibit the
transcription of this protein.34 This approach enhances the silence efficiency compared
antisense strategies because it shut down the original source of type I collagen. However,
to enter the nuclear, it is necessary for our TFOs to reach the cytoplasm of HSCs in high
concentration in cytoplasm in HSCs, the target cells. Specific carriers and ligands were
taken into account, such as BSA and M6P. BSA showed enhanced delivery efficiency,
however, even though already conjugated to M6P, this conjugate still has immune and
size problems.38 Therefore, HPMA copolymer, as an alternate carrier was considered.27
HMPA is a non-immunogenic copolymer containing a lysosomal degradable GFLG
tetrapeptide spacer, facilitating TFO release from the conjugate for nuclear translocation
to inhibit collagen transcription. Furthermore, we determined previously that TFO
conjugation to M6P-HPMA has no adverse effect in its ability to triplex formation.27
M6P-HPMA-TFO also inhibited type I collagen synthesis in HSC-T6 cell line. The
difference in TNF-α level is not significant between TFO group and M6P-HPMA-TFO
group after two weeks short term therapeutics. Neutrophil infiltration was much less in
M6P-HPMA-TFO group compared to TFO injected group. This result implies that
reduced neutrophil accumulation might not only come from less exposure to
pro-inflammatory factors, which were thought as one reason for neutrophil infiltration.
The extra relief of neutrophil infiltration may be due to the protection from conjugated
HPMA to TFO to prevent or at least lighten the attack from immune system to the
intruder, free TFO.
Our short term experiments also unveiled that the continual TFO function helps the
damaged hepatocytes to recover. CK-7 is expressed in the bile duct epithelia of both
healthy and hepatic fibrotic rats.228 However, CK-7 is only expressed in injured
hepatocytes.223 The staining of CK-7 in liver parenchyma were reduced a lot especially in
M6P-HPMA-TFO treated group (Figure 4-4). This result indicates damaged hepatocytes
recovered because of the inhibition of excessive collagen synthesis whereas staining of
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the hepatocytes by CK-7 predicts subsequent progression of fibrosis. M6P-HPMA-TFO
group showed higher effects because of the efficient targeted delivery of TFO.
Cell adhesion molecules facilitate leukocyte-endothelial cell interactions and
coordinate many other cell interactions through a variety of adhesion receptors, including
integrins, selectins, immunoglobulin-like molecules and cadherins.229-231 These cell
adhesion molecules regulate leukocyte infiltration through a mechanism of ligand
binding. This typically includes qualitative changes in receptor surface expression and
transient activation of leukocyte infiltration.232,233 CD-11 is α component of various
integrins and therefore mediates leukocyte adhesion. The most frequently observed β
component is CD18 (β2). CD11b/CD18 was initially described as receptors which
facilitate the adhesion of T cells, expressing CD11a/CD18 too.233 Neutrophil infiltration
into the inflammatory site and subsequent release of toxic factors by these cells is partly
responsible for liver fibrosis. There was strong staining for CD11 in CBDL rats (Figure
4-6B), which indicated enhanced neutrophil accumulation. M6P-HPMA-TFO injection
group (Figure 4-6D) relieve this infiltration more than free TFO group (Figure 4-6C).
Besides systemic or local exposure to pro-inflammatory mediators, such as TNF-α
(Figure 4-5D), neutrophil infiltration reduction may results from the protection of HPMA
to TFO to decrease immune response.
Generally, M6P-HPMA-TFO enhanced the efficacy of TFO in hepatic fibrosis
treatment.
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CHAPTER 5. TGF-β1 GENE SILENCING FOR TREATING LIVER FIBROSIS
5.1.

Introduction

Liver fibrosis is the excessive accumulation of extracellular matrix (ECM) proteins
resulting from chronic liver damage. In general, it is an imbalance between the synthesis
and degradation of ECM. In the presence of chronic liver injuries, hepatic stellate cells
(HSCs) become activated and transform to proliferative myofibroblast-like cells, which
account for major source of ECM expression.220,234
There is no standard treatment for liver fibrosis and therefore the effective
anti-fibrotic medicines are needed urgently.220,235 Among many inflammatory cytokines
involved in liver fibrosis, TGF-β1 appears to be the most important (Figure 5-1).28,220
Cytokines of TGF family affect a variety of cellular processes, including differentiation,
proliferation, apoptosis and migration. Among them, TGF-β1 is the most potent
profibrogenic factor involved in initiation and maintenance of fibrogenesis in the
liver.236,237 Stimulation of activated HSC by TGF-β1 is believed to be the key fibrogenic
response in liver fibrosis because of following evidences: i) higher TGF-β1 expression in
activated HSC; ii) potency of TGF-β1 to up-regulate ECM expression; iii) higher
expression of TGF-β receptors on HSC; iv) TGF-β1 increases the expression of tissue
inhibitor of metalloproteinases 1 (TIMP-1).236-238 TGF-β1 in the liver is also secreted by
hepatocytes, kupffer cells, stellate cells, endothelial cells and infiltrating mononuclear
cells.236
Strategies aimed at disrupting TGF-β1 expression or signaling pathways are
extensively being investigated because blocking this cytokine may not only inhibit matrix
production, but also accelerate its degradation.239 Animal experiments using different
strategies to block TGF-β1 have demonstrated significant anti-fibrotic effect for liver
fibrosis.44,237,240-244 RNA interference (RNAi) is the phenomenon in which siRNA of
21-23 nt in length silences a target gene by binding to its complementary mRNA and
triggering its degradation. Potent knockdown of the target gene with high sequence
specificity makes siRNA a promising therapeutic strategy.245 Compared to antisense
oligonucleotides, neutralizing antibodies and soluble TGF-β receptors strategies, siRNA
has the potent knockdown of the target gene with high sequence specificity. siRNAs
targeting other pathways have been proven effective in treating liver fibrosis246-249 and
renal fibrosis.147 There are three ways to deliver siRNA: synthetic duplex, plasmid and
viral vectors. While viral vectors give high transfection efficiency, their immune
reactions limit their application in therapeutics. Plasmid DNA complexes with cationic
liposomes to form particle in the size of 250 nm, which may not pass through the
sinusoidal gaps, because these fenestrae get lost during liver fibrosis. In contrast, low
molecular weight of synthetic duplex siRNA is expected to pass through the sinusoidal
gaps of fibrotic liver and thus it may be an ideal candidate for treating liver fibrosis.
In this study, we screened ten chemically synthesized siRNAs targeting different
regions of TGF-β1 mRNA and then converted the most potent siRNA sequences into
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Figure 5-1 Role of TGF-β1 in liver fibrosis. TGF-β1 is the most potent single
profibrogenic factor involved in initiation and maintenance of fibrogenesis in the liver.
TGF-β1 accelerates activation of quiescent hepatic stellate cells (HSCs), upregulates
collagen expression, and decreases collagen degradation.
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shRNA via cloning into pScilence1.0 vector. Both synthetic siRNA and shRNA
expression plasmids were tested in HSC-T cells for gene silencing and therapeutic
efficacy.
5.2.

Materials and Methods

5.2.1.

Materials

Trizol was purchased from Invitrogen Corporation (Carlsbad, CA). pScience1.0 was
purchased from GenScript Corporation (Piscataway, NJ). Bovine serum albumin (BSA)
(fraction V, purity >98%) was purchased from USB Corporation (Cleveland, OH).
Dulbecco’s modified eagle’s medium (DMEM), penicillin G (5000 U/mL),
Trypsin-EDTA, Trizol, DNase I, Lipofectamine 2000 were purchased from Invitrogen
Life Technologies (Carlsbad, CA). Restriction enzymes were purchased from New
England Biolabs (Ipswich, MA). SYBR Green-1 dye universal master mix and
Multiscript reverse transcriptase were purchased from Applied Biosystems, Inc. (Foster
City, CA). TGF-β1 ELISA kit was purchased from R&D Systems, Inc. (Minneapolis,
MN). TNF-α and IL-1β ELISA kits were purchased from eBioscience, Inc. (San Diego,
CA).
5.2.2.

siRNA Design and Synthesis

Ten siRNA sequences targeting TGF-β1 mRNA (Accession#: NM_021578) and one
control siRNA were designed using BLOCK-iTTM RNAi Designer and purchased from
Invitrogen Corporation (Carlsbad, CA) and their sequences are listed in Table 5-1. These
siRNAs are of 19-21 nt with a 2 thymidine deoxnucleotide overhangs at the 3’-end. All
designed siRNA sequences were blasted against the rat genome database to eliminate
cross-silence phenomenon with non-target genes.
5.2.3.

Design and Construction of shRNA Expression Plasmids

Following screening of different siRNA sequences, two effective and one control
siRNA sequences were converted into shRNA (Table 5-2). pshRNA-769, pshRNA-1033
and control vectors were constructed using pScilence1.0 vector, which carries shRNA
expression cassette under the control of U6 promoter (GenScript Corporation,
Piscataway, NJ). These shRNAs contain two complementary oligonucleotides that were
annealed to form a double-stranded DNA for ligation into pScilence1.0 vector at
corresponding sites under U6 promoter using T4 DNA ligase for 2 h at 25°C. Following
transformation in Top10 supercompetent cells and amplification in broth media, plasmids
were purified using QIAGEN Plasmid Kit.
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Table 5-1 Predesigned siRNAs for rat TGF-β1 using BLOCK-iT RNAi designer.
Start

Sequence (DNA)

297

GCCAGATCCTGTCCAAACT

448

GGACTACTACGCCAAAGAA

499

CGCAATCTATGACAAAACC

640

GCAACACGTAGAACTCTAC

769

GAACCAAGGAGACGGAATA

888

GCACCATCCATGACATGAA

1033

GCAGCTGTACATTGACTTT

1036

GCTGTACATTGACTTTAGG

1167

CCCTCTACAACCAACACAA

1245

TCTACTACGTGGGTCGCAA
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Table 5-2 Sequences of shRNA against different target regions of TGF-β1.
shRNA insert

Sequence

Control shRNA

Antisense: 5’-ACTTCATAAGGCGCATGCTTTCAAGAGAAGCATGCGCCTTATGAAGTTTTTTT-3’
Sense: 5’-AATTAAAAAAACTTCATAAGGCGCATGCTTCTCTTGAAAGCATGCGCCTTATGAAGTGGCC-3’

shRNA-769

Antisense: 5’-GAACCAAGGAGACGGAATATTCAAGAGATATTCCGTCTCCTTGGTTCTTTTTT-3’
Sense: 5’-AATTAAAAAAGAACCAAGGAGACGGAATATCTCTTGAATATTCCGTCTCCTTGGTTCGGCC-3’

shRNA-1033

Antisense: 5’-GCAGCTGTACATTGACTTTTTCAAGAGAAAAGTCAATGTACAGCTGCTTTTTT-3’
Sense: 5’-AATTAAAAAAGCAGCTGTACATTGACTTTTCTCTTGAAAAAGTCAATGTACAGCTGCGGCC-3’
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5.2.4.

Transfection of siRNA and shRNA

Immortalized rat hepatic stellate cells (HSC-T6), kindly provided by Dr Scott
Friedman, Mount Sinai School of Medicine, New York, were seeded in 6-well plates at a
density of 11×105 cells 12 h before transfection. siRNA duplexes were mixed with 4 µL
Lipofectamine 2000 in 200 µL Opti-MEM I medium for 20 min at room temperature to
allow complex formation. The transfection mixture was then added to each plate with 1.3
mL fetal bovine serum (FBS) free Dulbecco's Modified Eagle's Medium (DMEM) at a
concentration of 150 nM after washing cells with PBS. After 24 h of incubation, 0.5 mL
DMEM containing 10% FBS was added and incubated for another 24 h.
In case of shRNA expression plasmids, cells were transfected with shRNA expression
vectors at doses of 1 µg/well. The shRNA plasmids were mixed with Lipofectamine 2000
in 250 µL Opti-MEM I medium for 20 min at room temperature to allow complex
formation. The transfection mixture was then added to each plate with 2 mL fetal bovine
serum (FBS) free Dulbecco's Modified Eagle's Medium (DMEM). After 8 h of
incubation, 200 μL FBS was added and incubated for another 42 h. The supernant was
collected for western blot assay. Results were normalized with total protein content of
cells.
5.2.5.

Real Time RT-PCR

Total RNA was isolated from the cell pellets using Trizol reagent. Total RNA (1 μg)
was converted to cDNA using MultiScribe Reverse Transcriptase Reagent and random
hexamers (Applied Biosystems, Inc., Branchburg. NJ). One hundred nanograms of the
cDNA was amplified by Real Time PCR using SYBR Green-1 dye universal master mix
on ABI Prism 7700 Sequence Detection System (Applied Biosystems, Inc., Foster City,
CA). We used the following primers: (i) TGF-β1: Forward: 5’-CATCCATGACAT GAA
CCG ACC CTT-3’ and reverse: 5’-ACAGAAGTTGGCATGGTAGCCCTT-3’; (ii)
TIMP-1: forward: 5’-CCTCTGGCATCCTCTTGTTGCTAT-3’and reverse:
5’-CATTTCCCACAG CGTCGAATCCTT-3’; (iii) α1(I) collagen mRNA: Forward:
5’-TGGTCCCAAAGGTTC TCC TGG T-3’ and reverse:
5’-TTAGGTCCAGGGAATCCCATCACA-3’; and (iv) α-SMA: forward:
5’-ACAACGTGCCTATCTATG AGGGCT-3’ and reverse:
5’-AGCGACATAGCACAGCTTCTCCTT-3’. We used 18S ribosomal RNA as an
internal control: forward: 5’-GTCTGTGATGCCCTTAGATG-3’ and reverse:
5’-AGCTTATGACCCGCACTTAC-3’. To confirm PCR specificity, the PCR products
were subjected to a melting-curve analysis. Comparative threshold (CT) method was used
for calculating the relative amount of mRNA of treated sample to control samples (Figure
5-2).250
In case of in vivo evaluation in fibrotic mice, we used the following primers: (i)
TGF-β1: forward 5’-CATCCATGACATGAACCGGCC-3’ and reverse:
5’-ACAGAAGTTGGCATGGTAGCCCTT-3’; (ii) TIMP-1: forward:
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Figure 5-2 The real time PCR plot. Black curve is the intrinsic reference (18s). Red curve
is the control group. Green curve is the group with treatment. The following two
equations are used in calculating the silencing effect.
∆∆C

C sample

C 18s

C control

Silencing effect % of remaining mRNA

100

76

C 18s
1
2∆∆

5’-CATCTGGCATCCTCTTGTTGCTAT-3’and reverse:
5’-CATTTCCCACAGCCTTGAATCCTT-3’; and (iii) α-SMA were
5’-ACAACGTGCCTATCTATGAGGGCT-3’ and reverse:
5’-AGCGACATAGCACAGCTTCTCCTT-3’. All other conditions were the same.
5.2.6.

Western Blot Assay

Proteins in the cell culture medium were purified using Microcon YM-30 columns
(Millipore) and then lysed using 2×Laemmli sodium dodecyl sulfate (SDS) sample buffer
containing 100 mM Tris, pH 6.8, 200 mM dithiothreitol (DTT), 4% SDS, 20% glycerol
and 0.2% bromophenol blue. To immunodetect cellular proteins, cells were lysed directly
with 1×Laemmli SDS sample buffer. The lysate was then boiled at 100°C for 5min and
subjected to 6% or 10% SDS-polyacrylamide (SDS-PAGE) gel electrophoresis and
subsequent transfer to Immobilon polyvinylidene fluoride (PVDF) membrane (Millipore).
After blocking with 5% nonfat dried milk in 1×PBST containing 0.05% Tween-20 in
PBS for 1h at room temperature, the membranes were incubated with rabbit anti-rat type I
collagen (Calbiochem), TGF-β1 (Santa Cruz); β-actin (Santa Cruz) primary antibodies
for 16 h at 4°C. Membrane was then incubated with horseradish peroxidase-conjugated
goat anti-rabbit secondary antibody (Santa Cruz) for 1 h at room temperature. Target
proteins were detected by enhanced chemiluminescence (ECL, GE Healthcare).
5.2.7.

ELISA Assay of TNF-α and IL-1β

Cells were transfected with shRNA expression vectors at doses of 1 µg/well. The
shRNA plasmids were mixed with 8 µL Lipo-lin in 250 µL Opti-MEM I medium for 20
min at room temperature to allow complex formation. The transfection mixture was then
added to each plate with 2 mL fetal bovine serum (FBS) free Dulbecco's Modified Eagle's
Medium (DMEM). After 3 h of incubation, 200 μL FBS was added and incubated for
another 42 h. Then the supernant of the cultured cells were collected. The concentration
of TNF-α and IL-1β were measured using enzyme-linked immunosorbent assay (ELISA)
(eBioscience, USA), according to the manufacturer's protocol. Briefly, Corning Costar 96
well ELISA plate was coated with 100 μL/well of capture antibody in Coating Buffer.
Sealed the plate and incubated overnight at 4°C. Then aspirated wells and washed 5 times
with >250 μL/well Wash Buffer. Blocked wells with 200 μL/well of 1×Assay Diluent.
The plate was incubated at room temperature for 1 hour. Wells were aspirated and
washed 5 times again. 100 μL/well of sample was added to the appropriate wells and was
incubated for 2 hours under room temperature. The wells were washed again. 100
μL/well of detection antibody was added and incubated for 1 hour at room temperature.
The wells were washed and added 100 μL/well of Avidin-HRP. The plate was sealed and
incubated at room temperature for 30 minutes. After being washed for 7 times, each well
was added by 100 μL/well and incubated at room temperature for 15 minutes. Then 50
μL of Stop Solution was added to each well. The TNF-α and IL-1β concentration was
determined spectrophotometrically at an absorbance of 450 nm.
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5.2.8.

Persistence of TGF- β1 Gene Silencing

HSC-T6 cells were seeded in 6-well plates at a density of 11×105 cells 12 h before
use. Both siRNA and shRNA were applied to the cells when the conflunce of the cells
reached 40%. 1 μg siRNA duplexes or shRNA were mixed with 8 µL Lipofectamine in
200 µL Opti-MEM I medium for 20 min at room temperature to allow complex
formation. The transfection mixture was then added to each plate with 2 mL FBS free
DMEM at a concentration of 150 nM for siRNA and 1 µg per well for shRNA, both
conditions are optimized condition for siRNA and shRNA transfection in this case, after
washing cells with PBS. After 8 h of incubation, 200 μL FBS was added and incubated
for another 24 h, 48 h and 72 h. In different time points, the cells are collected and total
mRNA was isolated for Real Time PCR analysis.
5.2.9.

Statistical Analysis

Data were expressed as the mean ± standard deviation (SD). Difference between any
two groups was determined by ANOVA. p<0.05 was considered statistically significant.
5.3.

Results

5.3.1.

Effect of siRNA Sequences and Dose on TGF-β1 Gene Silencing

To examine the ability of siRNA to silence gene expression, we selected 19 bp siRNA
duplexes targeting different regions of the rat TGF-β1 genome (Table 5-1). These siRNA
duplexes were transfected into rat HSC-T6 cells after complex formation with
Lipofectamine 2000. As shown in Figure 5-3, TGF-β1 gene silencing by siRNAs was
sequence specific. Three siRNAs targeting TGF-β1 start sites of 769, 886, 1033 and 1036
caused significant inhibition of TGF-β1 expression, while the control siRNA had no
effect on TGF-β1 gene expression. Among all the siRNA sequences tested, siRNA-1036
showed the highest silencing effect up to 70%, while siNA-1033 showed up to 55% of
gene silencing. Therefore, we selected siRNA-1036 and siRNA-1033 to determine the
effect of siRNA dose on TGF-β1 gene silencing. We also tested the pool of siRNAs
targeting 769 and 1033, which also showed high TGF-β1 gene silencing (Figure 5-3). As
shown in Figures 5-4A and 5-4B, there was significant increase in the TGF-β1 silencing
effect as we increased the doses of siRNA-1033 and siRNA-1036 from 10 nM to 150 nM,
with siRNA-1036 showing the highest TGF-β1 gene silencing at 150 nM.
We also determined the level of TGF-β1 secreted into the cell culture medium by
Western blot analysis at days 2 post-transfection of HSC-T6 cells with siRNAs targeting
TGF-β1 start sites of 769 and 1033 as well as the pool of these two siRNAs. As shown in
Figure 5-4, the level of TGF-β1 protein secreted in the culture medium was significantly
lower than that of non-transfected and control-siRNA transfected samples.
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Figure 5-3 Effect of siRNA sequence on TGF-β1 gene silencing. Ten different siRNAs
targeting different regions of TGF-β1 mRNA were transfected into HSC-T6 cells at a
dose of 150 nM after complex formation with Lipofectamine 2000. TGF-β1 gene
silencing was determined by real time RT-PCR at 48 h post-transfection. Results were
represented as the mean±SD (n=3). *p<0.05, **p<0.01.
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Figure 5-4 Effect of siRNA concentration on TGF-β1 silencing. Lipofectamine
2000/siRNA complexes were transfected into HSC-T6 cells at doses of 10, 25, 50, 100,
and 150 nM. TGF-β1 gene silencing was determined by real time RT-PCR at 48 h
post-transfection. Results were represented as the mean±SD (n=3). *p<0.05, **p<0.01.
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5.3.2.

Effect of TGF-β1 Gene Silencing on TIMP-1 Expression

TGF-β1 is the key cytokine of fibrotic response to chronic liver injuries. It not only
enhances ECM synthesis, but also inhibits ECM degradation by down-regulating
matrix-degrading enzymes and inducing tissue inhibitor of metalloproteinases-1
(TIMP-1).251 Therefore, we measured TIMP-1 mRNA expression of HSC-T6 cells after
transfection with TGF-β1 siRNAs. As shown in Figure 5-5, both siRNA-1033 and
siRNA-1036 inhibited TIMP-1 expression, while the control siRNA did not show any
effect on TIMP-1 expression. These results suggest the similar inhibition profile of
TIMP-1 and TGF-β1 after transfection of HSC-T6 cells with siRNA targeting TGF-β1.
5.3.3.

Effect of siRNA on Type α(I) Collagen and α-SMA Expression

Inhibition of TGF-β1 should enhance the degradation of ECM, in which type I
collagen is the main component. Therefore, we designed type α(I) collagen mRNA
specific primers to determine the effect of TGF-β1 siRNA on type α(I) collagen mRNA
expression. At 150 nM, siRNA-1036 showed significant inhibition of type α(I) collagen
mRNA (Figure 5-6A), while the control siRNA had little effect on α(I) collagen mRNA
expression. We also determined the effect of TGF-β1gene silencing on type α(I) collagen
protein expression by Western blot analysis of lysates of HSCT-6 cells after transfection
with siRNA targeting TGF-β1 start sites of 769 and 1033 as well as the pool of these two
siRNAs (Figure 5-6B). Consistent with the RT-PCR results, there was significant
decrease in collagen of siRNA-769, siRNA-1033 and siRNA pool, while there was no
decrease in collagen concentration for the control-siRNA treated sample.
5.3.4.

Construction of shRNA Expression Vector

Following screening of different siRNA sequences for TGF-β1 gene silencing, we
selected two potent siRNA sequences, which contain unique restriction sites at the 5’ and
3’ ends for cloning and a TTTTTT stretch in the sense to create the pol III terminal signal
(Table 5-2). Then, these shRNA sequences were cloned into pRNAT-H1.1 and
pSilencer1.0 as illustrated in Figure 5-7. The vector contains GFP under the control of
CMV promoter, which can be used to track the transfection efficiency. pshRNA 769,
pshRNA-1033 and pshRNA-1036 were confirmed by DNA sequencing using the
following primers: forward: 5’-TAATACGACTCACTATAGGG-3’ and reverse:
5’-TAGAAGGCACAGTCGAGG-3’.
5.3.5.

Effect of shRNA Expression on TGF-β1 Silencing

We determined the silencing effect of shRNA at different doses (0.5 and 1 µg) per
well. shRNA expression plasmids showed higher TGF-β1 gene silencing effect at 1 µg
than that at 0.5 µg (Figure 5-8A). Among all the three shRNA expression plasmids we
used, the plasmid encoding shRNA targeting 1033 and 1036 coding regions showed
81

Figure 5-5 Western blot analysis for TGF-β1 gene silencing after transfection of HSC-T6
cells with Lipofectamine/siRNA complexes. From left to right, no siRNA, control
siRNA, siRNA-1033, siRNA-769 and pool of siRNA-1033 and siRNA-769. From top to
bottom, TGF-β1 and β-Actin.

82

Figure 5-6 Effect of TGF-β1 gene silencing on TIMP-1 gene expression after transfection
of HSC-T6 cells with Lipofectamine 2000/siRNA complexes. At 48 h posttransfection,
cells were harvested, total RNA was extracted, and TIMP-1 gene expression was
determined at mRNA level using real time RT-PCR. Results were represented as the
mean±SD (n=3). *p<0.05, **p<0.01.
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Figure 5-7 Effect of TGF-β1 gene silencing on type α1(I) collagen and α-SMA
expression after transfection of HSC-T6 cells Lipofectamine 2000/siRNA-1033, 769 and
pool complexes. A) At 48 h post transfection, cells were harvested, total RNA was
extracted, and type α1(I) collagen and α-SMA expression was determined at mRNA
levels using real time RT-PCR. Results were represented as the mean±SD (n=3).
**p<0.01. B) Western blot analysis for type α1(I) collagen expression after TGF-β1 gene
silencing.
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Figure 5-8 Effect of TGF-β1 gene silencing on type α1(I) collagen and TGF-β1
expression after transfection of HSC-T6 cells with pshRNA-1033 or pshRNA-769 after
complex formation with pyridinium lipid / DOPE cationic liposomes.147 At 42 h
post-transfection, cells were harvested, total RNA was extracted, and TGF-β1 expression
was determined at mRNA levels using real time RT-PCR. A) In addition, protein levels
of TGF-β1 and type I collagen in the supernatant were determined using Western blot. B)
Results were represented as the mean±SD (n=3). **p<0.01.
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significantly higher TGF-β1 gene silencing compared to that of the shRNA expression
plasmid targeting TGF-β1 start site of 769. There was also similar decrease in TGF-β1
gene expression (Figure 5-8B), which is in good agreement with the results of synthetic
siRNAs. However, the silencing effect of shRNA was somewhat lower than that of
synthetic siRNA targeting at the same coding region.
The shRNA constructed by pSilence1.0, delivered by mixture with Lipo-Lin, shows
great transfect effect on protein level. The shRNA expression plasmids targeting TGF-β1
start site of 1033 and 769 apparently decreased the expression of both TGF-β1 and
Collagen type I.
5.3.6.

ELISA Analysis of TNF-α and IL-1β

Since liver inflammation correlates with hepatic fibrosis, silence of TGF-β1 might
affect inflammation in the liver. To determine whether the down-regulation of TGF-β1
decreased the expression of collagen through changing the extent of inflammation, we
measured the concentration of TNF-α and IL-1β using ELISA kits.
From Figure 5-9, the amount of TNF-α was decreased to 43.41±4.03% and
51.85±4.75 respectively comparing to the group which was not treated with TGF-β1
shRNA. In the same trend, the level of IL-1β also been down regulated to 49.12±5.78%
and 59.49±9.67% respectively comparing to the control group (Figure 5-9).
5.3.7.

Persistence of Gene Silencing

To compare siRNA and shRNA on TGF-β1 gene silencing, we transfected HSC-T6
cells with siRNA-1033 and pshRNA-TGF-β1-1033 after complex formation with
pyridinium liposomes at 3/1 (+/-) ratio. As shown in Figure 5-10, the level of TGF-β1
mRNA was significantly low for the pshRNA-TGF-β1 group, which was lowest at 48 h
post-transfection compared to 24 h post-transfection for siRNA-TGF-β1 group. The level
of TGF-β1 gene silencing significantly decreased with time, being the lowest at 72 h
post-transfection for siRNA groups. However, for shRNA group, the silence still took
effect after 72 h.
5.4.

Discussion

Liver fibrosis results from chronic injuries to the liver by chronic hepatitis, alcohol
abuse, and toxic agents. Among all fibrogenic cytokines, TGF-β is the key mediator of
liver fibrosis and thus has gained very high attention. TGF-β contains three isoforms,
such as TGF-β1, TGF-β2 and TGF-β3. TGF-β1 is the dominant stimulus to ECM
production from HSCs and its expression increases during liver fibrosis. TGF-β1 can be
secreted by Kupffer cells, biliary cells and infiltrated inflammatory cells, while the
autocrine expression of TGF-β1 by HSCs is the most important. Compared to quiescent
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Figure 5-9 Effect of TGF-β1 gene silencing on TNF-α and IL-1β secretion. HSC-T6 cells
were transfected with pshRNA-1033 and pshRNA-769 after complex formation with
pyridinium lipid (C16:1, amide linker, transisomer)/DOPE (1:1 mol/mol) cationic
liposomes. Following transfection, TNF-α and IL-1β concentrations were measured by
enzyme-linked immunosorbent assay (ELISA). Results were represented as the mean±SD
(n=3). *p<0.05, **p<0.01.
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Figure 5-10 Persistence of siRNA and shRNA gene silencing. HSC-T6 cells were
transfected with siRNA-1033 and shRNA-769 after complex formation with pyridinium
lipid (C16:1, amide linker, trans)/DOPE(1:1 mol/mol) cationic liposomes as described
above. After 3 h of transfection, 200 μL of FBS was added and incubated for another 24
h, 48 h and 72 h. At different time points, the cells were collected and total RNA was
isolated for real time RT-PCR analysis.
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HSCs, fully activated HSCs are relatively unresponsive to TGF-β1, possibly due to the
down-regulation of TGF-β receptor. TGF-β1 knockout mice have shown reduced
collagen accumulation to liver injury compared to that of normal mice.252 Disrupting
TGF-β1 synthesis or signaling pathways significantly decreased fibrosis in experimental
animal model.237,240 However, due to its multiple actions, TGF-β represents a potentially
important link between neoplasia and fibrosis in the liver. Mutation of TGF-β receptor or
signaling intermediates has been found in various epithelial cancers.242 Strategies aimed
at disrupting TGF-β1 expression or signaling pathways are being extensively investigated
for treating liver fibrosis and various animal studies demonstrated antifibrotic
effect.44,237,240-244 Currently, neutralizing antibodies, soluble TGF-β receptors, antisense
oligonucleotide and siRNA were explored to block TGF-β1 signaling pathway.
Selection of a potent siRNA sequence targeting a specific gene is a crucial step in
developing its therapeutic applications. In this study, we used BLOCK-iT RNAi Designer
from Invitrogen to design ten synthetic siRNAs (Table 5-1) targeting at different coding
regions of TGF-β1 mRNA. As shown in Figure 5-3, only 4 siRNAs showed significant
effect on TGF-β1 gene silencing, while other 6 siRNAs did not show any effect. All these
4 sRNAs are located in the coding regions of TGF-β1 mRNA starting from 769 to 1036.
Among these 4 siRNAs, siRNAs targeting 1033 and 1036 coding sites showed the
highest TGF-β1 gene silencing. This may be due to the local secondary structure of target
mRNA.
Two selected siRNAs, such as siRNA-1033 and siRNA-1036, showed dose
dependent inhibition of TGF-β1 mRNA (Figure 5-3). The silencing effect of siRNA-1036
was similar to that of siRNA-1033 at low concentration, but more significant at high
concentration (150 nM). At low concentrations, both siRNAs showed little inhibition and
therefore it is difficult to distinguish which one is more effective. Considering there is
only 3 base sequence shift between siRNA-1033 and siRNA-1036, the significant
difference in silencing indicated that the silencing was very sequence specific.
The in vivo stability of synthetic siRNA and the high cost for in vivo studies hamper
its therapeutic application. Therefore, we decided to construct a plasmid based shRNA
targeting the most potent region of the TGF-β1 mRNA. Compared to synthetic siRNA,
shRNA expression plasmid showed relatively poor transfection and gene silencing in
HSC-T6 cell lines. The silencing effect of shRNAs targeted at 1033 and 1036 was less
than synthetic siRNA targeted at the same position (Figure 5-2 and Figure 5-8A).
Nevertheless, shRNA showed similar silencing trend as synthetic siRNA. Its consistent
expression ability in the cells and ease to produce makes it a promising vector for
therapeutic application.
The development of chronic liver diseases is mediated by sustained hepatic
inflammation. Many studies have shown various cytokines, which are crucial indicators
of inflammation, such as TGF-β1 and TNF-α, are very important activators during the
process of liver fibrosis.253-255 TNF-α has been reported closely related to liver fibrosis
and cirrhosis.255 We investigated the level of TNF-α after we treated HSCs with TGF-β1
shRNA. It was demonstrated that application of TGF-β1 shRNA decreased the TNF-α
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concentration in the cell culture serum. The possibility is that decreasing of TGF-β1
might down regulate the extent of inflammation and then affect the level of TNF-α.256
IL-1β is another very important in the liver fibrosis and enhanced local inflammatory
response contribute to IL-1beta release, which is crucial to chronic liver fibrosis. IL-1β is
another important cytokine, which is known to promote local inflammatory response and
consequently promotes chronicliver fibrosis.257 Our results also showed that there is
significant decrease in secreted IL-1β upon TGF-β1 gene silencing (Figure 5-9B). Both
TNF-α and IL-1β levels correlated with TGF-β1 gene silencing levels.
In summary, we have successfully designed and validated TGF-β1-specific siRNAs
and then converted two potent siRNA sequences into shRNAs, which effectively silenced
TGF-β1 gene expression in HSC-T6 cells. TGF-β1 gene silencing significantly reduced
the production of type I collagen, TIMP-1, and inflammatory cytokines. Our results
suggested that silencing of TGF-β1 by siRNA and shRNA may be an efficient and more
specific approach for therapy of liver fibrosis.
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CHAPTER 6. GFAP PROMOTER-DRIVEN RNA INTERFERENCE ON TGF-Β1
TO TREAT LIVER FIBROSIS
6.1.

Introduction

Fibrosis is a scarring response that occurs in almost all patients with chronic liver
injury. If not controlled, liver fibrosis leads to cirrhosis, which is associated with nodule
formation and organ contraction.258 Transforming Growth factor beta 1 (TGF-β1) is a
potent stimulus of hepatic stellate cells (HSCs), which produce excess collagen and other
extracellular matrices (ECM).259 The positive feedback production of TGF-β1 by
activated HSCs liver injury make situation worse. Therefore, TGF-β1 gene silencing
produced by HSCs becomes crucial in treating liver fibrosis.
Strategies for disrupting TGF-β1 expression are extensively being investigated
because inhibiting this cytokine may not only inhibit ECM production but also accelerate
its degradation.239 The use of different strategies to inhibit TGF-β1 gene expression has
shown antifibrotic effect for treating liver fibrosis in animal models.44,240-243 RNA
interference (RNAi) is the phenomenon in which small interfering RNA (siRNA) of
21-23 nt in length silences target gene expression by binding to its complementary
mRNA and triggering mRNA degradation.260 Compared to antisense ODNs, antibodies
and soluble TGF-β1 receptor, siRNA is likely to be quite potent in inhibiting TGF-β1
gene expression. We have also recently demonstrated siRNA sequence and dose
dependent TGF-β1 gene silencing.29
The standard polymerase III (pol III) promoters, such as U6 and H1, have robust and
constitutive activity across multiple cell types.261 However, these Pol III promoters do not
provide the spatial or temporal control of target gene silencing that is desirable for
treating liver fibrosis. TGF-β1 is a growth factor involved in many physiological
activities. The promoter which can only drive TGF-β1 shRNA expression by specific cell
types in the body should be utilized for target gene silencing.
In this chapter, to avoid the side effect of nonspecific TGF-β1 gene silencing, we
constructed an HSC-specific expression plasmid. It is the first time to construct TGF-β1
pri-miRNA mimic plasmids driven by glial fibrillary acidic protein (GFAP) promoter,
which relies on RNA polymerase II to achieve RNAi if the shRNA inserts are bracketed
by pri-miRNA backbone. Even though we found that the silencing level of GFAP driven
TGF-β1 pri-miRNA mimics were less than U6 drivien ones, the pri-miRNA cluster
mimics of two shRNA inserts showed high silencing effect to compensate this
phenomenon.
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6.2.

Materials and Methods

6.2.1.

Materials

Dulbecco’s modified Eagle’s medium (DMEM), penicillin G (5000 U/mL),
trypsin-EDTA, Trizol, DNase I, and Lipofectamine 2000 were purchased from Invitrogen
(Carlsbad, CA). pSilencer1.0 was purchased from GenScript Corporation (Piscataway,
NJ). All of the restriction enzymes were purchased from New England Biolabs (Ipswich,
MA). SYBR Green-1 dye universal master mix and MultiScribe reverse transcriptase
were purchased from Applied Biosystems, Inc. (Foster City, CA). All the primers for
Real Time PCR were purchased from Integrated DNA Technologies, InC. TGF-β1
primary antibody, type α1(I) collagen primary antibody and rabbit anti-rat secondary
antibody were purchased from Santa Cruz Biotech, Inc. (Santa Cruz, CA). TNF-α
enzyme-linked immunosorbent assay (ELISA) kits were purchased from eBioscience,
Inc. (San Diego, CA).
6.2.2.

Construction of shRNA Expression Plasmids

Based on our recently published results, we selected two potent siRNA sequences
targeting 769 and 1033 start sites of TGF-β1 mRNA and converted them into shRNA
sequences for cloning into pSilencer 1.0 vector, which carries an shRNA expression
cassette under the control of a U6 promoter. These shRNAs contain two complementary
oligonucleotides, which were annealed to form a double stranded DNA for ligation into
pSilencer vector. pU6-shRNA-769, pU6-shRNA-1033, pU6-shRNA-769+1033 and
pU6-shRNA-scramble were constructed as mentioned in our previous study.29 For
HSC-specific gene silencing, GFAP promoter was cloned by the Long Range PCR kit by
using pGFA2 vector as a template, which is a gift from Dr. Michael Brenner of the
Depatment of Neurology at the University of Alabama. Then, GFAP promoter fragment
was inserted into pRNAT H1.1 to replace the H1 promoter in pRNAT H1.1 to make
pGFA-RNAT H1.1 vector. pGFAP-mi-shRNAs were constructed by inserting the
pre-designed mi-shRNA sequence with microRNA 30 context to pGFA-RNAT H1.1.
The sequences for all the predesigned mi-shRNA sequences are shown in Table 6-1.
6.2.3.

Transfection

The day before transfection, HSC-T6 cells were seeded in 6 well plate at a number of
1×106 cells per well. When the cell confluence reached 80 to 90%, cells were transfected
with shRNA expression vectors at doses of 1 µg/well. The shRNA plasmids were mixed
with Lipofectamine 2000 at a 1:3 w/v (µg/μL) ratio in 250 µL Dulbecco's Modified
Eagle's Medium (DMEM) without serum for 20 min at room temperature to allow
complex formation. The transfection mixture was then added to each plate with 2 mL
fetal bovine serum (FBS) free DMEM. After 4 h of incubation, 200 μL FBS was added
per well and incubated for additional 42 h.
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Table 6-1 Pri-miRNA mimic inserts sequences.
mi-shRNA insert

Sequence

mi-shRNA-1033

GGATCCGTCGACTAGGGATAACAGGGTAATTGTTTGAA
TGAGGCTTCAGTACTTTACAGAATCGTTGCCTGCACAT
CTTGGAAACAGCTGGGATTACTTCTTCAGGTTAACCCA
ACAGAAGGCTCGAGAAGGTATATTGCTGTTGACAGTG
AGCGCCGCAGCTGTACATTGACTTTGTGAAGCCACAGA
TGTAAAAGTCAATGTACAGCTGCTGCCTACTGCCTCGT
CTAGAAAGGGGCTACTTTAGGAGCAATTATCTTGTTTA
CTAAAACTGAATACCTTGCTATCTCTTTGATACATTTTT
TGGATCC

mi-shRNA-769

GGATCCGTCGACTAGGGATAACAGGGTAATTGTTTGAA
TGAGGCTTCAGTACTTTACAGAATCGTTGCCTGCACAT
CTTGGAAACAGCTGGGATTACTTCTTCAGGTTAACCCA
ACAGAAGGCTCGAGAAGGTATATTGCTGTTGACAGTG
AGCGCCGAACCAAGGAGACGGAATAGTGAAGCCACAG
ATGTATATTCCGTCTCCTTGGTTCTGCCTACTGCCTCGT
CTAGAAAGGGGCTACTTTAGGAGCAATTATCTTGTTTA
CTAAAACTGAATACCTTGCTATCTCTTTGATACATTTTT
TGGATCC

mi-shRNA-769+1033

GGATCCGTCGACTAGGGATAACAGGGTAATTGTTTGAA
TGAGGCTTCAGTACTTTACAGAATCGTTGCAGCTGTAC
ATTGACTTTGTGAAGCCACAGATGTAAAAGTCAATGTA
CAGCTGCGCCTGCACATCTTGGAAACAGCTGGGATTAC
TTCTTCAGGTTAACCCAACAGAAGGCTCGAGAAGGTAT
ATTGCTGTTGACAGTGAGCGCCGAACCAAGGAGACGG
AATAGTGAAGCCACAGATGTATATTCCGTCTCCTTGGT
TCTGCCTACTGCCTCGTCTAGAAAGGGGCTACTTTAGG
AGCAATTATCTTGTTTACTAAAACTGAATACCTTGCTAT
CTCTTTGATACATTTTTTGGATCC
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6.2.4.

Real Time PCR

Following transfection, total RNA was extracted from the cells by RNAeasy Mini Kit
and the RNA concentration was measured by UV spectrophotometry using Nanodrop
spectronanometer (Thermo Scientific, Pittsburgh, PA). Then, 385 ng of the total RNA per
sample was reverse transcribed into cDNA using MultiScribe Reverse Transcriptase
Reagent and random hexamers. The obtained cDNA was amplified by real time PCR
using SYBR Green-1 dye universal master mix on ABI Prism 7700 Sequence Detection
System (Applied Biosystems, Inc., Foster City, CA).
6.2.5.

Western Blot Assay

Transfected cells were lysed using 1×Laemmli sodium dodecyl sulfate (SDS) sample
buffer. The lysed protein was then boiled at 100°C for 5 min and subjected to 4% or 10%
SDS-polyacrylamide (SDS-PAGE) gel electrophoresis and subsequent transfer by iBLot
system. After blocking with 5% nonfat dried milk in 1×PBST containing 0.05%
Tween-20 in PBS for 1 h at room temperature, the membranes were incubated with goat
anti-rat type I collagen, rabbit anti-rat TGF-β1 and goat anti-rat β-actin primary
antibodies for 16 h at 4°C. Membrane was then incubated with horseradish peroxidase
conjugated goat anti-rabbit secondary antibody for 1 h at room temperature. Target
proteins were detected by enhanced chemiluminescence detection kit (ECL, GE
Healthcare).
6.2.6.

Trypan Blue Staining

Transfected HSC-T6 cells were suspended in DMEM medium at a concentration of
1×105/mL in a 1.5 mL tube. Five hundred microliter of cells and 0.1 mL 0.4% trypan blue
staining buffer were mixed thoroughly. The staining samples were allowed standing at
the room temperature for 5 min and then 10 µL was applied to a hemocytometer for cell
counting.
6.2.7.

ELISA Assay of TNF-α

After transfection, the supernatant of the cultured cells was collected and the
concentration of TNF-α was measured using enzyme-linked immunosorbent assay
(ELISA) (eBioscience, San Diego, CA), according to the manufacturer's protocol.
6.2.8.

HSC Wound Healing Assay

Wound healing assay of transfected HSC-T6 cells was carried out as described by Liu
et al.262 with minor modification. Briefly, HSC-T6 cells were seeded in 6-well plates at a
number of 1×106 per well and allowed to grow in DMEM growth medium containing
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10% serum. The cells were then deprived of serum for 6 h when the cell’s confluence
reached 95%. Then, the cells were transfected with Lipofectamine 2000/pshRNA
complexes at a dose of 1 μg plasmid per well. After transfection, the cells were still
cultured in DMEM without serum. The cell monolayer was disrupted by a scratch to
mimic wound. The cells were then cultured for additional 16 h, and the wound was
observed under a microscope.
6.2.9.

Cell Migration Assay

Migration assays were performed in Transwell membrane filter inserts in 24-well
tissue culture plates (BD Labware, Bedford, MA) with the pore size in polycarbonate
membranes of 8 μm. The lower surface of inserts membranes were pre-incubated with
fibronectin diluted in 10 mmol/L NaHCO3 4°C overnight and then blocked with 0.1%
heat-inactivated BSA at 37°C for 30 min. Cells tansfected with pri-miRNA mimics were
detached, washed once in PBS, and then resuspended in DMEM containing 0.1% BSA. A
300 μL cell suspension containing 8×103 cells was added to each insert. DMEM
containing 1% FBS was added to the lower wells in the 24-well cell culture plate.
Migration was allowed to proceed at 37°C for 4 h. Cells that did not migrate through the
filters were removed by cotton swabs. After fixing and staining with Diff-Quick (Baxter
Healthcare Corp., McGraw Park, IL), the cells were photographed by microscope.
6.3.

Results

6.3.1.

Effect of shRNA Sequence on TGF-β1 Silencing

To examine the effect of shRNA sequence on TGF-β1 gene silencing, we transfected
HSC-T6 cells with pU6-shRNA-scramble, pU6-shRNA-769, pU6-shRNA-1033 and
pU6-shRNA-769+1033 respectively after complex formation with Lipofectamine 2000.
Real time RT-PCR results (Figure 6-1A) showed decrease in TGF-β1 gene expression in
HSC-T6 cells to 53.60±1.33%, 48.05±7.51% and 24.09±0.25% by pU6-shRNA-769,
pU6-shRNA-1033 and pU6-shRNA-769+1033, respectively, compared to
pU6-shRNA-scramble. The plasmid encoding two shRNAs targeting two different
regions such as 769 and 1033 start sites of TGF-β1 mRNA were more effective in
TGF-β1 gene silencing, compared to the plasmids encoding single siRNA.
TGF-β1 gene silencing should enhance the degradation of type I collagen. We,
therefore, determined the effect of TGF-β1 gene silencing on type I collagen protein
expression by Western blot analysis. There was significant decrease in collagen of
pU6-shRNA-769, pU6-shRNA-1033 and pU6-shRNA-769+1033 treated groups, while
little decrease in collagen concentration for the control shRNA treated samples (Figure
6-1B).
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Figure 6-1 Effect of shRNA sequences on TGF-β1 gene silencing and its effect on
collagen gene expression. HSC-T6 cells were transfected by pU6-shRNA-scramble,
pU6-shRNA-769, pU6-shRNA-1033 and pU6-shRNA-769+1033, respectively after
complex formation with Lipofectamine 2000. A) Real-time RT-PCR. Results are
expressed as the mean±SD (n=4). B) Western blot analysis.
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6.3.2.

Effect of Promoters and Pri-miRNA Mimics on TGF-β1 Gene Silencing

For HSC-specific gene silencing, we used pGFA-shRNA-1033 driven by GFAP
promoter but failed to produce any TGF-β1 silencing effects (Figure 6-2A). However,
still directed by GFAP promoter, the pri-miRNA mimic, pGFA-mi-shRNA-1033,
reduced the total amount of TGF-β1 mRNA to 44.05±1.60% of that in the HSC-T6 cell
line administrated by pGFA-RNAT H1.1 with scramble sequence as the control (Figure
6-2A). pGFA-mi-shRNA-1033 driven by GFAP promoter had less silencing efficiency
than pU6-shRNA-1033 driven by U6 promoter by comparing the third bar and the fourth
bar in Figure 6-2A. The total amount of TGF-β1 mRNA in HSC-T6 treated by
pU6-shRNA was only 29.28±1.59% of the control.
HSC-T6 cells were transfected by GFAP promoter driven plasmids, which produced
pri-miRNA mimics or pri-miRNA cluster mimics and decreased TGF-β1 mRNA level
(Figure 6-2B). Real time RT-PCR results revealed TGF-β1 gene expression in HSC-T6
cells was decreased to 69.54±5.04%, 45.95±2.45% and 35.65±3.82% by
pGFA-mi-shRNA-769, pGFA-mi-shRNA-1033 and pGFA-mi-shRNA-769+1033,
respectively, compared to the control.
6.3.3.

HSC-T6 Proliferation and Apoptosis

To determine the effect of GFAP driven TGF-β1 pri-miRNA mimics and pri-miRNA
cluster mimics on HSC-T6 proliferation and apoptosis, we did MTT assay.
pGFA-mi-shRNA-769, pGFA-mi-shRNA-1033 and pGFA-mi-shRNA-769+1033
effectively prevented HSC-T6 cell proliferation (Figure 6-3A). Similarly, Western blot
analysis showed decrease in the phosphorylation of extracellular-signal related kinase
(p-ERK) due to TGF-β1 gene silencing, which further proved the inhibition of HSC-T6
proliferation after transfection of HSC-T6 cells with TGF-β1 pGFA-mi-shRNA plasmids
(Figure 6-3B). Western blot of ERK did not show any change in band thickness,
suggesting an equal amount of proteins in each sample.
Trypan blue staining and caspase activity analysis demonstrateded that TGF-β1
silencing also increased HSC-T6 apoptosis (Figure 6-4A, B). The caspase-3/7 activity
was dramatically increased in HSC-T6 cells after transfection of HSC-T6 cells with
pGFA-mi-shRNAs, especially for 769+1033 cluster (Figure 6-4A), which correlated well
with decrease in HSC-T6 cell viability (Figure 6-4B).
6.3.4.

TGF-β1 pGFA-mi-shRNAs Decreases TNF-α Amount in Cell Culture Medium

TNF-α concentration was decreased after transfection with pGFA-mi-shRNA
plasmids. pGFA-mi-shRNA-769, pGFA-mi-shRNA-1033 and
pGFA-mi-shRNA-769+1033 decreased TNF-α concentration in HSC-T6 cell culture
medium to 281.27, 275.85 and 235.55 pg/mL from 483.50 pg/mL of the control group
(Figure 6-5).
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Figure 6-2 Effects of promoters and pri-miRNA mimics on TGF-β1 silencing. After 42 h
post-transfection of pri-miRNA mimics and pri-miRNA cluster mimics, cells were
harvested, total RNA was extracted, and TGF-β1 gene expression was determined at
mRNA levels using real-time RT-PCR. Results were represented as the mean±SD (n=3).
A) pGFA-shRNA-1033 showed no TGF-β1 gene silencing, whereas
pGFA-mi-shRNA-1033 reduced the total amount of TGF-β1 mRNA.
pGFA-mi-shRNA-1033 had less silencing efficiency than pU6-shRNA-1033. B)
pGFA-mi-shRNA-769, pGFA-mishRNA-1033 and pGFA-mishRNA-769+1033
decreased TGF-β1 mRNA level in HSC-T6 cells. pGFA-mi-shRNA-769+1033,
producing pri-miRNA cluster mimics, had more silencing effects.
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Figure 6-3 Effects of GFAP-driven TGF-β1 pri-miRNA mimics and pri-miRNA cluster
mimics on HSC-T6 proliferation. After 42 h posttransfection with TGF-β1 pri-miRNA
mimics plasmids and pri-miRNA cluster mimics plasmids, cells were harvested. A) MTT
assay showed the cell viability of the HSC-T6 cells transfected by pGFA-control,
pGFA-mi-shRNA-769, pGFAmi-shRNA-1033 and pGFA-mi-shRNA-769+1033. Results
are expressed as the mean±SD (n=3). B) Western blot analysis of p-ERK after
transfection of HSC-T6 cells with pGFA-control, pGFA-mishRNA-769,
pGFA-mi-shRNA-1033 and pGFA-mi-shRNA-769+1033. Western blot analysis of ERK
was also performed for normalizing the amounts of proteins in each sample.
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Figure 6-4 Effects of GFAP-driven TGF-β1 pri-miRNA mimics and pri-miRNA cluster
mimics on HSC-T6 apoptosis. After 42 h post-transfection with TGF-β1 pri-miRNA
mimics plasmids and pri-miRNA cluster mimics plasmids, cells were harvested. A)
caspase activity analysis demonstrated the change after transfection of HSCT6 cells with
pGFA-control, pGFA-mi-shRNA-769, pGFA-mi-shRNA-1033 and
pGFA-mi-shRNA-769+1033. B) trypan blue staining displayed the ratio of apoptotic
HSC-T6 cells after transfection with pGFA-control, pGFA-mi-shRNA-769,
pGFA-mi-shRNA-1033 and pGFA-mi-shRNA-769+1033. Results are expressed as the
mean±SD (n=4).
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Figure 6-5 Effects of GFAP-driven TGF-β1 pri-miRNA mimics and pri-miRNA cluster
mimics on secretion of inflammatory cytokines by HSC-T6 cells. After 42 h
post-transfection with TGF-β1 pri-miRNA mimics plasmids and primiRNA cluster
mimics plasmids, concentration of TNF-α in cell culture medium was measured by
ELISA. Results are expressed as the mean±SD (n=4).
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6.3.5.

Pmi-shRNAs-TGF-β1 Impedes HSC-T6 Migration

The wounded HSC-T6 monolayers transfected with GFAP promoter driven
scrambled shRNA expression vectors induced cell migration leading to wound closure at
16 h after wounding (Figure 6-6A.a). However, transfection of pGFA-mi-shRNA-769
(Figure 6-6A.b), pGFA-mi-shRNA-1033 (Figure 6-6A.c) and
pGFA-mi-shRNA-769+1033 (Figure 6-6A.d) impeded wound closure and remained
wound gaps. In the directional cell migration toward fetal bovine sera, HSC-T6
transfected with pGFA-mi-shRNA-769+1033 showed the least migration ability (Figure
6-6B.d) compared to the control group (Figure 6-6B.a). Both of groups transfected with
pGFA-mi-shRNA-769 (Figure 6-6B.b), pGFA-mi-shRNA-1033 (Figure 6-6B.c) also
showed less migration.
6.3.6.

Cell Specificity of GFAP Promoter Driven shRNA Expression

After transfection with pGFA-mi-shRNA-1033 and U6-mi-siRNA-1033, the
remaining TGF-β1 mRNA level in rat INS-1E cell line was decreased to 57.77±7.55% by
U6 promoter driven plasmids, compared to the blank control (Figure 6-7). However,
GFAP promoter did not show this phenomenon.
6.4.

Discussion

Chronic liver injuries often activate HSCs to overproduce ECM proteins and several
fibrogenic proteins. Among them, TGF-β1 is the key mediator of liver fibrosis. TGF-β1
knockout mice have shown reduced collagen accumulation in response to liver injury.252
Inhibition of TGF-β1 gene expression or its signaling has been shown to decrease fibrosis
in experimental animal model.251,263 Therefore, in this study, we selected two potent
siRNA sequences for converting into shRNA and then cloning into pSilencer1.0 vector
driven by a ubiquitous U6 promoter due to its relatively ease of producing shRNA
transcripts. Transfection of HSC-T6 cells with these plasmids showed decent
down-regulation of TGF-β1 mRNA. Co-expression of two shRNAs targeting 769 and
1033 TGF-β1 mRNA start sites showed higher TGF-β1 gene silencing. This finding is in
good agreement with our previous study where we demonstrated that the mixture of two
potent siRNA sequences, targeting 769 and 1033 start sites of TGF-β1 mRNA showed
higher TGF-β1 gene silencing compared to single siRNA application at the same total
concentration.29
TGF-β1 is overexpressed by HSCs and U6 promoter drives high levels of shRNA
expression by all types cells which may elicit toxicity. Pri-miRNA mimics have the
potential to mitigate this problem as they can utilize low expression RNA polymerase II
(pol II) promoter. GFAP is an intermediate filament protein identified as a biomarker for
both quiescent and activated HSCs.264 Furthermore, GFAP promoter has recently been
utilized for HSC-specific gene expression265,266 and is effective controlled by pol II,
which can only recognize microRNA but not shRNA. Therefore, we selected miR-30
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Figure 6-6 Wound-healing and chamber migration assays. A) HSCs were grown to
confluence and were disrupted to generate a linear wound, and then transfected with a)
pGFA-control, b) pGFA-mi-shRNA-769, c) pGFAmi-shRNA-1033 and d)
pGFA-mi-shRNA-769+1033 plasmids after complex formation with lipofectamine 2000
at a dose of 1 μg/well. After another 16 h incubation in none serum medium, photographs
were taken by microscope. B) After transfection with a) pGFA-control, b)
pGFA-mishRNA-769, c) pGFA-mi-shRNA-1033, and d) pGFA-mi-shRNA-769+1033
plasmids, purple spots indicated the migrated HSC-T6 cells to the bottom of the
chambers.
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Figure 6-7 Cell specificity of GFAP promoter-driven shRNA expression. After
transfection with pGFA-mi-shRNA-1033 and U6-mi-siRNA-1033, the remaining
TGF-β1 mRNA level in rat INS-1E cell line was decreased to 57.77±7.55% by U6
promoter driven plasmids, compared to the blank control.
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to be incorporated into the constructed plasmids. miR-30 has been investigated a lot in
recent years, which are involved in many areas in the body. miR-30 was upregulated in
activated HSCs.267 Ji et al. demonstrated the expression of miRNA-30 was upregulated to
more than 3 folds in activated HSCs than quiescent HSCs. This phenomenon facilitates
TGF-β1 gene silencing in activated HSCs and reduces the unnecessary silencing in
quiescent HSCs. However, there were some studies already demonstrated that the
silencing effects of pri-miRNA mimics were decreased compared to matched
shRNAs.268,269 It is good for the body because there may be some protective machinery
from excessive intrinsic microRNA production to prevent toxicity in the cells, compared
to artificial shRNA. In our study, the pri-miRNA mimics driven by GFAP promoter
showed TGF-β1 gene silencing significantly less than the matched shRNA driven by U6
promoter (Figure 6-2A). The choice between target expression and non-specific
expression was affected by the balance between shRNAs and pri-miRNA mimics
silencing effects. Fortunately, the pri-miRNA cluster mimics, which can target multiple
sites in the same gene, in our case is TGF-β1, controlled TGF-β1 level to a lower level
relative to pri-miRNA mimics (Figure 6-2B).
Besides the function of promoters, the secondary structure of pre-miRNA mimics
plays an important role in efficient processing of miRNA-based silencing in vitro270 and
in vivo.271 The extended stem-loop structure in pri-miRNA mimics need to be bracketed
by single stranded RNA, otherwise Drosha cannot recognize pri-miRNA transcriptions
and process them correctly.272 From the secondary RNA structure software RNAstructure
version 5.1, the pre-miRNA cluster mimic designed by our lab did have its extended
stem-loop structure been flanked by single strand RNA (Figure 6-8).
TGF-β1 is a protein that controls proliferation, apoptosis, and other functions in most
cells. The TGF-β family is considered as a negative cell proliferation controller and
positive apoptosis inducer. TGF-β1 has been shown recently to increase the proliferation
of variety of cells, for instance, airway smooth muscle cells,273 colon carcinoma
cells,274,275 and wounded epidermal cells.276 TGF-β1 is the most potent stimulus to HSCs
in hepatic fibrosis. In quiescent HSCs, TGF-β1 inhibits the proliferation. However, once
the quiescent HSCs are activated by the positive feedback activation mechanism, TGF-β1
loses its control to inhibit the proliferation of activated HSCs.277 Although the
mechanisms of TGF-β1 to induce ECM accumulation have not been fully understood,
TGF-β1 has been suggested to activate MAPK/ERK pathway,278 which is related closely
to HSC proliferation. Although SMAD pathway has been reported to get activated after
TGF-β1 application, it was also revealed that SMAD2 pathway was not initiated by
TGF-β1.275 Our results suggest that TGF-β1 gene silencing inhibited the proliferation of
HSC-T6 cells by MAPK/ERK pathway (Figure 6-3B). The role of TGF-β1 on apoptosis
was also changed after HSC activation. Saile et al. reported that DNA-NF-κB binding
ability was inhibited by TGF-β1 in activated HSCs,279 which meant TGF-β1 had antiapoptotic effect on fibrotic HSCs. Thus, the inhibition of TGF-β1 allowed activated
HSCs to undergo apoptosis partial (Figure 6-4).
In conclusion, effective HSC-specific TGF-β1 gene silencing is possible using GFAP
promoter which is a pol II promoter to modulate miR30-shRNA expression in the
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Figure 6-8 The prediction of the secondary structure of the pri-miRNA cluster mimic
transcribed from pGFA-mi-shRNA-769+1033 plasmid. The arrows points to the single
strands flanking the extended stem-loops of pri-miRNA cluster mimics. The ovals
indicate the shRNA inserts.
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pri-miRNA mimic plasmids. The pGFA-mi-shRNA 769+1033 showed higher efficiency
in reducing HSC TGF-β1 mRNA level.
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CHAPTER 7. SYSTEMIC ADMINISTRATION OF MICELLAR FORMULATED
PTP, A NOVEL LPA ANTAGONIST, TO TREAT HEPATIC FIBROSIS
7.1.

Introduction

Hepatic fibrosis is excessive accumulation of ECM from an uncontrolled healing
process leading to various liver injuries, such as viral infections, autoimmune reactions,
etc. After hepatic damage, the connective tissue replaces injured hepatocytes, which
prevents the regeneration of the liver.239 Fibrosis is also closely related the morbidity and
mortality, including in cancer metastasis and chronic graft rejection. Damaged
hepatocytes produce pro-inflammatory cytokines, such as TGF-β1, and recruit
inflammatory cells. Then, more pro-fibrotic mediators are secreted and results in the
activation of α-SMA expressing myofibroblasts. The major inducer of myofibroblast
activation is TGF-β1, which can be enhanced by IGF-1, bFGF, LPA etc.
Liver fibrosis has become a major problem on public health cost. However, efficient
treatments that directly target fibrosis are lacking. So far, only pirfenidone has been
evaluated in a Phase III trial.280 Treatment with this molecule decreases ECM
accumulation in fibrotic liver.281 Nevertheless, pirfenidone also showed gastrointestinal
adverse responses in a significant number of patients.
LPA is a growth factor-like mediator acting on G-protein-coupled receptors
(GPCR)282 presenting in various physiological fluids. LPA has been reported to involve
in many diseases, such as cardiac ischemia, atheriosclerosis, obesity and hepatic fibrosis.
The composition of LPA is long chain fatty acids, saturated (C18:0, C16:0) or
unsaturated (C18:1, C20:4), linked to the glycerol backbone by acyl- or alkyl-group. At
least six LPA receptors have been found.283 LPA1R, LPA2R and LPA3R are members of
the endothelial differentiation gene family while LPA4R, LPA5R and LPA6R belong to
the purinergic GPCR family.284 LPA1R is the most widely distributed subtypes
throughout the organism. It is shown that LPA can activate hepatic myofibroblasts45 and
increase the proliferation and survival of stellate cells.46,47 The correlations between
plasma LPA concentration and the histological stages of liver fibrosis markers have been
established in patients with chronic hepatitis C.48,49
It is demonstrated that LPA1R antagonists to reduce the extent of fibrosis in kidney
and lung. This result also provides a potential pharmacogical approach to treat liver
fibrosis. Despite a growing number of LPAR antagonists have shown pharmacological
ability, few of them have been validated for treatments in animals. It becomes very urgent
that to develop more efficient anti-fibrotic drugs that may have important preclinical
effects to imply the potent clinical applications in the management of liver fibrosis.
PTP, a novel synthesized LPA antagonist, showed significant inhibition effect on the
proliferation of HSC-T6 cell line, which suggests the potent application on liver fibrosis
therapeutics. However, the most difficult issue for PTP in vivo administration is the low
water solubility. Surfactants, such as DMSO and Tween-80, have been commonly
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utilized to enhance the solubility for hydrophobic drugs. These surfactants also have their
own problem, hepatic toxicity. To solve this problem, novel polymers synthesized by our
group, poly(ethylene glycol)-b-poly(carbonate-co-lactide) copolymers, were used to
make micellar formulation to enhance solubility.
In this chapter, PEG-PCcL micelles were applied to increase the aqueous solubility of
PTP. After that, the anti-proliferation and anti-fibrosis abilities of this formulation were
evaluated in vitro. Different doses of PTP loaded PEG-PCcL were intravenous
administered to common bile duct ligated mice to check therapeutic effects on fibrosis in
vivo.
7.2.

Material and Methods

7.2.1.

Materials

Goat anti-rat type I collagen and β-actin primary antibodies were purchased from
Santa Cruz Biotech, Inc. (Santa Cruz, CA). Serum alanine transaminase (ALT) and
aspartate transaminase (AST) kits were purchased from ID Labs, Inc (London, Canada).
Citric acid and sodium citrate were procured from Curtin Matheson Scientific, Inc
(Houston, TX). Sodium hydroxide was purchased from Fisher Scientific (Fair Lawn, NJ).
Isoflurane was purchased from Baxter Pharmaceutical Products, Inc. (Deerfield, IL). All
solvents and chemicals used in this study were used as available without further
purification.
7.2.2.

In Vitro Application of PTP

Cells were cultured in a 24-well plate to 60% confluence and treated with PTP
dissolved in DMSO in various doses for 24 h.
7.2.3.

MTT Assay

HSC-T6 cells were seeded in 48-well plate and reached 60% confluence before
treated. After 24 hours treatment, the old medium was removed and 200 μL medium with
0.5 mg/mL MTT was added. The cells were incubated for 1 h at 37°C. After carefully
removing the media again, 400 μL of DMSO was added into each well to dissolve the
formazan crystals. The absorbance was measured in a microplate reader at a wavelength
of 560 nm. Cell viability was expressed as the percentage of control group.
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7.2.4.

Determination of HSC-T6 Proliferation

HSC-T6 cells were seeded in 6-well plate and reached 60% confluence before treated.
After 24 hours treatment and 1 hour before collection, BRDU was given to the cells. The
proliferation of PTP treated HSC-T6 was determined by Cell Proliferation Assay Kit
according to the manufacturer’s protocol.
7.2.5.

Measurement of Caspase Activity

Caspase-Glo 3/7 (Promega, Madison, WI) assay kit was used to determine the effect
of PTP micelles on caspase-3/7 activity. Briefly, cell was seeded in 48-well plate and
reached 60% confluence before treated. At 24 h post-treatment, supernant medium was
moved and 100 μL Caspase-Glo reagent was added to each well and incubated at room
temperature for 1 h. The contents were transferred into culture tubes, and luminescence
was determined using a luminometer (Berthold, Germany).
7.2.6.

Preparation of Micelles

PTP loaded micells were prepared by a film dispersion methods.285 3 mg PTP and 20
mg PEG-PCcL copolymer were dissolved in chloroform and a thin film was formed after
removing organic solvent under reduced pressure. The resulting film then was hydrated
and sonicated in 1 mL water. After that, the result formulation was centrifuged to remove
un-encapsulated PTP and used at the same day.
7.2.7.

Determination of Drug Loading Efficiency

To determine the PTP loading efficiency, un-encapsulated PTP during micelle
preparation was dried and re-dissolved in dichloromethane. The drug concentration was
measured by UV spectrometer and calculated according to the standard curve in various
concentration of PTP in dichloromethane. The loading efficiency and density were
calculated as previous publication.50
Drug loading efficiency=(Drug fed–Drug un-encapsulated)/Drug fed
Drug loading density=(Drug fed–Drug un-encapsulated)/Polymer fed
7.2.8.

Particle Size Measurement

The particle size distribution of micelles was determined by dynamic light scattering
with Malvern Nano ZS. The intensity of scattered light was detected at 90°.
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7.2.9.

Animal Model and In Vivo Administration

Male BALB/c mice weighing 20-25 g were purchased from Harlan Co. (San Diego,
CA) and were housed individually under the conditions as per the NIH
(http://grants1.nih.gov/grants/olaw/references/phspol.html) and Institutional Animal Care
and Use Committee (IACUC) using the approved protocols. All animals were housed in
microisolator cages in virus-free facilities and fed laboratory chow and water ad labium.
Common bile duct ligation (CBDL) or sham operation was performed as described in
our recent publication.222 In the first day of CBDL, animals were divided into 4 groups:
sham (midline abdominal incision and closure), CBDL, CBDL+low dose PTP loaded
micelles (1 mg/kg) and CBDL+ high dose PTP loaded micelles (10 mg/kg). Micelle
solution was given via the tail vein injection from the first day of CBDL three times a
week for two consecutive weeks. At the end of experiment, blood was collected when
animals were sacritificed under isoflurane anesthesia by puncture of the right heart
vehicle and exsanguinations. Liver tissues were collected, washed, blotted dry and frozen.
7.2.10. Standard Serum Parameters
Traditional serum biomarkers for liver fibrosis, aspartate aminotransferase (AST) and
alanine aminotransferase (ALT), were determined. Serum ALT and AST concentrations
were measured using IDToxTM Alanine Transaminase color endpoint assay kit and
IDToxTM Aspartate Transaminase Enzyme Assay Kit (ID LabsTM Inc, London, ON,
Canada) according to the manufacturer’s instructions and absorbance was measured using
a spectrophotometer.
7.2.11. Real Time PCR
Total RNA was extracted from 20 mg liver tissue by RNAeasy Mini Kit and the RNA
concentration was measured by UV spectrophotometry using Nanodrop
spectronanometer (Thermo Scientific, Pittsburgh, PA). Then, 385 ng of the total RNA per
sample was reverse transcribed into cDNA using MultiScribe Reverse Transcriptase
Reagent and random hexamers. The obtained cDNA was amplified by real time PCR
using SYBR Green-1 dye universal master mix on ABI Prism 7700 Sequence Detection
System (Applied Biosystems, Inc., Foster City, CA). The sequences of primers for
detecting TGF-β1, α-SMA and 18S as an internal control are the same as our previous
report.222
7.2.12. Hydroxyproline Assay
30 mg liver tissues were hydrolyzd with 6 N HCl and heating in an oven at 110°C for
18 h. Then, citrate buffer and Chloramine-T reagent were added and allowed to react for
20 min at room temperature. Fresh prepared Ehrlich’s reagent was then added to each
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sample and react for 15 min at a warm water bath (60.8°C). Following cooling to room
temperature, absorbance was read at 550 nm and the results were expressed as
micrograms of hydroxyproline per grams of liver.
7.2.13. Histological Staining
Formalin-fixed liver specimens from mice in various groups were dehydrated in 70%
alcohol, incubated in xylene, and embedded in paraffin. Five-micron-thick tissue sections
were cut and stained with Masson’s Trichrome staining for collagen.
7.3.

Results

7.3.1.

Effects of PTP on HSC-T6 Cell Lines Proliferation and Apoptosis

BRDU 1 hour pulse showed PTP inhibit HSC-T6 proliferation (Figure 7-1A). The
green fluorescence indicated the cells which incorporated BRDU to the genome DNA
during replication. MTT assay showed the same trend as BRDU assay (Figure 7-1B).
However, PTP treated HSC-T6 cells did not show any inhibition on caspase activity
(Figure 7-1C), which related to apoptosis. It suggests the decrease on cell viability only
came from the down-regulation on proliferation.
7.3.2.

In Vitro Characterization of PTP in PEG-PCcL Micells

PEG-PCcL (L:C=70:30) micelles showed the least particle size in both no-PTP and
PTP loaded situation, while PEG-PCcL (L:C=50:50) and PEG-PCcL (L:C=30:70)
micelles showed the slightly bigger in size (Table 7-1). After loading PTP, PEG-PCcL
(L:C=50:50) micelles showed smaller size, but PEG-PCcL (L:C=70:30) micelles gave a
much bigger size compare to their empty capsule. All of these micelles were stable for at
least 5 days without significant change in particle size.
Under the same fed condition, PEG-PCcL (L:C=50:50) micelles showed the highest
loading efficiency, while PEG-PCcL (L:C=30:70) micelles showed the lowest (Table
7-2). The loading efficiency in PEG-PCcL (L:C=50:50) micelles can meet the
requirement for in vivo administration.
7.3.3.

Blood Chemistry

The level of traditional liver disease markers, ALT and AST, were determined
(Figure 7-2). Administration of PTP loaded micelles in a dose of 1 mg/kg did not show
any relief on both ALT and AST level. The dose of 10 mg/kg resulted in decreased levels
of ALT and AST, which indicated the therapeutics on hepatic fibrosis.
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Figure 7-1 Effects of PTP on HSC-T6 proliferation and apoptosis. A) BRDU 1 hour pulse,
green fluorescence indicated the cells which incorporated BRDU to the genome DNA
during replication, B) MTT assay, demonstrating cell viability, C) caspase-3/7 activity
assay.
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Table 7-1 Particle size measurement of empty and PTP loaded PEG-PCcL micelles.
Polymer

Z-Ave
(nm)

PDI

PK1 mean
(nm)

PK2 mean
(nm)

PK1
(%)

PK1
(%)

PEG-PCcL (L:C=70:30)

102

0.257

159

42.4

78.4

21.6

PEG-PCcL (L:C=70:30) LPA-ANT

106

0.256

132

39.5

85.2

14.8

PEG-PCcL (L:C=50:50)

127

0.156

155

48.3

92.8

7.2

PEG-PCcL (L:C=50:50) LPA-ANT

122

0.168

158

61.0

84.3

15.7

PEG-PCcL (L:C=30:70)

124

0.210

172

54.4

83.6

16.4

PEG-PCcL (L:C=30:70) LPA-ANT

141

0.211

169

42.0

92.8

7.2
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Table 7-2 Micelle loading efficiency and loading density.
Polymer

Drug concentration (mg/mL)

Loading efficiency (%)

Loading density (%)

PEG-PCcL (L:C=70:30)

0.99

33

5.0

PEG-PCcL (L:C=50:50)

1.70

57

8.5

PEG-PCcL (L:C=30:70)

0.48

17

2.5
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Figure 7-2 The level of traditional liver disease markers, ALT and AST, were determined.
A) ALT level, B) AST level.
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7.3.4. High Dose PTP Micelles Inhibits Both Profibrogens and Myofibroblast
Activation
TGF-β1 is a potent fibrogenic cytokine believed to regulate fibrosis. Both low dose
and high dose treated group showed significant decrease on hepatic TGF-β1 gene
expression (Figure 7-3A).
The progression of liver fibrosis enlarge the pool of the cells, which can express
α-smooth muscle actin (α-SMA).222 Therefore, we determined α-SMA concentration in
mRNA level before and after treatment. Only high dose treatment significantly decreased
α-SMA mRNA synthesis in CBDL mice (Figure 7-3B). Low dose group did not show
significant inhibition on α-SMA mRNA production.
7.3.5.

Collagen Levels

To confirm therapeutic effects of PTP on inhibition of collagen production, Masson’s
trichrome staining was applied to mouse liver tissues. In sham operated mice, collagen
expression was very low (Figure 7-4A). In rats administrated with PTP on a dose of
10mg/kg, there was a significant decrease in collagen deposition compared to CBDL
mice.
The level of type I collagen gene expression, the major component in ECM, was also
determined by Western blot analysis (Figure 7-4B). Only high dose treated group showed
inhibition on type I collagen expression, with relatively higher level of collagen in low
dose group.
To quantify the total collagen level, the liver tissue was measured by hydroxyproline
assay (Figure 7-4C). There was significant increase in hydroxyproline content in the liver
after CBDL, suggesting the liver fibrosis model was successfully established.
Hydroxyproline content of the livers showed significant decrease in high dose treated
group compared to CBDL group.
7.4.

Discussion

In various organs in animals and humans, fibrosis is associated with increased LPA
production or of some LPA receptor, mainly LPA1R, expression.286 Treatment of animal
models with specific antagonists clearly indicates the contribution of LPA to the
development of kidney, lung, vascular and dermal fibrosis. The involvement of LPA
antagonist in liver fibrosis treatment is also strongly suspected but still unproven.
In our experiment, it was clearly shown that the LPA antagonist, PTP, inhibited the
proliferation of hepatic stellate cells in vitro. The drug works in concentration of both 10
μM and 100 μM. There was no significant difference between 10 μM and 100 μM treated
groups. MTT assay showed the same trend after measuring the cell viability. However,
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Figure 7-3 mRNA expression level of fibrotic related factors. A) mRNA level of TGF-β1,
B) mRNA level of α-SMA.
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Figure 7-4 Measurement of type I collagen and total collagen. A) Mason’s Trichrome
staining for total collagen, a) non-fibrotic mice, b) CBDL mice, c) low dose group, d)
high dose group. B) Western blot for type I collagen, upper is type I collagen, lower is βactin, PC means CBDL mice, NC means normal mice, LD means low dose group and HD
means high dose group. C) Hydroxyproline level of total collagen.
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the caspase-3/7 activity did not show any inhibition or activation from these two treated
groups. These results may suggest PTP only affect the proliferation process in liver
fibrosis. Inhibition on proliferation in HSC-T6 cell line gave us the hint to slow down the
HSCs activation by this strategy. Inhibition of proliferation may have the similar results
as activation of apoptosis in vitro. However, it is totally different in vivo. Induction of
apoptosis in vivo may create disaster during treating procedure, while control on
proliferation has fewer problems.287
Many potent drugs have the same problem, low aqueous solubility, to prevent their
practical application in vivo. Polymeric micelles are capable of preventing drug
degradation and have the potential of targeted delivery after modification to avoid
adverse effects.288 In this study, PEG-PCcL copolymers were utilized to make micelle
delivery system to enhance the solubility of PTP. The maximum solubility by formulated
with 20 mg PEG-PCcL (L:C=50:50) reached to 1.7 mg/mL. Polymeric micelles enhance
solubilization of hydrophobic compounds by accommodating them in their hydrophobic
core of polymer. When the drugs are loaded, the size of micelles may change compared
to empty ones. PTP loaded PEG-PCcL (L:C=30:70) micelles increase particle size to
almost 115% and PTP loaded PEG-PCcL (L:C=70:30) micelles also increase particle size
slightly. Whereas, PTP loaded PEG-PCcL (L:C=50:50) micelles decrease the particle
after formulation, which may suggest the higher compatibility between PEG-PCcL
(L:C=50:50) and PTP. This higher compatibility can enhance the drug loading efficiency
and make the whole delivery system more shrinkable.
LPA antagonist used as an agent to treat liver fibrosis is applicable if reasonable
aqueous solubility can be reached. The control on proliferation is much easier to handle
to than the control on apoptosis in treating fibrotic disease. PTP showed good therapeutic
effects both in vitro and in vivo, which may act as an excellent drug to treat hepatic
fibrosis in the future.
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